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I 
Abstract 
In  order  for  cells  to  proliferate,  a  certain  size  has  to  be  reached,  which  depends 
primarily on the rate of translation.  RNA polymerase (pol) III plays a key role in 
protein synthesis by catalysing the production of small, untranslated RNA molecules 
such as transfer (tRNA) and 5S ribosomal RNA (5S rRNA).  Indeed, recent evidence 
suggests that tRNAi
Met production is limiting for translation and proliferation in some 
cell types.  Therefore, the rate of pol III transcription plays a fundamental role in 
cellular  growth  and  proliferation.    Regulation  of  pol  III  output  is  mediated  via  a 
number of different mechanisms that can alter the activities of the transcription factors 
which are responsible for directing pol III transcription.  Work presented in this thesis 
aimed at investigating the mechanisms behind the regulation of pol III transcription 
by the protein kinase CK2. 
CK2 is a highly conserved protein kinase involved in cell growth and proliferation.  It 
has  been  shown  to  stimulate  transcription  of  tRNA  genes  by  pol  III  both  in 
Saccharomyces cerevisiae and mammals.  Addition of a specific CK2 inhibitor, 2-
dimethylamino-4, 5, 6, 7-tetrabromo-1-H-benzimidazole (DMAT) caused a decrease 
in  the  level  of  pol  III  transcripts,  confirming  that  CK2  exerts  a  potent  effect  on 
mammalian  pol  III  transcription.    Furthermore,  inhibition  of  CK2  resulted  in  a 
decrease in the promoter occupancy of pol III and its associated factor TFIIIB.  Co-
immunoprecipitation and GST pull-down assays show that mammalian CK2 binds to 
the TFIIIB subunit Brf1, an essential subunit of TFIIIB.  In addition, phosphorylation 
assays and the use of a phosphospecific antibody reveal that Brf1 is phosphorylated at 
S450 by CK2.  
One of the ways by which activators of pol III transcription can enhance pol III output 
is by promoting transcription complex formation.  Brf1 is brought to target genes 
through interaction with the promoter-binding factor TFIIIC.  Mutation of S450 to A 
compromises  the  ability  of  Brf1  to  bind  to  TFIIIC,  associate  with  promoters  and 
activate pol III transcription in transfected fibroblasts.  
Pol III output can be elevated during virus-induced cell transformation.  This thesis 
also examined whether the increase in pol III transcription following transformation  
II 
by  the  Polyomaviridae  viruses  polyoma  (Py)  and  simian  virus  40  (SV40)  was 
accompanied by changes in phosphorylation of Brf1 S450.  Phosphorylation of S450 
is  increased  during  cell  transformation  by  these  Polyomaviridae  viruses,  which 
suggests  that  this  phosphorylation  event  could  contribute  to  the  mechanisms 
employed by these viruses to stimulate pol III transcription.  
Nuclear RNA synthesis is repressed when eukaryotic cells enter mitosis.  Reversible 
inhibitory phosphorylation of Brf1 was proposed to be one of the mechanisms by 
which transcription by pol III is repressed during mitosis.  Phosphosphorylation of 
Brf1 S450 did not change when cells entered mitosis.  However, phosphorylation of 
Brf1  T270  by  polo-like  kinase  1  compromises  the  binding  of  pol  III  to  Brf1, 
contributing to the mitotic repression of pol III transcription. 
In conclusion, the data demonstrate that phosphorylation of Brf1 S450 by CK2 is 
required  for  the  efficient  recruitment  of  Brf1  to  pol  III-transcribed  genes  in 
mammalian cells.  This work has provided new insight into the molecular basis of 
how CK2 can stimulate the expression of pol III-transcribed genes.  
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1  Introduction 
1.1 Eukaryotic Transcription 
In order for the cell to use the biological information contained within its genome, 
individual  genes,  each  of  which  represents  a  single  unit  of  information,  have  to  be 
expressed in a co-ordinated manner.  This co-ordinate gene expression determines the 
make up of cellular ribonucleic acid (RNA), which in turn specifies the nature of the 
proteome and defines the activities that the cell is able to carry out (Voet and Voet, 
1995). 
Transcription  is  the  process  during  which  RNA  is  synthesised  using  specific 
deoxyribonucleic acid (DNA) templates and is crucial to gene expression (Voet and 
Voet, 1995).  In eukaryotes, the task of transcribing nuclear genes is divided between 
three  highly  related  complex  enzymes  known  as  RNA  polymerases  I,  II  and  III 
(commonly referred to as pol I, pol II and pol III) (reviewed in White, 2001) and a 
recently  discovered  single  polypeptide  fourth  nuclear  RNA  polymerase  (pol  IV) 
(Kravchenko  et  al,  2005).    Each  of  these  RNA  polymerases  is  devoted  to  the 
transcription of specific genes.  Pol I is distinctive among the nuclear RNA polymerases 
in transcribing only one type of gene, the large tandemly repeated, ribosomal RNA 
(rRNA) genes [reviewed in (Grummt, 2003) and (Russell and Zomerdijk, 2006)].  Pol II 
transcribes the protein-coding genes which encode the messenger RNA (mRNA), as 
well as some small nuclear RNA (snRNA) genes [reviewed in (Thomas and Chiang, 
2006)].  The genes transcribed by pol III are referred to as class III genes and encode a 
variety of small stable RNA molecules, including 5S rRNA and transfer RNAs (tRNAs) 
[reviewed in (Dieci et al., 2007)].  Pol IV is expressed as an alternative transcript of the 
mitochondrial RNA polymerase and is responsible for the transcription of a number of 
mRNAs (Kravchenko et al, 2005). 
Transcription is the first step in gene expression and is subject to a wide variety of 
control (Voet and Voet, 1995).  It allows the cell to constantly adjust in response to 
environmental changes and metabolic requirements (White, 2001).  The regulation of 
transcription  is  implicated  in  almost  every  biological  process  including  growth  and Introduction 
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development (White, 2005).  It is vital to understand the regulation of transcription, 
since defects therein are the basis of many diseases. 
This thesis focuses on transcription by pol III and its regulation by the protein kinase 
CK2 (formerly known as Casein Kinase II).  In order to gain an appreciation for this 
research  project,  this  chapter  will  give  an  overview  of  the  various  functions  of  the 
products of class III genes, the transcription machinery involved in their production and 
how their transcription can be regulated.  The involvement of CK2 in the regulation of 
transcription by pol III will be touched upon in this chapter and discussed further in 
Chapters Three, Four, Five and Six. 
1.2 Class III Genes 
Pol III is responsible for approximately 10% of all nuclear transcription (White, 2002).  
Microscopy studies of HeLa nuclei have demonstrated that pol III transcription occurs 
at discrete locations (~2000 sites) within the nucleoplasm (Pombo et al., 1999).  The 
genes transcribed by pol III encode a variety of small RNA molecules [usually shorter 
than 400 base pairs (bp)] that are untranslated (White, 2002).  These RNA molecules 
have essential functions in cellular metabolism (Dieci et al., 2007).  Some of the major 
pol III transcripts are described in the following sub-sections.  
1.2.1 5S ribosomal RNA (rRNA)   
Eukaryotic  ribosomes  are  composed  of  two  subunits,  which  together  contain  four 
molecules  of  RNA  (28S,  5.8S,  5S  and  18S)  and  approximately  80  proteins  (Wool, 
1979).  5S is the only rRNA to be produced by pol III, while the other three rRNAs are 
made by pol I.  The four rRNAs are required in equal stoichiometry, each being present 
in one copy per ribosome (Phillips and McConkey, 1976), 5S is therefore, essential for 
protein synthesis.  As with other class III genes, 5S is transcribed in the nucleoplasm 
and is transported to the nucleolus where it is processed and incorporated into the large 
ribosomal  subunit  (Lafontaine  and  Tollervey,  2001).    Eukaryotes  contain  multiple 
copies of 5S genes, ranging from 140 in S. cerevisiae (Elion and Warner, 1984) up to 
20,000 copies in Xenopus laevis (Fedoroff and Brown, 1978; Miller et al., 1978).  The Introduction 
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human genome contains 200 to 300 5S genes and numerous dispersed pseudogenes, 
many of which occur in tandem array (Consortium, 2001). 
1.2.2 Transfer RNAs (tRNAs) 
Transcription  by  pol  III  also  gives  rise  to  the  tRNA  molecules  (73-93  nucleotides) 
(Sharp et al., 1984).  tRNAs function as molecular adaptors which serve to translate the 
genetic information carried by mRNA into a particular order of amino acid residues in a 
protein  (Creighton,  1997).    When  processed,  a  tRNA  molecule  adopts  an  L-shaped 
secondary  structure  with  a  3'  terminal  site  for  amino  acid  attachment  (Hopper  and 
Phizicky, 2003).  It also contains a three base region called the anticodon that can base 
pair to the corresponding three base codon region on the mRNA nucleotide sequence 
(Hopper and Phizicky, 2003).  This ensures the accurate synthesis of the polypeptide 
chain encoded by the mRNA.  The human genome contains 497 nuclear genes encoding 
cytoplasmic tRNA molecules; there is considerable redundancy as the average copy 
number for each amino acid tRNA adaptor is around 10 genes (Consortium, 2001).  The 
tRNA genes are mainly scattered throughout the genome, although some clustering can 
be observed (Consortium, 2001). 
1.2.3 U6 small nuclear RNA (snRNA) 
Small nuclear ribonucleoproteins (snRNPs) are a group of structurally related RNA-
protein  complexes  and  are  found  in  the  nuclei  of  eukaryotic  cells  (Weinberg  and 
Penman, 1968).  The most abundant snRNPs are the spliceosomes (Lerner and Steitz, 
1979), which are crucial for pre-mRNA processing (Lerner et al., 1980).  Spliceosomes 
contain five snRNA species, four of which are made by pol II whereas the smallest, U6, 
is made by pol III (Kunkel et al., 1986).  There are multiple copies of U6 snRNA genes 
in the human genome and there is a high degree of U6 conservation between different 
organisms (Consortium, 2001). 
1.2.4 Other class III genes encoding RNP components 
A  variety  of  other  pol  III  transcripts  are  components  of  ribonucleoprotein  (RNP) 
complexes such as 7SL, 7SK, H1 and mitochondrial RNA processing (MRP) RNAs. Introduction 
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The signal recognition particle (SRP) is a protein-RNA complex that recognises and 
delivers nascent polypeptide chains to the endoplasmic reticulum in eukaryotes.  The 
trafficking  of  proteins  through  this  organelle  is  critical  for  post-translational 
modifications, appropriate folding and delivery to their appropriate subcellular locations 
(Creighton, 1997).  The eukaryotic SRP is composed of six distinct polypeptides bound 
to an RNA molecule (the 7SL RNA).  7SL RNA forms the structural backbone of the 
SRP and is extremely conserved throughout evolution (Walter and Blobel, 1982). 
7SK is an abundant 330 nucleotide RNA that forms part of a 12S RNP together with 
eight proteins (Mattaj et al., 1993; Murphy et al., 1986).  7SK was found to act as a 
negative regulator of pol II transcription elongation (Nguyen et al., 2001; Yang et al., 
2001).  This occurs as a result of 7SK binding to the elongation factor P-TEFb; a factor 
responsible for phosphorylation of the C-terminal domain of the largest subunit of pol II 
(Nguyen et al., 2001; Yang et al., 2001). 
H1 is the 369 nucleotide component of RNase P, an endoribonuclease that processes the 
5’ termini of pre-tRNA (Bartkiewicz, 1989; Lee and Engelke, 1989).  H1 is encoded by 
a single copy gene in both yeast (Lee et al, 1991) and humans (Baer et al., 1990). 
RNase  MRP  is  an  endoribonuclease  with  the  ability  to  cleave  the  mitochondrial 
transcript to generate an RNA primer for replication of mitochondrial DNA (Chang and 
Clayton,  1987).    Despite  being  identified  in  the  mitochondrion,  the  majority  of  the 
RNase MRP is found in the nucleolus where it plays an important role in the processing 
of pre-rRNA (Clayton, 2001).  RNase MRP contains a 265 nucleotide RNA generated 
by pol III which shows several blocks of sequence homology to H1 RNA (Gold et al., 
1989). 
1.2.5 Viral class III genes 
A number of viruses use the cellular pol III transcription machinery to transcribe short 
transcription  units  within  their  genomes.    The  best  characterised  of  these  are  the 
adenovirus VA1 and VA2 genes; these are transcribed by pol III at high levels during 
late stages of viral infection (Akusjarvi et al., 1980; Soderlund et al., 1976).  The VA Introduction 
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RNA can undermine the host’s cell’s translational apparatus to allow synthesis of viral 
proteins (Thimmappaya et al., 1982). 
The genome of Epstein-Barr virus (EBV) also contains two small adjacent genes called 
EBER 1 and 2 that are also transcribed by pol III (Rosa et al., 1981).  These small 
nuclear  RNAs  have  regions  of  homology  to  the  VA  genes  and  are  166  and  172 
nucleotides long, respectively.  Like VA RNAs, EBERs can subvert the translational 
machinery of the host cell in order to promote synthesis of viral proteins (Rosa et al., 
1981). 
1.2.6 Short interspersed nuclear elements (SINEs) 
A variety of repetitive SINEs are pol III templates in higher organisms.  The major 
SINE in humans is the Alu family (Jelinek et al., 1980), whereas in rodents the B1 and 
B2 SINE families are the most abundant (Bennett et al., 1984).  B1 genes are highly 
homologous (~80%) to Alu genes, and both appear to have evolved from the 7SL gene 
(Britten, 1994; Quentin, 1992); however, the B2 genes are thought to have evolved from 
the tRNA genes and are essentially tRNA pseudogenes (Daniels and Deininger, 1985).  
SINE DNA constitute a significant proportion of mammalian genomes: over a million 
copies  of  Alu  are  encoded  by  the  haploid  human  genome  (Consortium,  2001),  and 
approximately 384 000 copies of B1 and 328 000 copies of B2 are present per haploid 
rat genome (Consortium, 2004).  The dispersal and amplification of SINEs throughout 
the genome is by retrotransposition (Rogers, 1985).  Little is known about the function 
of their encoded transcripts, although it has been suggested that some SINE families are 
involved in expression of adjacent genes (Hasler and Strub, 2006), splicing, translation 
(Pagano et al., 2007), cell stress responses (Liu et al., 1995; Chu, 1998; Li, 1999), 
regulation  of  growth  or  the  turnover  of  specific  mRNAs  (Hasler  and  Strub,  2006; 
Pagano et al., 2007). 
The selective transcription of genes by pols I, II and III is dictated by their distinct 
promoters.    The  following  section  describes  the  promoter  structures  specifically 
recognised by the pol III transcription machinery. 
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1.3 Promoter structure of class III genes 
Gene promoters contain specific DNA sequence elements which direct the recruitment 
of  the  appropriate  transcription  factors  and  RNA  polymerase  via  multiple  protein-
protein and protein-DNA interactions [reviewed in (Schramm and Hernandez, 2002)].  
This sequential recruitment is required for the transcription of a particular gene (Lassar 
et  al.,  1983).    One  of  the  distinguishing  features  of  the  majority  of  class  III  gene 
promoters is that crucial elements are found within the transcribed region of the gene, 
i.e.  downstream  of  the  transcription  start  site  in  comparison  to  upstream  promoter 
elements used by pol I and pol II (Bogenhagen et al., 1980; Galli et al., 1981; Kurjan 
and Hall, 1982).  These key elements are generally discontinuous structures composed 
of essential blocks separated by non-essential regions (Koski et al., 1980; Kurjan and 
Hall, 1982).  There are three types of promoters used by pol III, known as types I, II and 
III. 
1.3.1 Type I promoters 
Type I promoters are unique to 5S rRNA genes (Figure 1.1).  The promoter was initially 
characterised in X. laevis (Bogenhagen et al., 1980) and requires three internal promoter 
elements for efficient function: the A-block (+50 to +64 bp), an intermediate element 
(+67 to +72 bp) and the C-block (+80 to +97 bp) collectively known as the internal 
control region (ICR) (Pieler et al., 1985; Bogenhagen, 1985).  The spacing between 
these elements is restricted and conserved.  Mutations or alterations in the spacing of the 
elements considerably reduce transcriptional efficiency (Pieler et al., 1987).  This is in 
contrast  to  the  flanking  regions  that  display  little  conservation  and  show  a  greater 
flexibility to mutations (Bogenhagen, 1985; Pieler et al., 1985; Pieler et al., 1987). 
1.3.2 Type II promoters 
The  majority  of  pol  III-transcribed  genes,  including  the  tRNAs  and  adenovirus  VA 
genes have type II promoters (Figure 1.1).  These consist of two essential and highly 
conserved sequence elements: an A-block and a B-block found within the transcribed 
region (Galli et al., 1981).  The A- block of type II promoters is homologous to the A-
block contained within type I promoters, and in some species these elements can be Introduction 
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interchangeable (Ciliberto et al., 1983), although the A-block is much closer to the start 
site  of  transcription  in  type  II  promoters.    In  this  type  of  promoter  the  spacing  is 
variable, the A- and B- blocks are typically separated by 30-40 bp; however, a distance 
of up to 365 bp can still support transcription (Baker et al., 1987; Fabrizio et al., 1987). 
1.3.3 Type III promoters 
A minority of pol III-transcribed genes including the 7SK, MRP and U6 genes have a 
type III promoter (Figure 1.1) (Murphy et al., 1987).  Genes with type III promoters 
lack any requirement for internal promoter regions, with important sequence elements 
being found upstream of the start site (Schramm and Hernandez, 2002).  The human U6 
gene is the best characterised type III promoter.  For efficient transcription of U6 genes 
three  extragenic  promoter  elements  are  required:  a  TATA  box  (-30  to  -25  bp),  a 
proximal sequence element (-66 to -47 bp) and a distal sequence element (-244 to -214 
bp) (Das et al., 1988; Kunkel and Pederson, 1988; Lobo and Hernandez, 1989). Introduction 
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Figure 1.1  Schematic  diagram  of  the  organisation  of  the  3  general  types  of 
promoters used by pol III 
The start site of transcription is indicated by +1 and the site of termination is 
indicated by Tn. Also shown are the approximate positions of various promoter 
elements  including  the  intermediate  element  (IE),  proximal  sequence  element 
(PSE) and distal sequence element (DSE) [Adapted from (White, 2001) and (Paule 
and White, 2000)]. 
All three promoter types can specify a class III gene and direct its transcription by pol 
III.  Section 1.4 below describes the properties and functions of the various components 
of the transcription initiation complex required for the transcription of a class III gene. Introduction 
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1.4 Transcription of class III genes 
1.4.1  Assembly of the transcription complex 
Transcription  begins  with  the  assembly  of  a  transcription  initiation  complex  at  the 
promoter.  Despite the complexity of the pol III enzyme, it has little affinity for the 
promoter  sequence  and  so  relies  on  specific  transcription  factors  which  form  this 
transcription initiation complex for its accurate recruitment.  Each type of promoter has 
its  own  requirement  for  different  transcription  factors  [reviewed  in  (Schramm  and 
Hernandez, 2002)].   
1.4.1.1  Type II promoters 
The  initial  step  in  the  formation  of  the  transcription  initiation  complex  on  type  II 
promoters is the binding of the multi-subunit pol III-specific transcription factor TFIIIC 
to  the  promoter  (White,  2001).    TFIIIC  is  one  of  the  largest  and  most  complex 
transcription  factors  ever  studied.    In  S. cerevisiae,  TFIIIC  consists  of  six  subunits 
TFC1 (Swanson et al., 1991), TFC3 (Lefebvre et al., 1992), TFC4 (Marck et al., 1993), 
TFC6 (Arrebola et al., 1998), TFC7 (Manaud et al., 1998) and TFC8 (Deprez et al., 
1999).    TFIIIC  has  an  aggregate  mass  of  more  than  500  kDa  (Geiduschek  and 
Kassavetis,  2001).    The  subunits  arrange  into  two  globular  domains  capable  of 
specifically recognising and binding directly to the A- and B-block elements of type II 
promoters (Schultz et al., 1989).  Electron microscopy suggests that the two domains of 
TFIIIC can be linked by a flexible hinge which can stretch to give the appearance of a 
dumbbell (Conesa et al., 1993; Schultz et al., 1989).  However, on promoters with long 
interblock separations the ability to stretch is exceeded and intervening DNA is looped 
out (Baker et al., 1987).  Even though both A- and B-blocks are contacted by TFIIIC, 
the B-block is the major determinant of binding affinity (Baker et al., 1987).  
Human TFIIIC is composed of six polypeptides, known as TFIIIC220, 110, 102, 90, 63 
and  35  according  to  their  molecular  masses (Kovelman  and  Roeder,  1992; Dumay-
Odelot et al., 2007).  The largest subunit TFIIIC220, displays very little homology to 
any of the S. cerevisiae TFIIIC subunits and interacts specifically with the B-block 
(Shen et al, 1996; Yoshinaga et al., 1987).  TFIIIC63 binds the A-block and strengthens Introduction 
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the TFIIIC-DNA interactions (Hsieh et al., 1999a).  TFIIIC90 acts as the flexible linker 
region that bridges the two distinct sub domains formed by the other four subunits 
(Hsieh et al., 1999b).  The more highly diverged 220, 110 and 90 kDa subunits have 
histone  acetyltransferase  (HAT)  activities  and  may  play  a  role  in  determining  gene 
activity (Hsieh et al., 1999a; Hsieh et al., 1999b; Kundu et al., 1999). 
The  crucial  function  of  TFIIIC  is  to  recruit  the  initiation  factor  called  TFIIIB, 
positioning  this  factor  just  upstream  of  the  transcription  start  site  (Teichmann  and 
Seifart, 1995).  TFIIIB consists of three polypeptides: TATA box-binding protein (TBP) 
and  two  TBP-associated  factors,  known  as  Brf1  (TFIIB-related  factor  1;  a  90  kDa 
protein named for the homology of its amino (N)-terminal half to the pol II-specific 
transcription  initiation  factor  TFIIB)  and  Bdp1  (B  double  prime;  a  160kDa  protein 
which  displays  little  homology  with  any  known  protein)  (Schramm  and  Hernandez, 
2002).  Whilst TBP is needed for transcription by pols I, II and III (Cormack and Struhl, 
1992), Brf1 and Bdp1 are specifically involved in the transcription of class III genes.  
Brf1 forms a stable complex with TBP in solution but Bdp1 is only weakly associated 
with  this  complex,  if  at  all,  in  the  absence  of  a  DNA  template  (Huet  et  al.,  1994; 
Kassavetis et al., 1991; Schramm et al., 2000).  TFIIB interacts with TBP and it was 
expected that the TFIIB-like region in Brf1 would be responsible for interaction with 
TBP (Ha et al., 1993).  Indeed, a weak interaction is observed at this region; however, 
the principal region that mediates Brf1 binding to TBP is within the C-terminal domain 
of Brf1 (Khoo et al., 1994).  
The  recruitment  of  TFIIIB  to  class  III  gene  promoters  by  TFIIIC  has  been  greatly 
studied in S. cerevisiae.  The S. cerevisiae equivalent of human TFIIIC102 initially 
interacts with Brf1 (Kassavetis et al., 1992).  Subsequent interactions between each of 
the TFIIIB subunits and various TFIIIC components are also likely to play a role in the 
formation  of  a  stable  pre-initiation  complex  (Schramm  and  Hernandez,  2002).    In 
human  cells,  it  has  been  established  that  TFIIIC90  interacts  with  Brf1,  and  that 
TFIIIC102 and 63 interact with both Brf1 and TBP (Hsieh et al., 1999a; Hsieh et al., 
1999b).  In addition, TFIIIC63 was found to interact with a pol III subunit RPC 62 (Hu 
et al., 2002). Introduction 
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All three TFIIIB subunits are required for polymerase recruitment but only Brf1 and 
TBP have been shown to interact directly with pol III.  Of these interactions, the binding 
of Brf1 and the yeast pol III-specific subunit C34 (RPC39 in humans) appears to be 
crucial (Werner et al., 1993; Brun et al., 1997).  Moreover, it has been shown that 
various TFIIIC subunits are capable of interacting with pol III (Hu et al., 2002).  These 
additional interactions may help stabilise the transcription complex (Flores et al, 1999; 
Hsieh et al, 1999a, b). 
 
Figure 1.2  Schematic  illustration  of  the  assembly  pathway  used  to  form  an 
initiation complex on type II promoters. 
TFIIIC  recognises  and  binds  to  the  A  and  B-block  promoter  elements.    Once 
TFIIIC has bound to DNA, it recruits TFIIIB via protein-protein interactions.  Pol 
III is recruited by protein-protein interactions with TFIIIB.  The transcription 
start site is denoted by +1 (Adapted from White, 2002). Introduction 
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1.4.1.2   Type I promoters 
The recruitment of pol III to type I promoters also requires TFIIIB and TFIIIC.  Type I 
promoters lack a functional B-block (Figure 1.2), which is the major determinant of 
DNA-binding  affinity  of  TFIIIC.    As  a  result,  the  gene-specific  transcription  factor 
TFIIIA  is  required  for  the  productive  association  of  TFIIIC  with  5S  rRNA  genes 
(Engelke et al., 1980; Segall et al., 1980).  TFIIIA was the first eukaryotic transcription 
factor to be purified to homogeneity (Engelke et al., 1980) and cloned (Ginsberg et al., 
1984).  TFIIIA is composed of a single polypeptide of approximately 40 kDa, and is the 
founding member of the C2H2 zinc finger family of DNA-binding transcription factors 
(Miller  et  al.,  1985).    It  has  nine  zinc  finger  domains  which  bind  to  the  A-block, 
intermediate element and the C-block of 5S genes (Miller et al., 1985).  The N-terminal 
three zinc fingers specifically recognise the C-block and contribute to 95% of total 
DNA-binding affinity (Hanas et al., 1983).  Once TFIIIA is bound to 5S genes, it is able 
to recruit TFIIIC although the precise manner by which this occurs remains unclear 
(Braun et al., 1992).  TFIIIC recruitment then allows TFIIIB to bind upstream of the 
transcription start site, which is then followed by the recruitment of pol III (Kassavetis 
et al., 1995; Roberts et al., 1996) Introduction 
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Figure 1.3  Schematic  illustration  of  the  assembly  pathway  used  to  form  an 
initiation complex on of type I promoters. 
TFIIIA  binds  to  the  internal  promoter.    TFIIIC  is  then  recruited  followed 
sequentially by TFIIIB and pol III.  Once pol III has been recruited, transcription 
can commence. 
1.4.1.3   Type III promoters 
Type  III  promoters  have  distinct  transcription  factor  requirements  in  comparison  to 
types I and II promoters.  TFIIIB involved in transcription from these promoters does 
not contain Brf1, but instead consists of a Brf1-related factor known as Brf2 as well as 
Bdp1 and TBP, giving rise to a specific TFIIIB-like activity (Schramm et al., 2000).  Introduction 
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Assembly of the initiation complex begins with the binding of the PSE by a five-subunit 
factor known as snRNA activating complex (SNAPc) (Henry et al., 1996; Wong et al., 
1998) and of the TATA box by the TBP component of the specialised TFIIIB-like 
activity.  Type III promoter occupancy is relatively slow in comparison to type I and II 
promoters, but can be enhanced by a series of co-operative protein-protein interactions 
(Schramm and Hernandez, 2002).  The recruitment of SNAPc to the PSE and TFIIIB to 
the TATA box is enhanced by protein-protein interactions between these complexes 
(Mittal et al., 1996) (Mittal, 1997).  An additional transcription factor, known as Oct-1, 
can  bind  to  the  DSE  and  make  direct  contact  with  SNAPc  stimulating  promoter 
occupancy  through  protein-protein  interactions  (Mittal  et  al.,  1996;  Murphy  et  al., 
1992).  However, Oct-1 is not essential for basal transcription from type III promoters 
in vitro (Hu et al., 2003).  Once TFIIIB and SNAPc have assembled on the promoter, 
pol III can then be recruited.  The interactions responsible for pol III recruitment to 
these promoters have yet to be determined.  Figure 1.3 below represents a schematic 
representation of the transcription complex assembly on these promoters. Introduction 
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Figure 1.3   Schematic  illustration  of  the  assembly  pathway  used  to  form  an 
initiation complex on of type III promoters. 
TFIIIB and SNAPc bind cooperatively to the TATA box and PSE respectively.  
Binding  of  Oct-1  to  the  DSE  enhances  SNAPc/TFIIIB  recruitment.    Following 
SNAPc/TFIIIB recruitment, pol III binds and transcription can commence. 
1.4.2 Pol III 
RNA polymerases catalyse the covalent attachment of ribonucleotides to form an RNA 
chain that is complementary to the gene template being transcribed (Voet and Voet, 
1995).    Pol  III  is  the  largest  and  most  complex  of  the  eukaryotic  nuclear  RNA 
polymerases.  It  consists  of  seventeen  subunits  in  both  humans  and  in  yeast  and  an 
aggregate mass of 600-700 kDa [reviewed in (Geiduschek and Kassavetis, 2001)].  The 
seventeen subunits have been cloned and shown to be essential for pol III function and Introduction 
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cell viability (Chedin et al., 1998; Ferri et al., 2000).  This is in contrast to pol II, where 
several subunits have been shown to be dispensable for growth (Chedin et al., 1998).  
The seventeen subunits range from 10 to 160 kDa, ten of the seventeen subunits are 
unique to the pol III complex (known as the C subunits: C11, C17, C25, C31, C34, C37, 
C53, C82, C128 and C160),  five are shared by all three RNA polymerases (the ABC 
subunits: ABC 10α, ABC 10β, ABC14.5, ABC23, ABC27), and an additional two are 
common to both pols I and III  (the AC subunits: AC19 and AC40) (Breant et al., 1983; 
Buhler et al., 1980; Chedin et al., 1998).  The conserved and shared subunits are thought 
to form the catalytic core and the unique subunits are likely to reflect their unique 
functional requirements such as template selection and interactions with transcription 
factors (Geiduschek and Kassavetis, 2001). 
1.4.3 Transcription initiation, elongation and termination 
Upon binding of pol III to the promoter, the double-stranded DNA is melted to allow 
access to the template strand (Kassavetis et al., 1990; Lofquist et al., 1993).  The two 
strands of DNA unwind and form a small open complex referred to as the transcription 
bubble (Kassavetis et al., 1999).  This spontaneous separation of the DNA strands is 
performed by pol III, although the TFIIIB subunits, Brf1 and Bdp1 have also been 
shown to be involved in this process (Kassavetis et al., 1998).  As pol III progresses into 
the gene, the transcription bubble moves along with it. (Kassavetis et al., 1992)  In 
contrast to transcription by pol I and II, no elongation factors are required, possibly due 
to the short length of pol III genes (White, 2001).  
As RNA synthesis proceeds, pol III dissociates from the TFIIIB/DNA complex without 
causing any significant pausing or arrest (Kassavetis et al., 1992).  TFIIIC binds DNA 
within the transcribed region during the pre-initiation complex assembly and remains 
bound during elongation (Bogenhagen, 1985).  The elongation rates do not, however, 
appear to be affected by the presence of this transcription factor and the presence of 
TFIIIC delays polymerase by just 0.2 seconds at a single site upstream of the B-block 
making no difference in overall transcription rates (Bardeleben et al., 1994; Matsuzaki 
et al., 1994).  It is unclear at present how the polymerase passes DNA-bound TFIIIC 
during  transcription  (Bardeleben  et  al.,  1994).    Transcription  proceeds  until  pol  III 
recognises a small stretch of four or more thymidine (T) residues as termination signal Introduction 
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(Galli et al., 1981), rather than relying on termination accessory factors like pol I and II 
(Cozzarelli  et  al.,  1983).    Termination  signals  recognition  by  pol  III  can  also  be 
influenced by the region surrounding the T cluster (Braglia et al., 2005).  After the 
synthesis of the first transcript, pol III does not dissociate from the template and can be 
recycled so that multiple rounds of transcription of the same gene can take place (Jahn 
et al., 1987).  Subsequent cycles of transcription occur more rapidly (about 35 seconds) 
than  the  first  one  (about  5  minutes)  as  the  slow  preliminary  step  of  polymerase 
recruitment is avoided (Dieci and Sentenac, 1996).  The pol III transcription factors 
TFIIIA, TFIIIB and TFIIIC can bend the DNA duplex and may facilitate the reinitiation 
of transcription by bringing the start site into close spatial orientation with the end of the 
gene (Jahn et al., 1987).  Thus, when transcription complexes are assembled they are 
capable of multiple rounds of transcription (Dieci and Sentenac, 1996). 
1.5  Cell growth 
Cell growth (increase in cell mass) and cell proliferation (increase in cell number) are 
vital processes to eukaryotic life (reviewed in (Conlon and Raff, 1999).  Although the 
terms cell growth and cell proliferation are often used interchangeably, these processes 
are actually distinct.  It has been well documented that cells need to reach a certain size 
and duplicate their contents before they divide, in order to maintain a constant mean 
size (Johnston, 1977).  Thus, cell proliferation depends on cell growth.  Cell growth, on 
the  other  hand,  can  occur  independently  of  proliferation.    It  has  been  shown  that 
mutations that block cell cycle progression do not prevent cell growth (Johnston et al., 
1977; Neufeld et al., 1998).  Moreover, some cells such as nerve and muscle cells grow 
mainly after they have permanently withdrawn from the cell cycle and inactivated their 
cell cycle control system (Conlon and Raff, 1999). 
As a high proportion of the cell’s dry mass is protein, increase in cell mass requires 
accumulation of protein (Baxter and Stanners, 1978).  In fact, cell growth is directly 
proportional to the rate of protein accumulation (Baxter and Stanners, 1978).  The rate 
of protein synthesis is an important determinant of cellular growth (Baxter and Stanners, 
1978).    The  process  of  translation  mediates  protein  synthesis,  where  ribosomes 
synthesise proteins from mRNA templates.  Ribosomes constitute the core of the protein 
synthetic  machinery  making  ribosome  content  a  critical  determinant  of  protein Introduction 
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accumulation (Camacho et al., 1990; Zetterberg and Killander, 1965).  Synthesis of 
rRNA is a limiting step in ribosome production, as there is little wastage of rRNA since 
it is totally incorporated into ribosomes (Liebhaber et al., 1978).  Given its key role in 
determining  ribosome  production,  rRNA  gene  transcription  can  provide  a  crucial 
control point for regulating growth rate (Liebhaber et al., 1978).  Along with ribosomes, 
the accurate and efficient execution of translation requires many specialised pol III-
produced  tRNA  species,  which,  accordingly,  also  impinge  upon  cell  growth  rate 
(Francis and Rajbhandary, 1990).  Reducing levels of the initiator tRNA in yeast can 
influence cell growth and prolong cell doubling time (Francis and Rajbhandary, 1990) 
and recently it was shown that tRNAi
Met is limiting for translation and proliferation in 
mammalian cells (Marshall et al, 2008).  Regulating class III gene expression clearly 
has the potential to influence the capacity for cell growth (reviewed in (White, 2005)).  
Aberrant regulation of growth is a feature of diseases such as cancer; thus, elucidating 
the  mechanisms  involved  in  regulating  cell  growth  is  of  considerable  importance 
(White, 2005). 
1.6 Regulation of pol III transcription 
Section 1.5 suggested how regulation of protein synthesis is an important aspect of 
growth control.  Pol III plays a key role in this process and, as a consequence, pol III 
transcription activity is tightly linked to growth conditions.  Indeed, transcription by pol 
III varies considerably in accordance to the metabolic requirements of the cell.  Pol III 
transcription decreases when cells are deprived of serum or nutrients but is upregulated 
upon mitogenic stimulation (Clarke et al., 1996; Johnston, 1977; Mauck and Green, 
1974).    Control  of  pol  III  transcriptional  output  may  be  achieved  through  various 
mechanisms, mainly involving regulating its transcription factors, such as TFIIIB and 
TFIIIC (White, 2001).  The following sub-sections describe a number of ways in which 
pol III transcription can be regulated. 
1.6.1 Overexpression of transcription factors 
Increase in pol III transcriptional output can be achieved by raising the concentration of 
its  specific  transcription  factors  [reviewed  in  (White,  2004c)].    Overexpression  of 
transcription  factors  TFIIIB  or  TFIIIC  is  observed  in  a  number  of  transformed  cell Introduction 
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types.  Studies of model systems revealed that levels of five subunits of TFIIIC are 
overexpressed at both the mRNA and protein levels following transformation by simian 
virus 40 (SV40), polyomavirus (Py) and Epstein Barr virus (EBV) (Felton-Edkins et al., 
2006;  Felton-Edkins  and  White,  2002;  Larminie  et  al.,  1999).    TFIIIC  is  also 
specifically up-regulated in each of nine human ovarian carcinomas relative to healthy 
adjacent tissue and contributes to the abnormal abundance of pol III transcripts in these 
tumours (Winter et al., 2000). 
All three subunits of TFIIIB have also been shown to increase following transformation 
(Felton-Edkins  and  White,  2002;  Larminie  et  al.,  1999).    Cell  culture  studies  have 
shown  that  TBP  can  be  increased  following  infection  by  hepatitis  B  virus  and  Ras 
activation (Wang et al., 1998).  The pol III-specific subunits of TFIIIB have also been 
shown to be overexpressed in cell culture models (Felton-Edkins and White, 2002).  
Cell  lines  transformed  by  either  SV40  or  Py  were  shown  to  overexpress  the  Bdp1 
subunit (Larminie et al., 1999; Felton-Edkins and White, 2002).  Furthermore, the Brf 1 
subunit  is  elevated  in  a  subset  of  cervical  carcinomas  which  tested  positive  for  the 
highly oncogenic human papillomavirus 16 (HPV16) (Daly et al., 2005). 
1.6.2 Binding  of  co-repressing  and  co-activating  proteins  to 
transcription factors 
1.6.2.1  Retinoblastoma protein 
The product of the retinoblastoma susceptibility gene (Rb) is the protein RB [reviewed 
in (Knudsen and Knudsen, 2006)].  RB is a 105-kDa nuclear phosphoprotein that is 
ubiquitously expressed in normal mammalian cells.  RB plays a role in controlling the 
mammalian  cell  cycle  (Weinberg,  1995).    Loss  of  RB  function  results  in  abnormal 
cellular proliferation and tumour formation (Sherr, 1996).  When growth factors are 
limiting, RB regulates cell cycle progression by preventing the passage of cells into 
DNA synthesis (S) phase (Scott et al., 2001). 
RB  was  found  to  possess  a  potent  capacity  to  restrain  pol  III  transcription  (White, 
1996).  This is achieved by binding and repressing a variety of transcription factors such 
as TFIIIB (Sutcliffe et al., 2000; Scott et al., 2001).  When bound to RB, TFIIIB is Introduction 
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unable to interact with either pol III or TFIIIC and is therefore sequestered into an 
inactive  complex  (Sutcliffe  et  al.,  2000;  Larminie  et  al.,  1997).    Only  in  the 
hypophosphorylated form, found during the Go and early G1 phase, can RB bind and 
repress TFIIIB (Scott et al., 2001).  A major increase in tRNA synthesis occurs at the 
G1/S phase transition, which coincides with the hyperphosphorylation of RB by cyclin 
D- and E-dependent kinases (cdks) (Hulleman and Boonstra, 2001; Scott et al., 2001).  
Hyperphosphorylated RB releases TFIIIB, allowing it to interact with TFIIIC at the 
promoters of class III genes and subsequently recruit pol III to these templates (Brown 
et al., 2000; Scott et al., 2001). 
1.6.2.2  p53 
p53 is a major tumour suppressor that is lost or mutated in more than half of human 
cancers (Hollstein et al., 1991; Vousden, 2000) and has also been found to be involved 
in restraining pol III transcriptional output.  Like RB, endogenous p53 can interact with 
TFIIIB and compromise its function (Chesnokov et al., 1996; Cairns and White, 1998; 
Crighton et al., 2003).  This interaction appears to be mediated through TBP (Crighton 
et  al.,  2003).    Elevated  levels  of  p53  are  accompanied  by  a  decrease  in  TFIIIB 
occupancy at pol III transcribed genes and co-immunoprecipitations reveal that TFIIIB 
can no longer bind to TFIIIC and pol III (Crighton et al., 2003).  On the other hand, 
fibroblasts from p53-knockout mice display markedly elevated synthesis of tRNA and 
5S rRNA (Cairns and White, 1998).  Primary fibroblasts derived from individuals with 
Li-Fraumeni syndrome, who inherit a mutated p53 allele, frequently display elevated 
pol III transcriptional activity (Stein et al., 2002).  p53 function can also be lost through 
the action of viral or cellular oncogenes, such as the human papilloma virus E6 or 
cellular human double minute (hdm) 2 oncoproteins [reviewed in (Wise-Draper and 
Wells,  2008)].    Both  E6  and  hdm2  can  stimulate  pol  III  transcription  by  relieving 
TFIIIB from p53-mediated repression (Stein et al., 2002). 
1.6.2.3  c-Myc   
Several oncogenic proteins activate TFIIIB indirectly by neutralising RB or p53, others 
such as the oncogene product of c-myc can increase pol III output by targeting TFIIIB 
directly.  c-Myc has been shown to play an extensive role in cancer, as it can collaborate Introduction 
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with  other  oncogenes  to  induce  cellular  transformation  (Dang,  1999).    Chromatin 
immunoprecipitation (ChIP) analysis showed that c-Myc is present at pol III-transcribed 
genes in untransformed fibroblast cells, ovarian epithelial cells and in the transformed 
cervical line HeLa (Gomez-Roman et al., 2003).  This recruitment was found to occur 
by protein-protein interactions of TFIIIB with the N-terminal transactivation domain of 
c-Myc, which directly activates transcription.  Specific depletion of c-Myc using RNA 
interference reduced tRNA and 5S rRNA gene expression in HeLa cells (Felton-Edkins 
et al., 2003b).  However, type III genes such as 7SK do not appear to be regulated by c-
Myc,  which  suggests  that  c-Myc  regulation  of  pol  III  transcription  is  type  I  and  II 
promoter  specific  (Felton-Edkins  et  al.,  2003b).    Activation  of  c-Myc  results  in 
increased  translation  and  growth,  and  loss  of  c-Myc  decreases  growth  and  protein 
synthesis (Dang, 1999).  The growth promoting potential of c-Myc may be mediated in 
part through the regulation of pol III transcription.  
1.6.3 Direct phosphorylation of transcription factors 
Protein  kinases  play  a  global  role  in  the  regulation  of  transcription  by  catalysing 
reversible  phosphorylation  of  transcription  factors.    Phosphorylation  of  transcription 
factors  can  modulate  their  activity  by  triggering  conformational  change,  generating 
binding  sites  for  interaction  partners,  influencing  their  intracellular  localisation  or 
altering their stability [reviewed in (Whitmarsh and Davis, 2000)].  Phosphorylation of 
transcription factors such as TFIIIB is a common mechanism of controlling activity of 
genes transcribed by pol III (Fairley et al., 2003; Felton-Edkins et al., 2003a; Johnston 
et al., 2002). 
1.6.3.1  Extracellular signal- related kinase (Erk) 
The  mitogen-activated  Erk  cascade  promotes  growth  in  several  ways,  including 
activation of translational capacity [reviewed in (Meloche and Pouyssegur, 2007)].  It 
has been shown that Erk interacts with and phosphorylates the Brf1 subunit of TFIIIB in 
vitro and in vivo; this phosphorylation is required for the serum induction of pol III 
activity (Felton-Edkins et al., 2003a).  As a result, a substitution in the Erk docking 
domain  or  phosphoacceptor  site  of  Brf1  substantially  reduces  pol  III  transcription 
(Felton-Edkins et al., 2003a).  ChIP analysis of cells treated with a specific inhibitor of Introduction 
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Erk showed a reduced Brf1 and pol III occupancy at 5S rRNA and tRNA genes (Felton-
Edkins  et  al.,  2003a).    Felton-Edkins  and  co-workers  (2003)  suggested  that  Erk 
phosphorylation  of  Brf1  stimulates  initiation  complex  assembly  and  enhances 
interactions between TFIIIB and TFIIIC, resulting in an increase in pol III recruitment. 
1.6.3.2  Polo-like kinase 1 
When  eukaryotic  cells  enter  mitosis,  it  is  generally  accompanied  by  a  decrease  in 
transcription  (Prescott  and  Bender,  1962).    Reversible  phosphorylation  of  the  basal 
transcriptional machinery is thought to repress nuclear transcription during mitosis.  For 
pol III transcription, this is achieved via phosphorylation of TFIIIB (White et al., 1995).  
Fairley and co-workers demonstrated that Brf1 is hyperphosphorylated during mitosis, 
but remains associated with pol III promoters (Fairley et al., 2003).  Bdp1 is selectively 
released from pol III promoters (Fairley et al., 2003) and as a consequence, a mitotic 
reduction of pol III output is observed (Fairley et al., 2003).  
Polo-like kinases (Plks) are important regulators of cell cycle progression during mitosis 
[reviewed in (Martin and Strebhardt, 2006)].  Plks are required for numerous aspects of 
mitotic  progression  such  as  mitotic  spindle  formation  and  cytokinesis  [reviewed  in 
(Eckerdt and Strebhardt, 2006)].  In mammalian cells, Plk1 protein levels increase as 
cells  approach  the  mitotic  phase,  with  the  peak  of  phosphorylation  activity  reached 
during mitosis (Golsteyn et al., 1995; Hamanaka et al., 1995).  Unpublished data (J. 
Fairley  and  R.J.White)  suggest  that  Plk1  can  bind  and  phosphorylate  Brf1.  
Furthermore, ChIP analysis has revealed that Plk1 is found at the promoters of pol III-
transcribed  genes,  which  supports  its  role  in  the  control  of  transcription  by  pol  III 
(J.Fairley and R.J.White). 
1.6.4 Protein kinase CK2 
CK2 is a highly conserved enzyme which forms part of the Wnt signalling pathway in 
both  flies  and  mammals  (Willert  et  al.,  1997;  Song  et  al.,  2000).    Many  studies 
(discussed further in Chapter Three), have shown that increased abundance or activity 
of CK2 is associated with cell growth and proliferation, and that overexpression of CK2 
results in transformation and tumourigenesis (Ahmed et al., 2000; Faust et al., 1996; Introduction 
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Munstermann et al., 1990).  One aspect of CK2’s growth-promoting activity may be 
through its reported role in regulating pol III transcription (Hockman and Schultz, 1996) 
(Ghavidel and Schultz, 1997) (Johnston et al., 2002).  CK2 has been shown to have a 
potent effect on pol III transcription in both yeast and mammalian cells (Ghavidel and 
Schultz, 1997; Ghavidel and Schultz, 2001; Johnston et al., 2002).  This is achieved by 
phosphorylating  TFIIIB  and  enhancing  the  assembly  of  the  transcription  initiation 
complex (Johnston et al., 2002).  Introduction 
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Figure 1.4  Mechanisms  of  regulation  of  pol  III  transcription  during 
proliferation. 
CK2,  c-Myc  and  Erk  can  activate  pol  III  transcription  by  targeting  TFIIIB 
directly  and  aiding  in  transcription  initiation  complex  assembly. 
Hyperphosphorylation of RB and sequestration of p53 by proteins such as hdm2 
or E6 relieves TFIIIB from repression and can lead to increased pol III output. 
Activation  of  pol  III  transcription  gives  rise  to  increase  in  rRNA  and  tRNA 
involved  in  protein  synthesis,  which  in  turn  increase  cell  growth  and  cell 
proliferation.  Adapted from (Goodfellow and White, 2007) 
1.7  Structure and cellular functions of CK2 
Protein  kinase  CK2  (CK2)  is  a  serine/threonine  (S/T)  protein  kinase  present  in  all 
eukaryotic cells (Pinna, 1997; Jakobi et al., 1989).  CK2 exists predominantly as a 
tetrameric protein composed of two catalytic subunits, CK2α and/or CK2α’, and two 
regulatory subunits: CK2β, although there is evidence that the subunits can also be 
found in their dissociated form (Filhol et al., 1991; Marin et al., 1997; Meggio et al., 
1992).  In mammals, the two catalytic isoforms CK2α (42-44kDa) and CK2α’ (38kDa) 
are encoded by separate genes.  The two isoforms show greater than 90% sequence Introduction 
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identity over their N-terminal 330 amino acids, which include their catalytic domains 
(Litchfield and Luscher, 1993).  In 2001, a third catalytic isoform (designated CK2α’’), 
that is almost identical to CK2α that the last thirty two amino acids are completely 
unique, was also identified (Shi et al., 2001).  The various CK2 isoforms are closely 
related and show considerable functional overlap, but there is also evidence to support 
functional specialisation of the individual CK2 catalytic isoforms in yeast and mammals 
(Vilk  et  al.,  1999).    For  example,  a  knockout  of  CK2α’  shows  that  CK2α  cannot 
compensate for the loss of CK2α’ in spermatogenesis (Xu et al., 1999). 
In contrast to the catalytic subunits, the regulatory subunit CK2β (25kDa) does not 
share  extensive  homology  with  any  known  protein,  but  is  highly  conserved  among 
species.  Indeed, its whole 215-amino acid sequence is identical between birds and 
mammals (Litchfield, 2003).  CK2β has a number of characteristic features, such as an 
autophosphorylation  site  comprising  S2,  S3  and  possibly  S4  at  its  N-terminus 
(Boldyreff,  1993;  Litchfield  et  al.,  1991).    The  β  subunit  appears  to  stabilise  and 
modulate the ability of CK2 to interact with and phosphorylate substrates (Litchfield, 
2003). 
CK2 is a pleiotropic and ubiquitously expressed protein kinase (Olsten and Litchfield, 
2004).    It  has  over  300  substrates  which  can  be  found  in  a  variety  of  cellular 
compartments (mainly in the nucleus and cytoplasm) [reviewed in (Meggio and Pinna, 
2003)].  Table 1.1 below represents a selected few of CK2 targets and their functions.  Introduction 
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Substrate  Description  Reference 
Cytoplasmic substrates 
IRS-1 
PP2A 
 
Insulin receptor substrate 1 
Protein phosphatase 2A 
 
(Tanasijevic et al., 1993) 
(Heriche et al., 1997) 
Nuclear substrates 
c-Myc 
p53 
c-Jun 
c-Myb 
 
Oncogene c-Myc 
Tumour suppressor p53 
Transcription factor AP-1 
Oncogenic transcription factor c-Myb. 
 
(Luscher et al., 1989) 
(Meek et al., 1990) 
(Lin et al., 1992) 
(Luscher et al., 1990) 
Table 1.1  Selected examples of phosphorylation targets of CK2  
[Adapted from (Olsten and Litchfield, 2004)] 
Due to its ability to regulate numerous substrates and its ubiquitous expression, CK2 
has been implicated in a vast array of crucial cellular functions, including cell growth, 
proliferation and cell survival.  In fact, CK2 has been demonstrated to be essential for 
cell  viability  in  S.cerevisiae  (Glover,  1998).    Furthermore,  disruption  of  the  gene 
encoding CK2β in mice leads to failure in development (Buchou et al., 2003), as does 
RNA interference-mediated knockdown of CK2β in Caenorhabditis elegans (Fraser et 
al., 2000). 
1.7.1 Activation  of  pol  III  transcription  and  CK2  activity  in 
transformed cells 
The precise regulation of pol III transcription is an important feature of normal cellular 
growth and proliferation.  In contrast, deregulated pol III transcription is connected with 
the abnormal proliferation characteristic of many transformed and tumour cell types Introduction 
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[reviewed by (White, 2004b; White, 2004c)].  Several mechanisms have been suggested 
to cause the deregulation of pol III transcriptional control.  As discussed above, pol III 
transcription  can  be  decreased  by  two  key  tumour  suppressors,  p53  and  RB,  and 
activated by proto-oncogene products, including CK2 and c-Myc.  Mutations of p53 and 
RB, and abnormal activation of proto-oncogenes, are common features of most human 
cancers, and can contribute to the increase of pol III transcripts observed in tumour cells 
(Schwartz et al., 1974; Tang et al., 2005; Winter et al., 2000).  In addition, pol III 
transcription is activated by several viruses associated with cellular transformation and 
human cancers, through the activation of TFIIIB and/or TFIIIC (White, 2004b; White, 
2004c).  This activation of transcription factors may contribute to the deregulation of 
class III gene expression (Daly et al., 2005; Felton-Edkins and White, 2002; Larminie et 
al., 1999; Wang et al., 1995; Winter et al., 2000). 
CK2 has been involved in diseases such as cancer, which is not surprising as it plays an 
important  role  in  many  central  biological  processes.    Elevated  CK2  activity  was 
detected in leukaemia cells , in normal tissues with high mitotic index and in a variety 
of human cancers, including head and neck (Faust et al., 1996), prostate (Yenice et al., 
1994), kidney (Stalter et al., 1994) breast (Landesman-Bollag et al., 2001) and lung 
(Daya-Makin et al., 1994).  CK2 also exhibits oncogenic activity when overexpressed in 
transgenic mice and in cultured mammalian cells.  The activation of CK2 during cell 
transformation could give rise to an increase in pol III transcripts and contribute to the 
aberrant growth of cells. 
1.8 Objectives of PhD. 
Regulation of class III gene expression is an important aspect of cellular function. It is 
crucial  for  the  appropriate  regulation  of  the  biosynthetic  capacity  of  cells.    Protein 
kinase CK2 promotes growth and proliferation and increased rates of 5S rRNA and 
tRNA synthesis are also required for increased cell growth.  In addition, CK2 has been 
shown to be involved in the regulation of pol I transcription.  
The  overall  objective  of  this  thesis  was  to  investigate  the  regulation  of  pol  III 
transcription by the protein kinase CK2.  The first aim of the project was to confirm that 
the Brf1 subunit of TFIIIB is a target of phosphorylation by CK2 in mammalian cells. Introduction 
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This  was  achieved  by  testing  the  effects  of  specific  CK2  inhibitors  on  pol  III 
transcription and discussed in Chapter Three.  Chapter Four investigates the potential 
site(s) of phosphorylation of Brf1 by CK2, in vivo and in vitro.  The remainder of the 
investigation  was  concerned  with  uncovering  the  mechanisms  responsible  for 
upregulating pol III transcription by CK2 and are discussed in Chapters Five and Six.    
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2  Materials and Methods 
2.1 Cell Culture 
2.1.1  Growth conditions 
Cell  culture  was  performed  in  a  class  II  hood,  using  aseptic  technique  and  sterile 
equipment  and  reagents.    All  cell  types  were  grown  in  a  humidified  atmosphere 
containing 5% CO2 at 37°C.  HeLa cells, Chinese hamster lung fibroblast (CCL 39) 
cells  and  BALB/c  3T3  (A31)  cells  were  maintained  in  Dulbecco’s  modified  eagle 
medium (DMEM) (Cambrex) supplemented with 10% (v/v) foetal calf serum (FCS), 
100 units/ml penicillin and 100 µg/ml streptomycin (all Sigma).  Cells were passaged 
when sub confluent (approximately every 2 to 3 days) using buffered trypsin (0.05% 
trypsin, 0.02% EDTA; Sigma). 
2.1.2 Storage of cells 
Cells  were  stored  by  cryo-freezing.    For  cryo-freezing,  trypsinised  cells  were 
resuspended in 70% DMEM (plus penicillin and streptomycin), 20% FCS and 10% 
dimethyl sulphoxide (DMSO) or in 90% FCS and 10% DMSO.  1 ml aliquots were 
transferred to cryo-tubes, and frozen overnight at -80˚C.  Subsequently, the cells were 
transferred to liquid nitrogen for permanent storage.  Thawing of cells was performed 
rapidly by placing cryo tubes in a water bath at 37 °C until just thawed.  Cells were then 
diluted  in  fresh  media,  centrifuged  and  the  supernatant  was  aspirated  off  to  ensure 
removal of DMSO prior to resuspension in fresh media. 
2.1.3 Drug treatment of cells and cell extracts 
4,5,6,7-tetrabromo-1H-benzimidazole (TBB), 2-Dimethylamino-4, 5, 6, 7-tetrabromo-
1H-benzimidazole  (DMAT),  LY290042  and  rapamycin  (all  purchased  from 
Calbiochem) were resuspended in dimethyl sulfoxide (DMSO).  Quercetin (Sigma) was 
resuspended in sodium hydroxide (50 mg/ml in 1M NaOH) and this was diluted in 
water to give a final stock concentration of 1mM. Balb/c 3T3 (A31) and HeLa cells Materials and Methods 
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were incubated in the presence of DMAT at a final concentration ranging from 5 µM to 
50 µM for 4 hours.  CCL39 cells were incubated for 2 hours in the presence of quercetin 
at a final concentration of 60 µM, with LY290042 at a final concentration of 50 µM or 
with rapamycin at a final concentration of 100 nM. 
HeLa nuclear and whole cell extracts were treated with TBB, quercetin and DMAT at a 
final concentration of 10 µM for 15 minutes.  
2.1.4  SV40 Transformed and Mitotic cell extracts 
Cell extracts from Balb/c 3T3 A31 cells infected with SV40 of the wt830 strain were 
kindly donated by Dr Zoë Felton-Edkins described in (Larminie et al., 1997). 
Mitotic HeLa cell extracts were generated from asynchronous HeLa cells which had 
been blocked using thymidine followed by nocodazole treatment as described in (White 
et al., 1995), and were kindly donated by Dr Jennifer Fairley. 
2.2  RNA Extraction 
Total cellular RNA was extracted from cells using TRI reagent (Sigma), according to 
the manufacturer’s instructions.  Media was aspirated from the cells, followed by two 
washes of 5ml of ice-cold phosphate buffered saline (PBS).  Cells were scraped into 
TRI reagent and transferred to sterile 1.5ml eppendorf tubes (1 ml of TRI reagent was 
used per 2 to 3 wells of a 6-well plate and per 10 cm dish).  The samples were incubated 
for 5 minutes at room temperature, to allow the complete dissociation of nucleoprotein 
complexes, followed by the addition of 200 µl of chloroform to each tube.  Thorough 
mixing of chloroform and TRI reagent was ensured by vortexing each sample for 15 
seconds.  The samples were incubated at room temperature for a further 5 minutes and 
then centrifuged at 16000g for 15 minutes at 4˚C.  This centrifugation separated the 
samples into 3 phases: a lower organic phase containing proteins, a middle interphase 
containing DNA, and an upper aqueous phase containing RNA.  The RNA-containing 
phase was carefully removed, and transferred to a fresh eppendorf tube.  To precipitate 
RNA,  0.5  ml  of  isopropanol  was  added;  samples  were  mixed  by  vortexing  for  10 
seconds, and then incubated for 10 minutes at room temperature.  Next, the samples Materials and Methods 
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were  centrifuged  at  16000g  for  10  minutes  at  4˚C.    Following  centrifugation,  the 
supernatant was discarded, and the remaining RNA pellet was washed using 1ml of 
75%  ethanol,  made  using  diethylpyrocarbonate  (DEPC)-treated  H2O  (0.1%  DEPC).  
Samples were centrifuged for a further 5 minutes at 16000g (4˚C), then the supernatant 
was aspirated off, and RNA pellets left to air dry for approximately 10 minutes.  Once 
dry, RNA was resuspended in 10-30 µl of DEPC-treated H2O.  To aid resuspension, 
pre-warmed DEPC-treated H2O was used, and samples were incubated at 65˚C for 15 
minutes. Following resuspension, a spectrophotometer was employed to measure the 
absorbance of each sample at 260 nm, and the following formula was used to calculate 
the RNA concentration: RNA concentration (µg/ml) = absorbance at 260 nm x 40 x 
dilution factor.  All RNA samples were stored at -80˚C. 
2.3  Northern Blot Analysis 
10-20 µg of RNA was diluted in DEPC-treated H2O to give a total volume of 10 µl.  
Each sample was mixed with 10 µl of 2 X RNA sample buffer (1 X MOPS [20 mM 
MOPS (pH 7.0), 8 mM sodium acetate, 1 mM EDTA (pH 8.0)], 4.4 M formaldehyde, 
54% formamide) the samples were then incubated at 65˚C for 15 minutes to denature 
RNA secondary structure.  Subsequently, samples were immediately cooled on ice to 
prevent any renaturation of the RNA.  2 µl of 1 mg/ml ethidium bromide and 2 µl of 10 
X RNA loading dye (50% glycerol, 1 mM EDTA, 0.25% bromophenol blue, 0.25% 
xylene  cyanol)  were  added  to  each  sample,  prior  to  loading  onto  a  denaturing 
formaldehyde 1% agarose gel (1% agarose, 2.2M formaldehyde, 1 X MOPS) that had 
been pre-run at 40V in 1 X MOPS for 30 minutes.  Electrophoresis was performed for 4 
to  5  hours  at  40V  in  1  X  MOPS;  afterwards  the  gel  was  visualised  under  a  UV 
transilluminator to ensure effective RNA separation and equal loading. 
The gel was then washed in 20 X SSC (3 M NaCl2, 0.3 M sodium citrate pH 7.0) with 
gentle shaking for 10 to 15 minutes. For capillary transfer of the RNA, the gel was 
inverted and placed on a wick of Whatmann 3MM chromatography paper, which had 
been pre-soaked in and was fed from a reservoir of 20 X SSC.  A gel-sized piece of pre-
soaked Hybond N nylon membrane (Amersham), followed by 2 pieces of pre-soaked 
Whatmann paper, was placed on the gel ensuring no air bubbles between layers.  A 
stack of folded paper towels was then added followed by a 0.5 kg weight, to ensure Materials and Methods 
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efficient  transfer  of  RNA  to  the  membrane  by  capillary  action.    The  transfer  was 
allowed to proceed for 16 to 18 hours.  Following transfer, the RNA was fixed to the 
membrane by UV crosslinking at 1200 µJ.  The membrane was rinsed for 5 minutes in 
DEPC-treated H2O and stored in Saran wrap until use. 
To specifically detect the RNA of interest, radiolabelled complementary DNA probes 
were  used:  the  B2  gene  probe  was  prepared  from  a  240bp  EcoRI-PstI  fragment  of 
pTB14, and the probe for acidic ribosomal phosphoprotein P0 (ARPP P0) was prepared 
from  a  1kb  EcoRI-HindIII  fragment  of  the  mouse  cDNA.    A  Megaprime  DNA 
Labelling  Kit  (Amersham)  was  used  to  label  the  probes  by  random  oligonucleotide 
priming,  according  to  the  manufacturer’s  instructions.  Random  hexamer 
oligonucleotides were mixed with 25 ng of the DNA fragment to be probed, and made 
up to a total volume of 50 µl with DEPC-treated H2O.  This was heated at 95˚C for 5 
minutes  to  denature  the  DNA.    Slow  cooling  of  the  mixture  to  room  temperature 
allowed the random hexamer oligonucleotides to anneal to the DNA.  10 µl of reaction 
buffer (dATP, dGTP, dTTP in Tris pH 7.5, β-mercaptoethanol and MgCl2), 2 µl (2U) of 
DNA polymerase I Klenow fragment, and 50 µCi of [α-
32P] dCTP (Amersham) were 
added, and labelling was allowed to proceed at 37˚C for 1 hour.  The labelled DNA was 
then denatured by heating at 100˚C for 5 minutes, and then stored on ice until use. 
Prior to hybridising the membrane with an appropriate radiolabelled probe, it was pre-
hybridised  in  a  hybridisation  oven  at  45˚C  for  45  minutes  by  rotating  in  25  ml  of 
hybridisation buffer (0.2 M sodium phosphate buffer pH 7.2, 1 mM EDTA, 1% bovine 
serum albumin (BSA), 7% sodium dodecyl sulphate (SDS), and 45% formamide in 
DEPC-treated  H2O).    The  radiolabelled  probe  was  then  added  to  25  ml  of  fresh 
hybridisation buffer, and incubated with the membrane overnight at 45˚C with rotation. 
The  following  day,  the  membrane  was  washed  with  rotation  in  hybridisation  wash 
buffer (40 mM sodium phosphate buffer pH 7.2, 1 mM EDTA and 1% SDS) twice for 5 
minutes at 65˚C, then twice for 15 minutes at 65˚C, to remove any unincorporated 
radioactivity.    The  membrane  was  then  exposed  to  autoradiography  film  for  an 
appropriate length of time at –80˚C.  To reprobe the membrane, it was boiled in DEPC-
treated H2O for 4 minutes, then pre-hybridised and probed as before. Materials and Methods 
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2.4  Reverse Transcriptase-Polymerase Chain Reaction 
(RT-PCR) 
2.4.1 Preparation of cDNAs 
3 µg of RNA and 200 ng of random hexanucleotide primers (Roche) were diluted in 
DEPC-treated H2O to give a final volume of 24 µl.  Primer annealing was carried out 
for 10 minutes at 80˚C.  Following this, samples were transferred to ice and then 1 µl 
(200 U) of Superscript II reverse transcriptase (Invitrogen Life Technologies), 8 µl of 5 
X First Stand Buffer (Invitrogen Life Technologies), 4 µl of 0.1 M dithiolthreitol (DTT) 
(Invitrogen Life Technologies) and 2 µl of a mix containing 10 mM of each of the four 
dNTPs  (Promega)  were  added  to  each.    Reverse  transcription  was  then  allowed  to 
proceed for 1 hour at 42˚C. Heating at 70˚C for 15 minutes stopped the reaction. cDNAs 
were stored at –20˚C. 
2.4.2 PCR 
PCRs were performed using a Techgene thermal controller (TECHNE). Each reaction 
contained  2  µl  of  cDNA,  20  pmol  of  the  appropriate  primers,  0.5  U  of  Taq  DNA 
polymerase (Promega), 1 X Taq DNA polymerase buffer (Promega), 1.5 mM MgCl2, 
0.2  mM  of  each  non-radioactive  dNTP,  and  1.8  µCi  of  [α-
32P]  dCTP  (Amersham).  
Table 2.1 below lists the sequences of primers used for PCR.  The cycling parameters 
employed and product sizes obtained for each primer set are indicated in the Table 2.2 
below.    Reaction  products  were  diluted  1:1  with  formamide  loading  buffer  (98% 
formamide,  0.01%  bromophenol  blue,  0.01%  xylene  cyanol,  5  mM  EDTA),  and 
resolved on 7% polyacrylamide sequencing gels containing 7 M urea and 0.5 X TBE 
(45 mM Tris, 45 mM boric acid, 0.625 mM EDTA pH 8.0).  Gels were pre-run at 40W 
for 30 minutes in 0.5 X TBE prior to loading samples (1.5 µl of each).  Before loading, 
samples were heated at 95˚C for 2 minutes, and then quenched on ice. Electrophoresis 
was carried out for 1 hour at 40W in 0.5 X TBE; the gels were vacuum-dried for 1 hour 
at 80˚C. Radiolabelled PCR products were visualised by autoradiography.  Materials and Methods 
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Transcript  Forward (F) and reverse (R) primers 
ARPP P0  F: 5’-GCA CTG GAA GTC CAA CTA CTT C-3’ 
R: 5’-TGA GGT CCT CCT TGG TGA ACA C-3’ 
tRNA
Leu  F: 5’-GTC AGG ATG GCC GAG TGG TGT AAG GCG CC-3’ 
R: 5’-CCA CGC CTC CAT ACG GAG ACC AGA CCC-3’  
tRNA
Tyr  F: 5’-CCT TCG ATA GCT CAG CTG GTA GAG CGG AGG-3’ 
R: 5’-CGG AAT TGA ACC AGC GAC CTA AGG ATG TCC-3’ 
5S rRNA  F: 5’-GGC CAT ACC ACC CTG AAC GC-3’  
R: 5’-CAG CAC CCG GTA TTC CCA GG-3’ 
Table 2.1  Sequences of PCR primers used in RT.PCR. 
 
 
Transcript  Cycling parameters  Product size 
ARPP P0  95°C for 2 minutes, 18 to 22 cycles of [95°C for 1 
minute, 58°C for 30 seconds, 72°C for 1 minute], 
72°C for 3 minutes. 
265bp 
tRNA
Leu  95°C for 3 minutes, 25 to 29 cycles of [95°C for 
30 seconds, 68°C for 30 seconds, 72°C for 30 
seconds], 72°C for 5 minutes. 
88bp 
tRNA
Tyr  95°C for 3 minutes, 25 to 29 cycles of [95°C for 1 
minute, 62°C for 30 seconds, 72°C for 30 
seconds], 72°C for 5 minutes. 
84bp 
5S rRNA  95°C for 3 minutes, 18 to 22 cycles of [95°C for 
30 seconds, 58°C for 30 seconds, 72°C for 1 
minute], 72°C for 5 minutes. 
107bp 
Table 2.2  PCR cycling parameters and product sizes. 
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2.5  Storage, propagation and preparation of plasmid 
DNA 
2.5.1 Transformation of competent cells 
For plasmid storage and propagation, Escherichia coli XL-1 blue supercompetent cells 
(Stratagene) were transformed.  These cells were stored at –80˚C and were thawed on 
ice prior to use, to prevent loss of transformation efficiency. 10-20 ng of plasmid DNA 
was added to 50 µl of thawed cells and mixed gently.  The mixture was incubated on ice 
for 30 minutes, with occasional gentle agitation.  Following this time, cells were heat-
shocked for exactly 45 seconds at 42˚C, then transferred to ice for a further 2 minutes. 
450 µl of SOC medium [Luria Bertani (LB) broth, 0.04% glucose, 10 mM MgSO4, 10 
mM  MgCl2],  which  had  been  pre-heated  to  42˚C,  was  then  added  and  cells  were 
incubated at 37˚C for 1 hour on an orbital shaker (225-250 rpm).  Subsequently, 150 µl 
of the transformation mixture was plated on LB-agar (2% LB, 2% agar) containing 50 
µg/ml of the selective antibiotic ampicillin, and then incubated at 37°C overnight to 
allow colony formation.  
2.5.2 Preparation of plasmid DNA 
An isolated bacterial colony was selected from a streaked LB-agar plate, and used to 
inoculate 4 ml of LB medium containing 50 µg/ml ampicillin.  This mini-culture was 
incubated at 37˚C for approximately 6 hours on an orbital shaker (300 rpm), and then 
used to inoculate 250 ml of LB medium containing 50 µg/ml ampicillin.  This larger 
culture was incubated overnight under the same conditions.  The following day, plasmid 
DNA  was  purified  from  the  bacterial  cells  using  the  QIAGEN  Plasmid  Maxi  Kit, 
according to the manufacturer’s instructions. 
Bacterial cells were harvested by centrifugation (in Sigma Laboratory Centrifuge 4K15) 
at 6000g for 15 minutes at 4˚C and then resuspended in 10 ml of Buffer P1 (500 mM 
Tris pH 8.0, 10 mM EDTA, 100 µg/ml RNase A).  Cell lysis was achieved by adding 10 
ml of Buffer P2 (200 mM NaOH, 0.1% SDS).  This reaction was allowed to proceed at 
room temperature for 5 minutes before lysates were neutralised by adding 10 ml of Materials and Methods 
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chilled Buffer P3 (3 M potassium acetate, pH 5.5).  Addition of Buffer P3 caused the 
precipitation of potassium dodecyl sulphate, SDS-denatured proteins, and chromosomal 
DNA and cell debris.  Precipitation was enhanced by incubation on ice for 20 minutes. 
Plasmid DNA is circular, and therefore renatured correctly and remained in solution. 
Centrifugation at 20000g for 30 minutes was performed (at 4˚C) to separate precipitated 
debris from soluble material.  Following this centrifugation, the supernatant containing 
plasmid  DNA  was  promptly  removed  and  applied  to  a  QIAGEN-tip  500,  pre-
equilibrated with 10 ml of Buffer QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% 
isopropanol, 0.15% Triton X-100).  Plasmid DNA binds tightly to QIAGEN-tip resin, 
while the remainder of the supernatant passes through by gravity flow.  The resin was 
then washed twice with 30 ml of buffer QC (1 M NaCl, 50 mM MOPS pH 7.0, 15% 
isopropanol), before eluting the purified plasmid DNA into a Falcon tube with 15 ml of 
buffer QF (1.25 M NaCl, 50 mM Tris pH 8.5, 15% isopropanol).  DNA was precipitated 
with 10.5 ml of isopropanol.  The sample was then centrifuged at 15000g for 30 minutes 
at 4˚C.  Following this, the supernatant was carefully decanted out leaving the pelleted 
plasmid DNA, which was then washed with 70% ethanol and recentrifuged.  The pellet 
was air-dried for approximately 10 minutes, and then resuspended in an appropriate 
volume  of  sterile  distilled  H2O.    DNA  concentration  was  determined  by  measuring 
absorbance at 260 nm, and using the following calculation: DNA concentration (µg/ml) 
= absorbance at 260 nm x 50 x dilution factor.  All plasmid DNA stocks were stored at -
20˚C.  
2.6  Whole cell extract preparation 
All steps were performed on ice or at 4˚C. Buffers, reagents and plastic-ware were kept 
chilled.  
2.6.1 Preparation of extracts for in vitro transcription assays 
Extracts for in vitro transcription assays (IVTs) were prepared from Balb/c 3T3 (A31) 
cells grown on 10 cm tissue culture dishes and treated in presence or absence of CK2 
inhibitor DMAT as described in section 2.1.3.  Cells were placed on ice then washed 
twice in phosphate-buffered saline (PBS; 170 mM NaCl, 3.4 mM KCl, 1 mM Na2HPO4, 
and  2  mM  KH2PO4,  pH  7.2).    Cells  were  then  scraped  into  PBS  (5  ml/dish),  and Materials and Methods 
37 
collected in 50 ml Falcon tubes.  Cells were pelleted by slow centrifugation at 500g (in 
a Sorvall RT 6000 D) and the PBS was then discarded.  A small amount of fresh PBS 
(approximately 1ml) was then added to the cells to aid transfer into sterile eppendorf 
tubes.  This PBS was then also removed following centrifugation (in an Eppendorf 
Centrifuge 5415R) at 12000g for 1 minute.  The remaining cell pellets were gently 
resuspended in freshly made microextraction buffer (450 mM NaCl, 50 mM NaF, 20 
mM HEPES pH 7.8, 25% glycerol, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride 
(PMSF),  0.2  mM  EDTA,  40  µg/ml  bestatin,  1  µg/ml  trypsin  inhibitor,  0.7  µg/ml 
pepstatin, 0.5 µg/ml aprotinin, 0.5 µg/ml leupeptin).  The volume of microextraction 
buffer used was equivalent to the volume of the cell pellet.  Following resuspension, 
samples  were  immediately  snap-frozen  on  dry  ice  and  thawed  at  30˚C.    When  just 
thawed,  samples  were  again  returned  to  dry  ice.    This  freeze-thaw  procedure  was 
performed a total of 3 times to ensure optimal cell lysis.  Following the final thaw, cell 
debris was collected by centrifugation at 12000g for 10 minutes.  The supernatant was 
promptly aliquoted, then snap-frozen. Samples were stored at -80˚C. 
2.6.2  Preparation  of  extracts  for  polyacrylamide  gel 
electrophoresis 
Extracts for polyacrylamide gel electrophoresis were prepared from cells grown on 6-
well plates or 10 cm dishes.  Cells were placed on ice then washed twice in PBS.  Cells 
were then scraped directly into cell lysis buffer (20 mM HEPES (pH 7.8), 150 mM 
NaCl, 25% glycerol, 50 mM NaF, 0.2 mM EDTA, 0.5% Triton X-100, 0.5% NP-40, 10 
mM β-glycerophosphate, 1 mM sodium orthovanadate, 1 mM PMSF, 1 mM DTT, 0.5 
µg/ml leupeptin, 1.0 µg/ml trypsin inhibitor, 0.5 µg/ml aprotinin and 40 µg/ml bestatin) 
and transferred to sterile eppendorf tubes.  The cell lysates were incubated on ice for 15 
minutes,  and  then  passed  through  a  26-gauge  needle  three  times.    Cell  debris  was 
collected  by  centrifugation  at  16000g  for  10  minutes,  and  the  supernatants  were 
aliquoted, snap-frozen on dry ice, and then stored at –80˚C. Materials and Methods 
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2.6.3 Determination of protein concentrations 
The protein concentrations of whole cell extracts were determined using Bradford’s 
reagent (Bio-Rad) diluted 1 in 5 with distilled H2O.  The colour change produced upon 
mixing this reagent with protein can be quantified by measuring absorbance at 595 nm 
(using a spectrophotometer), and is directly proportional to the concentration of protein 
in the sample.  For each experiment, a standard curve was constructed by measuring the 
absorbance of 1, 2, 4, 6, 8, 10 and 12 µg of bovine serum albumin (BSA) in 1ml of 
Bradford’s  reagent.    Whole  cell  extracts  were  diluted  1  in  10  with  microextraction 
buffer, and then 10 µl added to 1 ml of reagent.  Absorbance readings at 595 nm were 
performed in duplicate, and the protein concentration of each sample determined from 
the standard curve. 
2.7 In vitro transcription assay (IVT) 
2.7.1  Plasmids used for IVTs 
Plasmids  used  for  IVTs  were  pLeu  (a  240bp  EcoRI-HindIII  fragment  of  human 
genomic  DNA  carrying  a  tRNA
Leu  gene  subcloned  into  pAT153  (McLaren  and 
Goddard,  1986)  and  pVA1  (a  221bp  SalI-BalI  fragment  of  adenovirus  2  DNA 
containing the VA1 gene subcloned into pUC18) (Dean and Berk, 1988). 
2.7.2  Peptide substrate inhibitors used in IVTs 
30µg  of  peptide  substrate  inhibitors  were  pre-incubated  with  HeLa  nuclear  extracts 
(obtained from the Computer Cell Culture Centre, Belgium) for 15 minutes at 30°C in 
IVTs.  The peptide inhibitors were the CK2 phosphoacceptor peptide RRREEETEEE 
(Cancer Research UK-CRUK) or the protein kinase A (PKA) phosphoacceptor peptide 
LRRASLG (CRUK). Materials and Methods 
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2.7.3  IVT 
In vitro transcription (IVT) of class III genes was performed using 15 to 20 µg of whole 
cell extract (prepared as described in section 2.6.1) or HeLa nuclear extract and 250 ng 
of plasmid DNA containing the class III templates (section 2.7.1).  Transcription was 
carried out at 30°C for 1 hour in a total volume of 25 µl containing 12 mM HEPES pH 
7.9, 60 mM KCl, 7.2 mM MgCl2, 0.28 mM EDTA, 1.2 mM DTT, 10% (v/v) glycerol, 1 
mM creatine phosphate, 0.5 mM of each rATP, rCTP and rGTP, and 10 µCi of [α-
32P] 
UTP (400 mCi/mmol) (Amersham).  Transcription was stopped by the addition of 250 
µl  of  1  M  ammonium  acetate/0.1%  SDS  containing  20  µg  of  yeast  tRNA  (which 
stabilises the newly synthesised RNA in the samples).  Phenol-chloroform extraction 
was then performed, to remove protein and DNA, by adding 250 µl of a 25:24:1 ratio 
solution of phenol/chloroform/isoamyl alcohol to each sample.  Samples were mixed 
thoroughly by vortexing, and then centrifuged at 13000g for 5 minutes. 200 µl of the 
resulting upper aqueous layer was then transferred to a fresh eppendorf tube containing 
750 µl of ethanol.  The samples were mixed by repeated inversion, and left at -20°C 
overnight to precipitate RNA.  The following day, samples were centrifuged at 13000g 
for 30 minutes to pellet the precipitated RNA.  The supernatant was carefully removed 
and discarded, then pellets were washed using 750 µl of 70% ethanol (prepared using 
DEPC-treated H2O) and re-centrifuged at 13000g for 5 minutes.  Again, the supernatant 
was  discarded.  RNA  pellets  were  dried  at  50°C  for  5  minutes.    Once  dry,  4  µl  of 
formamide loading buffer was added to each sample.  Samples were then vortexed for 
30 minutes to ensure complete resuspension of the RNA, and heated at 95°C for 2 
minutes.    Electrophoresis  and  autoradiography  of  radiolabelled  transcripts  was 
performed as described in section 2.4.2 for PCR products. Materials and Methods 
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2.8 Separation  of  proteins  by  SDS-polyacrylamide  gel 
electrophoresis (SDS-PAGE) and detection by Western 
blotting 
2.8.1 SDS-PAGE 
Proteins were resolved on denaturing sodium dodecyl sulphate polyacrylamide (SDS-
PAGE) gels according to their molecular weight.  Approximately 30 µg of whole cell 
lysate were loaded on polyacrylamide minigels (375 mM Tris pH 8.8, 0.1% SDS), with 
4% polyacrylamide stacking gels (125 mM Tris pH 6.8, 0.1% SDS).  Prior to loading, 
samples were boiled for 2 minutes in 1 X protein sample buffer (62.5 mM Tris pH 6.8, 
0.5%  SDS,  5%  β-mercaptoethanol,  10%  glycerol,  0.125%  bromophenol  blue).  
Electrophoresis  was  performed  in  1  X  SDS  running  buffer  (0.1%  SDS,  76.8  mM 
glycine, 10 mM Tris pH 8.3) at an initial voltage of 80V. Once the bromophenol blue 
dye had moved through the stacking gel and reached the resolving gel, the voltage was 
increased to 140V and electrophoresis was continued for 60 to 90 minutes. 
2.8.2 Western blot analysis 
Following  resolution  by  SDS-PAGE,  proteins  were  transferred  to  a  nitrocellulose 
membrane  (Bio-Rad)  using  the  Bio-Rad  mini  trans-blot  electrophoretic  transfer  cell 
system.  Transfer was carried out in 1 X transfer buffer (76.8 mM glycine, 10 mM Tris 
pH 8.3, 16.5% methanol) at 50V for 2 hours at 4°C.  Membranes were then blocked in 
non-fat  milk  buffer  [125  mM  Tris,  150  mM  NaCl,  and  0.2%  Tween-20,  and  5% 
skimmed milk powder (Marvel)] for 1 hour at room temperature, prior to incubation for 
3 hours at room temperature (or overnight at 4˚C) with the relevant primary antibody 
diluted in milk buffer.  The primary antibodies utilised for Western blotting are listed in 
Table 2.3.  The membranes were then washed three times for 5 minutes in milk buffer, 
to remove excess primary antibody.  Subsequently, membranes were incubated with the 
appropriate horseradish peroxidase-conjugated secondary antibody (Dako), diluted 1 in 
1000 in milk buffer, for 1 hour at room temperature.  To ensure removal of excess 
secondary antibody, the blot was sequentially washed in fresh batches of milk buffer: 
three 10-minute washes; followed by two fifteen minute washes.  Following a final 5-Materials and Methods 
41 
minute wash in 1 X Tris buffered saline (TBS; 25 mM Tris pH 7.6, 150 mM NaCl); the 
bound antibodies were detected using the enhanced chemiluminescence (ECL) method 
(Amersham), as directed by the manufacturer. 
Protein Detected  Antibody   Supplier  Dilution in 
milk 
buffer 
Brf1  128  In house  1:1000 
Bdp1  2663  In house  1:1000 
TFIIIC110  4286  In house  1:1000 
Total S6 Kinase  9202  Cell Signalling Technology  1:1000 
PhosphoS6 Kinase  9202  Cell Signalling Technology  1:1000 
Active Erk1 and 2   E10  Cell Signalling Technology  1:1000 
Total Erk1 and 2  9102  Cell Signalling Technology  1:1000 
Plk 1  F-8  Santa Cruz Biotechnology  1:1000 
Haemagglutinin 
(HA) 
F-7  Santa Cruz Biotechnology  1:1000 
Actin  C11  Santa Cruz Biotechnology  1:1000 
Table 2.3  Primary antibodies used for Western blot analysis 
 
2.9 Co-Immunoprecipitation 
Antibodies for immunoprecipitation were coupled with either protein A-Sepharose or 
protein G-Sepharose beads (Sigma).  25 µl of packed beads were used per sample and 
beads were washed twice with TBS prior to incubation with the appropriate antibody.  1 
µg of antibodies was used in a final volume of 50 µl and incubated with the beads on a 
shaker for 1 hour at 4°C.  Following incubation, the beads were washed twice with TBS 
to ensure removal of any unbound antibody.  300 µg of cell extract mixed with the 
beads containing bound antibody at 4°C for 3 hours on an orbital shaker.  After the 
incubation, the beads were pelleted by gentle pulse centrifugation and the supernatant 
discarded.  The beads were then subjected to three washes with TBS before the bound 
material was released by the addition of an equal volume of 2 x protein sample buffer 
(125 mM Tris-HCl pH 6.8, 1% (w/v) SDS, 10% (v/v) β-mercaptoethanol, 20% (v/v) Materials and Methods 
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glycerol, 0.25% (w/v) bromophenol blue) and analysed by SDS-PAGE and Western 
blotting. 
2.10 Transient transfection 
2.10.1  Plasmids used for transient transfection. 
Plasmids used for transient transfection of CCL39 or HeLa cells were  pVA1 which 
contains  the  adenovirus  VA1  gene,  peGFP  (Promega),  pcDNA3  expression  vector 
(Invitrogen Life Technologies) and pcDNA3-HABrf1, which encodes wild type Brf1 
(Sutcliffe  et  al.,  2000).    Plasmids  bearing  mutations  (T270A,  T270D,  S450A  and 
S450D)  that  were  introduced  into  pcDNA3-HABrf1  by  PCR-mediated  site-directed 
mutagenesis (as described in section 2.18) were also used for transfection. 
2.10.2  Transfection using lipofectamine 
HeLa and CCL39 cells were transfected using the Lipofectamine reagent (Invitrogen 
Life Technologies).  Transient transfection with lipofectamine required cells to reach a 
confluency of ~75% at the time of transfection.  Two wells of a 6 well plate were 
transfected  per  treatment.    Each  set  of  wells  were  transfected  with  the  appropriate 
plasmid  DNA  (2  µg)  and  0.12  ml  of  OptiMEM  (Gibco)  (volumes  per  well).    In  a 
separate  tube,  0.12  ml  OptiMEM  and  8  µl  lipofectamine  were  mixed  (volumes  per 
well), and these were transferred into the tube containing the plasmid with OptiMEM. 
The contents of the two tubes were pooled and incubated for 45 minutes in the dark at 
room temperature.  During the incubation period, each 6 well plate to be transfected was 
washed with 1 ml of OptiMEM per well, and then 0.76 ml of OptiMEM was added per 
well and the plates incubated at 37ºC.  After the incubation period, 1 ml of the DNA-
OptiMEM-Lipofectamine mix was overlaid dropwise into each well.  The plates were 
gently rocked back and forth to evenly distribute the complexes and then were left for 3 
hours  at  37ºC  in  an  incubator.    The  DNA-OptiMEM-Lipofectamine  mix  was  then 
removed by aspiration from each well and replaced with 3 ml of fresh growth medium.  
Cells were incubated for a further 48 hours to allow expression of the transfected DNA, 
with media being renewed again after 24 hours.  Cells were then harvested and total 
RNA or protein extracted for analysis.  Materials and Methods 
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10 cm dishes were transfected using the same method as the 6-well plates, although, 
volumes were adjusted.  Cells were transfected with 10 µg of plasmid DNA diluted in 
1.5  ml  of  OptiMEM  and  24  µl  Lipofectamine  per  dish.    The  DNA-OptiMEM-
Lipofectamine  mixes  were  incubated  as  before  for  45  minutes  in  the  dark  at  room 
temperature.  During this time, 10 cm plates were washed with 6 ml of OptiMEM and 
4.5 ml of OptiMEM was added until the end of the 45 minute incubation.  At this point, 
the  DNA-OptiMEM-Lipofectamine  mix  was  added  to  each  plate.    Media  on  plates 
containing transfected cells was replaced after 3 hours, and again after 24 hours. RNA 
or protein was extracted 48 hours post-transfection. 
2.11 Primer Extension 
Expression levels of the transfected pol III template VA1 (0.25 µg) and the GFP gene 
(0.25 µg), which was co-transfected as an internal control for transfection efficiency, 
were analysed by primer extension. VA1 (5’-CACGCGGGCGGTAACCGCATG-3’) or 
GFP  (5’-CGTCGCCGTCCAGCTCGACCAG-3’)  oligonucleotides  were  γ-
32P  end-
labelled using T4 polynucleotide kinase (PNK). For each primer extension reaction, 10 
µg of total RNA (made up to 10 µl with DEPC- dH2O) were incubated at 80ºC for 10 
minutes with 9 µl of First Strand Buffer (Invitrogen Life Technologies) and 1 µl of the 
relevant labelled probe to act as a primer.  Samples were immediately transferred to a 
hot block for two hours incubation.  30 µl of an elongation mix containing 1 M DTT, 5 
µl 5 mM dNTP mix (in DEPC- dH2O), 4 mg/ml actinomycin D, 100 U of Superscript II 
Reverse Transcriptase (Invitrogen Life Technologies), was then added to the samples to 
initiate reverse transcription and the reaction was allowed to proceed for 1 hour at 42ºC.  
Reaction  products  were  ethanol  precipitated  overnight,  as  described  in  section  2.8.  
Pellets were resuspended in 4 µl of formamide loading buffer (98% (v/v) formamide, 10 
mM EDTA pH 8.0, 0.025% (w/v) bromophenol blue, 0.025% (w/v) xylene cyanol FF) 
was added to each sample, which was then vortexed for 1 hour to ensure the RNA was 
fully  re-dissolved.    1.5  µl  of  each  sample  was  loaded  on  a  pre-run  7%  (v/v) 
polyacrylamide sequencing gel as described in section 2.4.2.  Quantification of results 
was achieved by densitometry (Total Lab v1.11). Materials and Methods 
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2.12 Chromatin immunoprecipitation (ChIP) assay 
A31 and HeLa cells were grown on 10 cm tissue culture dishes for ChIP assays.  One to 
three  dishes  were  used  per  immunoprecipitation.    To  crosslink  cellular  DNA  and 
proteins,  1%  formaldehyde  was  added  to  each  dish.    Crosslinking  was  allowed  to 
proceed for 10 minutes at 37˚C, then excess glycine was added at a final concentration 
of 0.125 M to stop the crosslinking, and plates were transferred to ice for harvesting.  
Cells were then harvested in the media/formaldehyde/glycine solution, and transferred 
to 50 ml Falcon tubes.  Tubes were centrifuged (in a Sorvall RT 6000 D) at 500g for 5 
minutes at 4˚C. Subsequently the cells were washed twice by resuspension in ice-cold 
PBS, followed by centrifugation at 500g for 5 minutes.  The cell pellets were then 
washed with ice-cold PBS/0.5% NP-40, and then centrifuged at 500 g for 5 hours at 
4°C.  Following removal of supernatant after the final wash, cells were resuspended in 
40 ml of high salt buffer (0.5% NP-40/PBS, 1 M NaCl) and incubated on ice for 30 
minutes.  Cells were then centrifuged at 500g for 5 minutes, and washed once in 0.5% 
NP-40/PBS.  Subsequently, hypotonic disruption was performed by resuspending cells 
in 40 ml of low salt buffer (0.1% NP-40, 10 mM Tris pH 8.0, 1 mM EDTA, 0.1 M 
NaCl) and incubating on ice for 30 minutes.  Following this, samples were centrifuged 
at 500g for 5 minutes at 4˚C, and the resulting pellets resuspended in 1 ml of low salt 
buffer. To obtain nuclei, samples were then passed through a 26-gauge needle three 
times.  The  samples  were  re-centrifuged  as  before,  but  this  time  the  pellets  were 
resuspended  in  2.7  ml  of  low  salt  buffer,  then  lysed  with  300 µl  of  20%  sarkosyl.  
Subsequently,  lysed  nuclei  were  transferred  to  a  sucrose  cushion  (40  ml  low  salt 
buffer/100  mM  sucrose)  and  centrifuged  at  4000g  for  10  minutes  at  4˚C.    The 
supernatant was discarded, and the pellet was resuspended in 3 ml of TE (10 mM Tris 
pH 8.0, 1 mM EDTA).  This 3 ml was then applied to a second sucrose cushion and the 
centrifugation  process  repeated.  The  final  pellet  containing  genomic  DNA  was 
resuspended in 2 ml of TE, and then the DNA was sheared into smaller fragments (1kb 
on average) by sonication (Branson Sonifier 250, 10 X for 10 second intervals, and 30% 
duty cycle). 0.2 ml of 11 X NET buffer (1.65 M NaCl, 5.5 mM EDTA, 5.5% NP-40, 
550 mM Tris pH 7.4) was added to 2 ml of sonicated material, then this was transferred 
to eppendorf tubes for centrifugation at 13000g for 5 minutes.  The supernatants were 
then aliquoted evenly into eppendorf tubes.  Each aliquot was incubated in the presence Materials and Methods 
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of  5  µg  (25  µl)  of  an  appropriate  antibody  overnight  at  4˚C  on  a  rotating  wheel.  
Antibodies used for ChIP analysis are listed in Table 2.4.  As a negative control, one 
aliquot was incubated in the absence of antibody.  10% of the aliquot volume was 
retained for use as an input control. 
The following day, Protein-A-Sepharose beads (Sigma) were added for a further 2 hours 
of incubation, and then recovered on polypropylene columns (Pierce). Columns were 
washed twice in 10 ml of RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 
0.5% deoxycholate, 1% NP-40), twice in 10 ml of LiCl buffer (10 mM Tris pH 8.0, 250 
mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1 mM EDTA pH 8.0) and twice in TE.  
Beads were then transferred to 1.5 ml eppendorf tubes and immunoprecipitated material 
eluted by incubating the beads with 200 µl of 1% SDS/TE on a rotating wheel for 10 
minutes at room temperature.  This was performed twice, and each time the supernatant 
was collected following centrifugation at 13000g for 1 minute.  The pooled supernatants 
along with the inputs were incubated overnight at 42˚C with 0.125 mg/ml Proteinase K 
(Promega)  to  degrade  the  antibodies  and  any  other  proteins  present.    Subsequently, 
genomic  DNA  was  extracted  twice  using  400  µl  phenol/chloroform/isoamylalcohol 
(25:24:1) and once using chloroform alone.  Ethanol precipitation of DNA was achieved 
by adding 1 ml of ethanol and 40 µl of sodium acetate to each sample; the tubes were 
then mixed and stored at -20˚C overnight.  The immunoprecipitated DNA was then 
resuspended in 40 µl TE, and quantified by PCR.  1 µl of immunoprecipitated or input 
DNA was used per PCR reaction following the protocol outlined in section 2.4.2.  PCR 
primers and cycling parameters are indicated in Tables 2.1 and 2.2.  Table 2.4 below 
indicates the antibodies used in the ChIP assays. 
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Protein recognised  Antibody   Supplier 
Brf1  128  In house 
Largest pol III subunit (RPC 
155) 
1900  In house 
TFIIIC110  4286  In house 
CK2β  C40420  BD Transduction Laboratory  
CK2  06-873  Upstate Biotechnology 
Haemagglutinin (HA)  F-7  Santa Cruz Biotechnology 
c-Myc  9E10  Santa Cruz Biotechnology 
TFIIA-γ  FL-109  Santa Cruz Biotechnology 
Table 2.4   Antibodies used for ChIP assays  
 
2.13 Expression of GST fusion proteins 
2.13.1  Plasmids used for expression of proteins 
Full length CK2α cDNA subcloned into the pGEX-2T vector (Amersham) was kindly 
donated  by  Dr  Yves  Goldberg.    Oligonucleotide  primers  were  designed  by  Dr  N. 
Kenneth and Dr J. Fairley to amplify portions of Brf1 (described in table 2.5 below). 
The PCR products were inserted between Bam HI/Xho I sites in the pGEX-4T3 vector 
(Amersham) for bacterial expression.  Furthermore the pGEX-4T3 vector containing the 
Brf1  H2  region  fragment  (table  2.5)  was  used  as  a  template  for  site-directed 
mutagenesis  as  described  in  section  2.18.    The  GST  fusion  proteins  generated  are 
indicated in table 2.6 below. Materials and Methods 
47 
 
Brf1 region  Primer sequence 
Zn-Ribbon 
domain 
F: 5’-GCC GAG GAT CCA TGA CGG GCC GCG TGT GCC-3’ 
R: 5’-GGC TTA CTC GAG TCA GAT GTG GCG CCT CCC ATT CTG-3’ 
 H1 region  F: 5’- CAA GGA TCC CAC CAC CTG GGG AAC CAG CTG-3’ 
 
R: 5’-CGT CGT CTC GAG CTA GAA CTC ATC AAT GGT CCA AC-3’ 
H2 region  F: 5’- GCA GGA TCC GAA GCA GCA GGA AGC C-3’ 
R: 5’-GTG CTC GAG TCA CCG TCG CTT GCA AGA CTT C-3’ 
Table 2.5  PCR primers used for amplifying portions of Brf1. 
 
2.13.2  Protein expression 
Escherichia  coli  BL21  Rosetta  competent  cells  (Invitrogen  Life  Technologies)  were 
used  for  expression  of  recombinant  native  and  mutated  portions  of  Brf1  and  for 
expression of recombinant CK2α.  A single colony of transformed bacteria from the 
appropriate plasmid was grown overnight in 10 ml of LB broth with 100 µg /ml of 
ampicillin and incubated at 37°C in an orbital shaker.  A total of 500 ml of fresh LB 
medium, containing 100 µg/ml of ampicillin was inoculated with 10 ml of the overnight 
pre-culture  and  incubated  at  37°C.    Optimal  protein  production  was  achieved  by 
induction with 0.1 mM IPTG (isopropyl-β-d-thiogalactopyranoside) when the cultures 
had reached an optical density at 600 nm of 0.8.  Cells were harvested by centrifugation, 
at 5000g for 10 minutes, washed once with phosphate-buffered saline, resuspended in 
20 ml of chilled lysis buffer (20 mM HEPES (pH 7)), and broken by three passages of 
30 seconds through the sonicator.  Cell extracts were cleared by centrifugation (10,000 
× g, 15 min, 4°C), and supernatants were divided into aliquots and stored at −80°C until 
they were used. GST and GST fusion proteins were coupled to glutathione agarose Materials and Methods 
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beads  (Sigma)  according  to  the  manufacturer’s  instructions  prior  to  use  for  kinase 
assays or pull down experiments. Materials and Methods 
49 
 
Brf1 portion  Residues (amino acids)  GST fusion protein 
Zn ribbon domain  1-93  GST-ZR 
H1 region  281-397  GST-H1 
H2 region  393-513  GST-H2 
H2  region  bearing 
mutation at S410 
393-513 (S410>A)  GST-H2S410A 
H2  region  bearing 
mutation at S426 
393-513 (S426>A)  GST-H2S426A 
H2  region  bearing 
mutation at S450 
393-513 (S450>A)  GST-H2S450A 
Table 2.6  GST-Brf1 fusion proteins expressed. 
 
2.14 Coomassie staining of SDS-PAGE gels 
When required, after SDS-PAGE, the gels were stained using Coomassie Brilliant Blue 
(5 % (v/v) glacial acetic acid, 45 % (v/v) methanol and 0.25 g/l Coomassie Brilliant 
Blue  R,  which  was  filtered  through  Whatmann  No.1  filter  paper).    The  gel  was 
submerged in stain for approximately 1 hour before rinsing and destaining in the same 
acetic acid/methanol/H2O mixture, without Coomassie dye.  The destaining solution 
was  changed  frequently  until  the  bands  on  the  protein  gel  appeared  sharp  and  the 
background on the gel clear, this typically took 3 hours.  Materials and Methods 
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2.15 Phosphorylation assays 
2.15.1  In vitro kinase assay using GST fusion proteins 
2 µg of recombinant GST protein alone and portions of recombinant Brf1 tagged with 
GST (table 2.6) were bound to glutathione agarose beads (20 µl).  These were incubated 
for 10 minutes at 30ºC in the presence of 50 µg of HeLa cell extract treated with either 
vehicle  (DMSO),  or  with  10  µM  CK2  inhibitors:  TBB,  DMAT  or  quercetin.  
Alternatively,  the  recombinant  proteins  were  incubated  with  250  ng  of  recombinant 
CK2α (New England Bio Labs). Samples were incubated for 15 minutes at 30ºC in a 
master mix containing 20 mM Tris-HCl pH 7.4, 20 µM ATP, 10 mM MgCl2, 1 mM 
DTT and 5 µCi of [γ-
32P] ATP.  The bound fusion proteins were then washed once with 
300 µl TBS/0.1 % (v/v) Triton X-100 (Sigma) and then washed a further twice in 300 µl 
TBS.  The samples were then re-suspended in 2x protein sample buffer, and analysed by 
SDS-PAGE. The amount of 
32P incorporated into GST-Brf1 fragments was assessed by 
autoradiography.  
2.15.2  In vitro kinase assay using synthetic peptides and 
thin layer chromatography. 
Polyetheneimine (PEI)-cellulose thin layer chromatography (TLC) was used to separate 
32P  labelled  synthetic  substrate  peptides  (generated  by  CRUK).    PKA  peptide 
(LRRASLG), CK2 peptide (RRREEETEEE), Brf1 peptide consisting of residues 446 to 
455  (ELDLSGIDDL)  and  Brf1  peptide  consisting  of  residues  554  to  563 
(PHREDAQPEH) were reconstituted in distilled H2O.  50mM concentrations of the 
peptides were incubated at 30°C for 30 minutes, in presence of 750 ng of recombinant 
CK2 (New England Bio Labs) and 15 µl of kinase buffer (20 mM Tris-HCl pH7.4, 20 
µM ATP, 10 mM MgCl2, 1 mM DTT and 15 µCi of [γ-
32P] ATP).  After incubation, the 
reaction was stopped by adding 20 µl of 150 mM phosphoric acid.  5 µl of the samples 
were then spotted onto the anion-exchange TLC plates (Machery-Nagel) that had been 
previously soaked with 0.5 M NaCl for about 5 minutes and rinsed with water.  The 
loaded TLC plates were then air-dried for about 10 minutes.  Chromatography was 
performed using 15 mM phosphoric acid and 0.25 M NaCl as the mobile phase.  The Materials and Methods 
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samples were allowed to migrate for an hour.  The TLC plates were allowed to dry and 
subsequently exposed to X-ray film.  The 
32P-labelled compounds were visualised by 
autoradiography.  
2.15.3  In vitro kinase assay using peptide array 
The Brf1 sequence from amino acids 1 to 677 was divided into 200 overlapping peptide 
fragments, each consisting of 16 amino acids with an offset of 2 amino acids.  The 
peptides were synthesised by CRUK as an array of spots on a cellulose membrane and 
remained covalently attached to the membrane via their carboxyl termini.  The entire set 
of peptide mixtures was incubated with radiolabelled 10 µCi [γ- 
32P] ATP and kinase 
buffer  (20  mM  Tris-HCl  pH7.4,  50  µM  ATP,  10  mM  MgCl2,  1  mM  DTT),  in  the 
absence  or  presence  of  750  ng  of  recombinant  CK2α  (NE  Biolabs).    After  the 
incubation, the membrane was washed five times in 75 mM phosphoric acid for 15 
minutes  and  twice  in  ethanol  for  2  minutes.    The  membrane  was  dried  at  room 
temperature and subjected to autoradiography. 
2.15.4  CK2 activity assay 
CK2  activity  was  assayed  using  synthetic  peptide  [RRRDDDSDDD  (Upstate)]  and 
nuclear  or  cell  extracts  which  have  been  subjected  to  the  various  treatments  (as 
indicated in the figure legends).  Phosphorylation assays were performed in a 30 µl 
reaction volume containing 20 mM Tris-HCl pH 7.4, 20 µM ATP, 10 mM MgCl2, 1 
mM DTT, 5 µCi of [γ-
32P] ATP, 1 mM peptide and 5 µg of protein.  After incubation 
for 15 min at 30°C, reaction mixtures were spotted onto Whatmann P81 ion-exchange 
papers  (Fischer  Scientific).    P81  filters  were  then  washed  three  times  with  75  mM 
phosphoric  acid  and  once  with  acetone.    The  filters  were  allowed  to  air  dry  and 
radioactivity  was  quantitated  with  a  liquid  scintillation  counter.      To  determine  the 
specific 
32P-incorporation  into  the  substrate  peptide,  the  incorporation  of  label  into 
proteins  obtained  in  the  absence  of  the  peptide  was  subtracted  from  the  total 
32P-
incorporation.  
32P incorporated into the sample of interest was expressed as a fold 
change in incorporation relative to the control samples, which were denoted as 1. Materials and Methods 
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2.15.5  Phosphate labelling in vivo 
Labelling  was  carried  out  by  incubating  CCL39  cells  with  0.5  mCi/ml  [
32P] 
orthophosphate for 3 hours in phosphate- free DMEM (Gibco).  After incubation, cells 
were washed twice in 5 ml of ice-cold PBS and then solubilised in 0.25 ml of lysis 
buffer (50mM HEPES pH 7.5, 5 mM EDTA, 10 mM NaF, 150 mM NaCl, 25% (v/v) 
glycerol,  0.5%  (v/v)  Triton  X-100,  0.5  mM  PMSF,  0.5  µg/ml  leupeptin,  0.7  µg/ml 
pepstatin, 0.5 µg/ml aprotinin, 40 µg/ml bestatin, 1 mM sodium vanadate and 50 mM β-
glycerophosphate) and left on ice for 15 minutes.  Samples were then passed through a 
26 gauge needle three times before centrifuging at 13, 000g for 10 minutes at 4ºC to 
pellet the cell debris.  An aliquot of the supernatant was then used in a Bradford protein 
assay  to  determine  protein  concentration  and  250-500  µg  of  protein  was  used  in 
subsequent immunoprecipitation as described in section 2.10. 
2.16 In vitro transcription-translation 
Proteins were synthesised in vitro using the Single Tube Protein System 3 (STP3)-T7 
kit (Novagen) following the manufacturer’s protocol.  Reactions were assembled on ice. 
8 µl of STP3 T7 Transcription Mix was added to 1 µg plasmid DNA to a final reaction 
volume of 10 µl made up with nuclease-free water.  These were incubated at 30ºC for 
20 minutes.  Translation was carried out by adding 30 µl of STP3 Translation Mix and 4 
µl (40 µCi) 
35S-labelled Met, made up to a final reaction volume of 50 µl with nuclease-
free water.  Reactions were gently mixed and incubated at 30ºC for 1 hour.  5 - 10 µl of 
each sample was analysed by SDS-PAGE.  The gel was then incubated with 20 ml of 
amplify  (Amersham)  for  2  hours.    Subsequently  the  gel  was,  Coomassie  stained, 
destained, dried and visualised by autoradiography.  The plasmids used for  in vitro 
transcription-translation  were:  pCDNA3HABrf1  described  in  section  2.10.1  and 
pCDNA3HATBP  (kindly  donated  by  Dr.  Stefan  Roberts);  both  contained  the  T7 
promoter. Materials and Methods 
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2.17 GST pull- downs  
Glutathione S-transferase (GST) fusion proteins were expressed in bacteria and purified 
on glutathione-agarose beads (Sigma) as described in section 2.14.  Equal amounts of 
immobilised GST and GST-fusion proteins (GST-CK2α, GST-H2 and GST-H2S450A; 
described  in  section  2.13.2)  were  used  in  the  pull  down  assays.    25  µl  of  packed 
glutathione beads bearing the GST-fusion proteins or GST alone were incubated with 
100 µg of HeLa nuclear extract in 500 µl of TBS or with 250 µl reticulocyte lysate 
containing either 
35S-labelled Brf1 or TBP.  Samples were incubated on a rotating wheel 
for 1 hour at 4ºC.  Beads were then washed once in 500 µl of TBS/0.25mM NaCl/ 0.5 % 
(v/v) Triton X-100 and followed by a further 4 washes with TBS.  Bound material was 
resolved by SDS-PAGE and either Western blotting or autoradiography was used to 
detect interacting proteins. 
2.18 Site-directed mutagenesis.  
Mutant forms of Brf1were prepared by using the plasmid pGEX-4T3 H2 (Brf1) and/or 
pcDNA3HA  Brf1  as  the  double  stranded  DNA  templates.    PCR-based  mutagenesis 
(Quik-Change site-directed mutagenesis kit; Stratagene) was used for all mutations.  For 
each mutant, synthetic oligonucleotide primers were designed containing the desired 
mutation.  The primers used to create mutants of Brf1 are described in table 2.7 below.  
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Enzyme mutation  Primer 
S410A  5’- CCGGCCCTGGGGGCCCTGCTGCACCC-3’ 
S426A  5’- GGCATCTCAGACGCCATCCGGGAATGC-3’ 
S450A  5’- AGCTGGACCTCGCTGGCATTGATGACCTG-3’ 
S450D  5’- AGCTGGACCTCGATGGCATTGATGACCTG-3’ 
T270A  5’- CGGAATTTGAAGACGCCCCCACCAGTCAGTTG 
3’ 
T270D  5’- CCGAATTTGAAGACGACCCCACCAGTCAGTTG-
3’ 
Table 2.7  Primers used in PCR to obtain each of the desired mutations  
 
Thermal cycling was used to extend the oligonucleotide primers.  The mutant strand 
synthesis reactions for thermal cycling were in a final volume of 25 µl and contained 
2.5 µl of 10X Quik-Change 
TM Multi reaction buffer, 0.75 µl QuikSolution, 1µl (stock 
100ng/µl) of double stranded-DNA template, 1 µl of mutagenic primers, 1 µl of dNTP 
mix and 1 µl of Quik-Change 
TM Multi enzyme blend.  The cycling parameters were 
95ºC for 1 minute and then 30 cycles of 95ºC for 1 minute, 55ºC for 1 minute, and 65ºC 
for 10 minutes.  Following the temperature cycling, the reaction was placed on ice for 2 
minutes to cool the reaction to below 37ºC.  Dpn 1 restriction enzyme (10U/µl) was 
added to each amplification reaction to digest the parental (non-mutated) DNA template 
and  immediately  incubated  at  37ºC  for  1  hour.    All  recombinant  plasmids  were 
propagated into XL-10 Gold 
® ultracompetent cells (Stratagene).  The entire gene was 
sequenced to confirm the desired mutation and to check PCR fidelity. 
2.18.1  Specificity of phosphorylation site specific antibody 
2.18.2   Antibody production 
Two antibodies were raised by immunising rabbits with an 11-amino-acid synthetic 
peptide  of  human  Brf1  containing  residues  444  to  460  coupled  to  keyhole  limpet Materials and Methods 
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haemocyanin  (Eurogentec,  Belgium).    One  antibody  was  specific  to  the  non-
phosphorylated peptide sequence (non-phosphoS450Brf1) and the other was specific to 
the  peptide  in  which  the  S  at  position  450  was  converted  to  phosphoS 
(phosphoS450Brf1)  
2.18.3  Peptide competition assay 
100 mM of phosphorylated and non-phosphorylated peptides [SHYD (p) SDGDKSD] 
and an equal volume water control were pre-incubated with aliquots of 0.5 µg/ml of the 
phosphoBrf1S450 specific antibody prior to use in the immunoassay procedures. The 
tubes were incubated for 30 minutes at room temperature with gentle rocking. In the 
meantime  HeLa  nuclear  extracts  were  resolved  by  SDS-PAGE  and  transferred  onto 
nitrocellulose (as described in section 2.9). The pre-incubated antibody in each of the 
three tubes was then ready for use.  The contents of each tube were pipetted onto the 
three identical nitrocellulose strips.  The strips were then subjected to Western blotting 
as described in section 2.9.2.  This procedure was repeated using total Brf1 (antiserum 
128-4; table 2.3). 
2.18.4  Alkaline phosphatase treatment 
Cell lysates from A31 and HeLa cells were treated with a final concentration of 1 U/µl 
of alkaline phosphatase (Roche) and subjected to Western blotting.  
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3  RNA Polymerase III Transcription is Activated 
by Protein Kinase CK2 
3.1 Introduction 
CK2 has been implicated in a number of essential cellular processes such as cell growth 
and proliferation [reviewed in (Guerra and Issinger, 1999)].  The significance of CK2 in 
cell growth is highlighted by an elevation in CK2 activity in some transformed cells 
compared to normal cells (Prowald et al, 1984; Rose et al, 1981).  Furthermore, in 
response to stimulation by insulin, epidermal growth factor (Klarlund and Czech, 1988; 
Sommercorn  et  al,  1987)  or  to  serum  (Orlandini  et  al,  1998,  Carroll  and  Marshak, 
1989), mammalian cells showed an increase in the activity of CK2.  In mammalian cells 
the use of antisense oligonucleotides (Pepperkok et al, 1991), microinjected antibodies 
that partially disrupt function of CK2 (Lorenz et al, 1993) and expression of kinase 
deficient CK2α’ (Vilk et al, 1999) all give rise to an inhibition of proliferation.  
The  growth-related  functions  of  CK2  are  supported  by  its  participation  in  the 
phosphorylation of a large number of substrates in the cell, many of which are proteins 
found in the nucleus which are involved in gene expression and cell growth [reviewed 
in Olsten and Litchfield, 2004].  The pol III machinery has been also been shown to be a 
target of phosphorylation by CK2 (Johnston et al, 2002; Ghavidel and Schultz, 1997; 
Hockman et al, 1996).  In S. cerevisiae, a biochemical complementation approach using 
conditionally CK2-deficient mutants was used to show that when a yeast strain carrying 
a temperature sensitive version of CK2 α’ is shifted to the non-permissive temperature, 
both growth and pol III transcription are selectively impaired (Hockman et al, 1996; 
Ghavidel et al, 1999).  The addition of TFIIIB was sufficient to rescue transcription in 
CK2α’ mutant cell extracts and dephosphorylation of TFIIIB by phosphatase treatment 
greatly reduced this effect (Ghavidel and Schultz, 1997).  Ghavidel and co-workers 
(1997) identified the TBP subunit of TFIIIB as the target of phosphorylation by CK2.  
The phosphorylation of TBP by CK2 is required for efficient association of TFIIIB with 
TFIIIC on type II promoters during the assembly of the pre-initiation complex on the 
promoter in yeast (Ghavidel and Schultz, 1997; Ghavidel et al, 1999). RNA Polymerase III is Activated by Protein Kinase CK2 
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The TAF components of TFIIIB, Brf1 (Johnston et al., 2002) and Bdp1 (Hu et al., 2004) 
have also been shown to be phosphorylated by CK2 in mammalian cells.  In 2002, 
Johnston  and  co-workers  showed  that  CK2  could  activate  pol  III  transcription  by 
binding  and  phosphorylating  TFIIIB  (Johnston  et  al.,  2002).    In  contrast, 
phosphorylation of Bdp1 has been shown to be inhibitory to pol III transcription (Hu et 
al.,  2003  and  Hu  et  al.,  2004).    Hu  and  co-workers  (2003)  used  a  minimal  pol  III 
transcription system composed of purified pol III enzyme and recombinant transcription 
factors SNAPc, Brf2-TFIIIB and TFIIIC which are required for transcription of genes 
with  type  III  promoters  (e.g.  human  U6  gene)  to  investigate  the  role  of  CK2  in 
regulating  transcription  by  pol  III  at  these  promoters.    Using  this  system  they 
demonstrated that both the pol III enzyme complex and Brf2-TFIIIB were targets of 
CK2 phosphorylation (Hu et al., 2003).  In 2004, Hu and co-workers established that the 
Bdp1 component of Brf2-TFIIIB is phosphorylated by CK2 during mitosis, and that this 
is accompanied by Bdp1 dissociation from the U6 promoter, giving rise to transcription 
repression.    However,  they  also  revealed  that  despite  having  an  inhibitory  role  in 
mitosis, CK2 can stimulate transcription by pol III in S phase by phosphorylating pol III 
itself.  They suggested that CK2 can be aimed to phosphorylate different targets within 
the basal pol III transcription machinery at different times during the cell cycle, with 
opposite transcriptional effects (Hu et al., 2004) (discussed further in Chapter Six). 
This  thesis  aims  to  further  characterise  the  role  of  CK2  in  the  activation  of  genes 
transcribed by pol III using type I and II promoters.  Work done in this chapter will not 
only reinforce observations made by Johnston and co-workers, but with the use of a 
newly  developed  CK2  inhibitor, 2 -dimethylamino-4,5,6,7-tetrabromo-1-H-
benzimidazole (DMAT), will demonstrate a more specific role for CK2 in the activation 
of  transcription  by  pol  III.    The  results  in  this  chapter  demonstrate  that  CK2  does 
activate  pol  III  transcription  in  human  cells  and  murine  fibroblasts  that  Brf1  is 
phosphorylated by CK2 in vivo, and that CK2 binds to TFIIIB. RNA Polymerase III is Activated by Protein Kinase CK2 
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3.2 Results 
3.2.1 CK2 activates pol III transcription in vitro 
To explore the role of CK2 in the regulation of transcription by pol III, it was necessary 
to  verify  that  reducing  CK2  activity  would  have  an  effect  on  pol  III  transcription.  
Johnston et al (2002) and Hu et al (2003; 2004) demonstrated a role for CK2 on pol III 
transcription, based on the use of kinase inhibitors such as quercetin and LY290042 
respectively.  Since the publication of these studies, more efficient inhibitors both in 
terms of potency and selectivity 4, 5, 6, 7-tetrabromo-1H-benzotriazole (TBB) and the 
TBB derivative DMAT have become commercially available.  These inhibitors are cell 
permeable, can bind to the hydrophobic pocket adjacent to the ATP/GTP binding site of 
CK2 and have been tested against a panel of ~30 kinases (Sarno et al, 2002; Pagano et 
al,  2004;  Sarno  et  al,  2005).    This  chapter  presents  data  obtained  using  these  two 
inhibitors, as well as data obtained using quercetin and LY290042. 
In  the  first  instance,  CK2  activity  was  repressed  using  a  specific  inhibitor  DMAT 
(Figure 3.1).  Indeed, Figure 3.1A shows that when 10 µM DMAT was pre-incubated 
with  HeLa  nuclear  extracts  for  15  minutes,  it  significantly  reduced  CK2  activity 
compared to the control DMSO-treated nuclear extracts.  An in vitro transcription (IVT) 
assay was performed and Figure 3.1B shows that the addition of 10 µM DMAT to HeLa 
nuclear extracts dramatically decreased transcription of a tRNA
Leucine (tRNA
Leu) gene 
and the adenoviral VA1 gene (lane 2) compared to the control samples (lane 1). RNA Polymerase III is Activated by Protein Kinase CK2 
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Figure 3.1.  DMAT blocks VA1 and tRNA expression in vitro 
A: CK2 activity assay of HeLa extracts in absence or presence of 10 µM DMAT. 
The activity of the control extracts was normalised to 100% and the activity of the 
treated extracts as a percentage of the control (bar graph, standard deviation of 3 
determinations).  B: Transcription using HeLa cell nuclear extract (15 µg) and a 
pLeu template (250 ng) or with pVA1 template (250 ng) after preincubation for 15 
min at 30°C with DMSO (lane 1), or with 10 µM DMAT (lane 2). 
An alternative manner in which CK2 activity was specifically reduced was by using a 
CK2 phosphoacceptor competitive substrate peptide.  The CK2 activity assay shown in 
Figure 3.2A confirmed that CK2 phosphorylates efficiently the CK2 substrate peptide 
and but not the control protein kinase A (PKA) peptide.  Figure 3.2B shows that pol III 
transcription  of  the  VA1  gene  and  tRNA
Leu  gene  templates  were  repressed  after 
preincubation of HeLa nuclear extracts with the CK2 phosphoacceptor peptide (Figure 
3.2B, lane 3).  This effect is highly specific, since expression of both pol III templates 
was  virtually  unaffected  by  equal  amounts  of  peptides  bearing  consensus 
phosphoacceptor sites for PKA (Figure 3.2B, lane 2).  From Figures 3.1 and 3.2, it can 
be  concluded  that  in  human  cell  extracts  CK2  exerts  a  strong  effect  on  pol  III 
transcription in vitro. RNA Polymerase III is Activated by Protein Kinase CK2 
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Figure 3.2.  CK2 phosphopeptide blocks VA1 and tRNA expression in vitro 
A:  CK2  activity  assay  using:  no  peptide,  CK2  peptide  or  PKA  peptide.    B: 
Transcription using HeLa nuclear extract (15 µg) a pVA1 template (250 ng) or 
pLeu  template  (250  ng)  after  preincubation  for  15minutes  at  30°C  with  buffer 
(lane  1)  or  with  30  µg  of  PKA  phosphoacceptor  peptide  (lane  2)  or  CK2 
phosphoacceptor peptide (lane 3). RNA Polymerase III is Activated by Protein Kinase CK2 
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3.2.2 CK2 activates pol III transcription in cultured mammalian 
cells 
To determine whether CK2 exerts an effect in vivo, several techniques were used to 
demonstrate that the inhibition of CK2 by DMAT results in a decrease in the level of 
class III transcripts.  In the first instance, Northern blotting was performed using RNA 
obtained from cells, which had been treated with increasing amounts of DMAT (5 to 50 
µM) or DMSO alone (control).  The experiment revealed that expression of the pol III 
transcript derived from the B2 middle repetitive gene family is reduced with addition of 
DMAT (Figure 3.3, lanes 2-5) in comparison to the control (Figure 3.3, lane 1).  This 
effect is specific, since the level of acidic ribosomal phosphoprotein P0 (ARPP P0) 
mRNA control is relatively unaffected by the treatment.  B2 RNAs have very short half-
lives  (less  than  5  minutes)  (Bladon  et  al,  1990),  and  therefore  an  increase  in  their 
abundance is indicative of the rate of ongoing transcription by pol III. RNA Polymerase III is Activated by Protein Kinase CK2 
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Figure 3.3.  DMAT  reduces  the  expression  of  the  B2  pol  III  transcript  in 
proliferating murine fibroblasts.  
A: Northern blot analysis of total RNA (10 µg) from A31 cells cultured in 10% 
serum and treated with 5 µM, 10 µM, 25 µM and 50 µM DMAT (lanes 2, 3, 4 and 5 
respectively) or DMSO alone (lane 1).  The upper panel shows the blot probed with 
a  B2  gene;  the  lower  panel  shows  the  same  blot  that  has  been  stripped  and 
reprobed with an ARPP P0 gene.  B: The B2 and ARPP P0 levels were quantified 
by densitometry and B2 levels were normalised to ARPP P0. 
As described in Chapter One, pol III transcribes a variety of genes in addition to B2.  To 
assess the effect of DMAT on the expression of a range of other pol III-transcribed 
genes, semi-quantitative RT-PCR analysis was used.  As previously, cells were treated 
with  DMAT.    Figure  3.4A  shows  a  decrease  of  around  45-50%  in  CK2  activity RNA Polymerase III is Activated by Protein Kinase CK2 
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following treatment with 50 µM DMAT.  The RNA was extracted from the treated and 
untreated cells and then analysed by RT-PCR using primers specific for various pol III 
templates.    This  experiment  revealed  a  decrease  in  tRNAs  tyrosine  (tRNA 
Tyr)  and 
Leucine  (tRNA
Leu)  (Figure  3.4B,  lane  2)  in  the  cells  treated  with  50µM  DMAT 
compared to the control cells (DMSO) (Figure 3.4B, lane 1).  The primers used to 
measure RNA levels were designed to hybridise to rapidly processed introns within the 
nascent tRNA transcripts.  The levels of tRNA
Tyr and tRNA
Leu provide a direct measure 
of transcriptional output (Winter et al, 2000).  
 
Figure 3.4.   DMAT reduces the levels of tRNA
Leu and tRNA
Tyr in vivo. 
A: CK2 activity assay of A31 cells treated with 50 µM DMAT. B: Specific primers 
for the transcripts indicated were used to PCR amplify cDNAs generated from 
total RNA of cultured cells treated with 50 µM DMAT. 
The decrease in various pol III transcripts following CK2 inhibition as determined by 
Northern blotting and RT-PCR analysis indicates that pol III transcription is activated 
by CK2.  In particular, the increase in intron-containing tRNAs directly demonstrated 
an induction of transcription by pol III.  This may have been due to an increase in the 
intrinsic activity of pol III transcription machinery.  To directly test whether the pol III 
machinery was more active following CK2 inhibition, IVTs were performed.  Whole 
cell extracts were prepared from DMAT-treated cells (Figure 3.5, lanes 2-5) and control RNA Polymerase III is Activated by Protein Kinase CK2 
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DMSO-treated  cells  (Figure  3.5,  lane  1)  and  were  incubated  in  presence  of  the  a 
tRNA
Leu template for 1 hour at 30 ºC.  RNA produced was resolved on a 7% acrylamide 
gel and in vitro transcription of pol III template tRNA
Leu was examined. 
 
Figure 3.5.  DMAT reduces pol III activity in proliferating murine fibroblasts. 
In vitro transcription assay using extracts (15 µg) from A31 cells cultured in 10% 
serum and treated with 5 µM, 10 µM, 25 µM and 50 µM DMAT (lanes 2, 3, 4 and 5 
respectively) and a pLeu template (250 ng). 
This  experiment  showed  that  pol  III  transcriptional  activity  was  higher  in  extracts 
derived from control cells (Figure 3.5, lane 1) compared to the DMAT-treated cells 
(Figure 3.5, lanes 2-5), this supports the conclusion that pol III transcription is activated 
by CK2.  
3.2.3 Brf1 is phosphorylated by CK2 
The data indicates that CK2 kinase activity has a strong stimulatory effect on pol III 
transcription both in vitro and in vivo.  The next set of experiments was to test whether 
any components of the pol III machinery are phosphorylated by CK2.  Brf1 has been 
shown  to  be  limiting  for  pol  III  transcription  in  yeast  (Sethy-Coraci  et  al,  1998).  
Indeed, Johnston and co-workers (2002) demonstrated that Brf1 is phosphorylated in 
vivo in Chinese hamster ovary (CHO) cells.  Figure 3.7 below investigates whether Brf1 
is  phosphorylated  in  Chinese  hamster  lung  fibroblast  (CCL  39)  cells.    To  examine RNA Polymerase III is Activated by Protein Kinase CK2 
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whether Brf1 is subject to phosphorylation in vivo, CCL39 cells were transfected with a 
vector encoding HA-tagged Brf1 (pBrf1).  The cells were cultured in the presence or 
absence  of  the  CK2  inhibitor  quercetin.    The  cells  were  then  labelled  with  [
32P] 
orthophosphate,  harvested  and  subjected  to  immunoprecipitation  with  an  anti-HA 
antibody.    The  precipitated  material  was  resolved  by  7.8%  SDS-PAGE  and  the 
experiment  revealed  that  Brf1  is  phosphorylated  in vivo  in  CCL39  cells.    Western 
blotting  confirmed  that  equal  amounts  of  Brf1  were  immunoprecipitated  in  each 
instance.  
 
Figure 3.6.  Brf1 is phosphorylated in vivo. 
CCL 39 cells growing in 10% FBS were transiently transfected with pBrf1 and 
labelled  48  hours  later  with  [
32P]  orthophosphate  for  2  hours  in  absence  or 
presence  of  60  µM  quercetin.    Cell  extracts  were  prepared  and  Brf1  was 
immunoprecipitated with anti-HA antibody F-7 transferred to nitrocellulose and 
visualised by autoradiography (top panel) or by Western blotting (lower panel). 
These findings confirm that CK2 contributes to the phosphorylation of Brf1 in vivo and 
that this phosphorylation is not restricted to CHO cells. 
The Target of Rapamycin (TOR) kinases, have also been shown to activate pol I and pol 
III transcription in yeast (James et al, 2004 and Zaragoza et al, 1998) and addition of the 
specific macrolide inhibitor of mTOR rapamycin to mammalian cells has been shown to 
decrease pol III transcription (Unpublished data, E. Graham, B. Ramsbottom and R.J. 
White).    The  TOR  kinases  can  co-ordinate  nutrient  availability  and  the  protein 
biosynthetic capacity of the cell, Figure 3.8 below show a simplified diagram of the RNA Polymerase III is Activated by Protein Kinase CK2 
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mTOR  pathway,  whereby  it  can  regulate  the  synthesis  of  ribosomal  proteins  and 
expression of ribosomal RNA. RNA Polymerase III is Activated by Protein Kinase CK2 
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Figure 3.7.  The  mammalian  target  of  rapamycin  (mTOR)  signalling  pathway 
activates pol III and pol I transcription. 
Activation of phosphatidylinositol 3-kinase (PI3K) by growth factors signals the 
cell to grow and proliferate; this signal is transmitted through the cell by Akt/PKB 
to mTOR.  Activation of the PI3K/Akt/mTOR pathway by growth factors controls 
protein  synthesis  at  the  level  of  translation  initiation  and  ribosome  biogenesis.  
Upon  stimulation,  mTOR  activates  proteins  via  phosphorylation  involved  in 
translation  such  as  ribosomal  S6  kinase  (S6K).    In  this  simplified  cartoon  Akt 
modulates  the  activity  of  transcription  factors  important  for  pol  I  and  pol  III 
activity and rRNA synthesis, thereby regulating ribosome biogenesis and global 
protein synthesis.  Rapamycin specifically inhibits mTOR and LY290042 inhibits 
PI3K (Adapted from Mayer and Grummt, 2006). 
 RNA Polymerase III is Activated by Protein Kinase CK2 
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In vivo  labelling  experiments  were  performed  to  check  whether  mTOR  could  also 
influence  Brf1  phosphorylation.    To  test  this  an  in  vivo  labelling  experiment  was 
performed whereby CCL39 cells were transfected with mammalian expression vector 
(pBrf1) and cultured in the presence or absence of rapamycin (Figure 3.9A, lane 3) or 
with LY290042 (Figure 3.9A, lane 4).  The cells were subsequently labelled with [
32P] 
orthophosphate,  harvested  and  subjected  to  immunoprecipitation  with  an  anti-HA 
antibody.  Figure 3.8A shows that Brf1 does not appear to be phosphorylated by mTOR, 
since no change in 
32P incorporation can be detected with the addition of rapamycin, 
which  specifically  inhibits  mTOR,  nor  with  LY290042.    This  suggests  that  mTOR 
could influence pol III transcription via a different target of the pol III machinery.   
In yeast the FKBP binding protein FKBP25 (Figure 3.7) can be found in complex with 
the CK2 and CK2 can phosphorylate one member of the FKBP family (Wilson, 1997 
and  Litchfield,  1993),  this  evidence  suggested  the  possibility  that  rapamycin  could 
influence pol III transcription in a CK2-dependent manner.  Figure 3.8C shows a CK2 
activity assay to test whether extracts from rapamycin treated cells have reduced CK2 
activity.  The results show that CK2 activity is almost identical in extracts from control 
and treated cells, arguing that rapamycin does not exert its effect on pol III transcription 
by reducing CK2 activity.   
LY290042 has been suggested to be a potential CK2 inhibitor (Davies et al, 2000), in 
this experiment the activity assay in Figure 3.7C demonstrates that there is little or no 
effect on the CK2 activity when cells had been treated with LY290042.  The Western 
blots in Figure 3.8B show that both the rapamycin and LY290042 were active since the 
phosphorylation of S6 Kinase was ablated with the addition of LY290042 and with the 
addition of rapamycin (Figure 3.8B, top panel), although the levels of total S6 Kinase 
were essentially unaffected (Figure 3.8B, second panel). 
Since the PI3K has been linked to the Erk pathway, the levels of phosphorylation of Erk 
were also verified for any variations as it has been shown that Erk can phosphorylate 
Brf1  (Felton-Edkins,  2003).    Figure  3.8B  (third  panel)  shows  that  the  levels  of 
phosphoErk in lane 2 are decreased slightly with the addition of LY290042 and that 
rapamycin does not affect the levels of phosphoErk in lane 3.  The bottom panel shows 
no change in the levels of total Erk.  RNA Polymerase III is Activated by Protein Kinase CK2 
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Figure 3.8.   Brf1 is not phosphorylated in vivo by mTOR. 
(A) CCL 39 cells growing in 10% FBS were transiently transfected with pBrf1 and 
labelled  48  hours  later  with  [
32P]  orthophosphate  for  2  hours  in  absence  or 
presence  of  rapamycin.    Cell  extracts  were  prepared  and  Brf1  was 
immunoprecipitated with an anti-HA antibody F-7, transferred to nitrocellulose 
and  visualised  by  autoradiography  (top  panel)  or  by  Western  blotting  (lower 
panel).  (B) Cell extracts were prepared and also subjected to Western blotting 
with  an  antibody  against  phospho  S6  kinase  and  total  S6  kinase  and  against 
phospho-Erk (p42/44) and total Erk (p42/44). (C) Cell extracts were also subjected 
to a CK2 activity assay following treatment with either DMSO alone, rapamycin or 
LY290042. RNA Polymerase III is Activated by Protein Kinase CK2 
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3.2.4 CK2 binds TFIIIB 
To  investigate  whether  CK2α  interacts  with  TFIIIB,  GST  pull  down  assays  were 
performed, whereby in vitro translated full length Brf1 and TBP were tested for binding 
to a GST-CK2α fusion protein (Figure 3. 9).  This experiment revealed that CK2α can 
directly interact with full length Brf1 and TBP (Figure 3.9, lane 3) but not to GST alone 
(Figure 3.9, lane 2).  Having established that CK2 interacts with TFIIIB in vitro, the 
interaction between native TFIIIB and CK2 was further analysed.  
 
Figure 3.9.  Interaction of TFIIIB and CK2α in vitro. 
Aliquots  of  5  µg  of  purified  GST  or  GST-CK2α  were  incubated  with  40  µl  of 
glutathione Sepharose beads as described in Chapter Two.  The TFIIIB subunits 
TBP  and  Brf1  were  produced  in  reticulocyte  lysate  using  the  TnT  T7  in  vitro 
transcription/translation system (Promega).  The newly synthesised proteins were 
labelled with [
35S] methionine and 5 µl of lysate were used in each reaction.  The 
precipitated  proteins  were  applied  to  SDS–PAGE;  0.5  µl  of  lysate  was  used  as 
input shown above. 
HeLa nuclear extract were immunoprecipitated with an anti-CK2α antibody and an anti-
TFIIA antibody.  The beads were then washed as described in Chapter Two and the 
bound material was analysed by Western blotting using an anti-Brf1 antibody.  Figure 
3.10  revealed  that  Brf1  can  specifically  interact  with  CK2α  (Figure  3.10,  lane  2) 
whereas Brf1 was not detected in lane 3, where anti-TFIIA was used as a negative 
control. RNA Polymerase III is Activated by Protein Kinase CK2 
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Figure 3.9.  Interaction of endogenous TFIIIB with CK2α. 
HeLa  nuclear  extract  (250µg)  was  immunoprecipitated  with  an  anti-CK2α 
antibody  and  a  negative  control  antibody  against  TFIIA.    The  precipitated 
material was resolved by SDS- PAGE and analysed by Western blotting using an 
anti-Brf1 antibody. 
 
From  the  data  in  Figures  3.9  and  3.10  it  can  be  concluded  that  CK2α  can  bind  to 
isolated TFIIIB subunits Brf1 and TBP in vitro and to endogenous TFIIIB. RNA Polymerase III is Activated by Protein Kinase CK2 
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3.3  Discussion 
This chapter supports the findings that the protein kinase CK2 can activate transcription 
of genes by pol III in mammalian cells.  Indeed, several research groups have shown 
that CK2 activity is required for efficient transcription by pol III in S. cerevisiae and in 
mammals (Hockman et al, 1996; Johnston et al, 2002 and Hu et al, 2003).  Disruption of 
CK2 causes the synthesis of tRNA and 5S rRNA to decline 80-90% in yeast (Hockman 
et al, 1996).  With the use of a very specific cell permeable inhibitor of CK2, DMAT 
(Pagano et al, 2004), Northern blotting, RT-PCR analysis and IVTs presented in this 
chapter,  revealed  that  specific  inhibition  of  CK2  by  DMAT  is  accompanied  by  a 
decrease in pol III transcription.  CK2 is a highly conserved protein and regulates pol III 
transcription in both yeast and mammals.  The conservation of this control suggests that 
CK2 may be a crucial regulator of pol III transcription. 
This study shows that Brf1 is subject to phosphorylation in vivo, when CCL39 cells 
were treated with the CK2 inhibitor quercetin there was a decrease in phosphorylation 
of Brf1.  This supports in vivo labelling experiments done in CHO cells by Johnston and 
co-workers (2002) and also demonstrates that it is not cell type-specific.  One common 
theme that emerges from the data is that CK2 can phosphorylate and regulate TFIIIB 
complexes in both yeast and mammals.  In S. cerevisiae, only TBP is phosphorylated by 
CK2 in vitro and in vivo, and it was concluded that the phosphorylation of TBP is 
responsible for the activation of TFIIIB by CK2.  Ghavidel and Schultz identified S128 
which is found on the surface of TBP, as a potential CK2 target.  Although a serine is 
found at the corresponding position of human TBP (S222), its surrounding residues do 
not match the CK2 consensus (S/Txxacidic where n=3 is the acidic residue).  Other 
residues in TBP might be phosphorylated by CK2 in humans; however, in vitro kinase 
assays from Hu et al (2004) showed that mammalian TBP does not seem to be target for 
phosphorylation  by  CK2,  despite  the  presence  of  CK2  phosphoacceptor  sites  found 
within TBP.  Transcription of the human U6 gene (which has a type III promoter) by 
pol  III  can  be  activated  by  CK2  following  phosphorylation  of  the  pol  III  enzyme 
complex itself (Hu et al, 2003).  These studies were performed using purified pol III and 
were done in vitro only, and it remains to be verified whether this applies to all class III 
genes and whether the pol III complex is phosphorylated in vivo.  RNA Polymerase III is Activated by Protein Kinase CK2 
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The TOR kinases can stimulate pol III transcription in yeast (Zaragoza et al, 1998), and 
there  is  evidence  that  this  signalling  pathway  can  also  influence  pol  III  activity  in 
mammals (unpublished data, E. Graham, B. Ramsbottom and R.J.White).  In this study 
Figure 3.9 shows that Brf1 does not appear to be subject to phosphorylation by mTOR, 
since there is no significant change in 
32P incorporation of Brf1 with the addition of 
rapamycin.  Their data have revealed that it is in fact the TFIIIC component of the pol 
III machinery which is subject to phosphorylation by mTOR.  Although CK2 has been 
found to bind to FKBP25 (Pinna et al, 1995), the CK2 activity assay in Figure 3.9 does 
not show considerable variations in activity when rapamycin is added which implies 
that the effects of rapamycin on pol III transcription appear to be CK2-independent.  
LY290042 has been used as a CK2 inhibitor (Davies et al, 2000 and Hu et al, 2003), but 
in this study no significant changes in CK2 activity were observed when LY290042 was 
added to proliferating cells.  In this experiment (Figure 3.9), LY290042 does not appear 
to  be  an  efficient  CK2  inhibitor,  even  though  it  is  able  to  inhibit  the  PI3K/mTOR 
pathway as shown in the Western blots. 
The next sets of experiments performed were to verify the associations of CK2 and 
TFIIIB.    CK2  and  Brf1  were  found  to  interact,  which  is  consistent  with  previous 
findings  (Johnston  et  al,  2002).    In  vitro,  CK2  was  also  shown  to  bind  to  TBP, 
consistent with yeast studies (Ghavidel et al, 1997). 
Pol I and pol III together are responsible for ~80% of RNA synthesis in cells and are 
often  subject  to  tight  co-regulation.    CK2  has  been  implicated  in  activation  of 
transcription by pol I both in mammals and in yeast (Johnston et al, 2002; Hockman et 
al, 1996).  The fact that CK2 can regulate transcription by pol I and pol III suggests that 
CK2 plays an important role in controlling the overall biosynthetic capacity of the cell. 
Having confirmed that pol III transcription is activated by CK2 in mammalian cells, the 
next  aims  of  the  project  were  to  determine  which  particular  residue(s)  of  Brf1  are 
phosphorylated by CK2, which will be investigated in the following chapter.  
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4  Serine 450 of Brf1 is Phosphorylated by CK2 
in vitro and in vivo. 
4.1  Introduction 
CK2 is rather unusual among the protein kinases in that it can use both ATP and GTP as 
phosphate donors (Allende and Allende, 1995).  The minimum consensus sequence for 
phosphorylation by CK2 is denoted by: S/T-X-X-D/E where X represents any residue 
and glutamate (E) or aspartate (D) can be found at the n + 3 position (Allende and 
Allende, 1995; Meggio et al., 1994).  However, the E or D at the third position can 
however be replaced by phosphoserine (Litchfield et al., 1990; Meggio et al., 1992) or 
phosphotyrosine (Meggio et al., 1991) but not phosphothreonine (Litchfield et al., 1990; 
Meggio et al., 1991).  There are thirteen consensus sites for CK2 in Brf1 which are T12, 
S30, T245, T265, T276, S323, S351, T365, S410, S426, S450, T520, and S580 (Figure 
4.1). 
Brf1 is a subunit of TFIIIB which is required for the recruitment of the pol III to the 
promoter.    It  consists  of  677  amino  acids  and  has  a  predicted  molecular  weight  of 
around  90  kDa  (Wang  and  Roeder,  1995).  Figure  4.1  shows  a  simplified  linear 
representation of Brf1 and highlights its key domains.  The amino (N)-terminal Zinc 
(Zn) binding domain which contains a sequence motif of Cys-X2-Cys-X15/17-Cys-X2-
Cys  (where  X=  any  residue  and  Cys=  Cysteine)  and  adopts  a  Zn  ribbon  structure 
(Colbert and Hahn, 1992).  The “core domain” consists of two imperfect repeats, which 
can  bind  to  TBP  (Juo  et  al,  2003).  T he  carboxyl  (C)-  terminal  half  of  Brf1which 
contains  three  homology  regions  designated  H1,  H2  and  H3,  which  are  also  well 
conserved and found in yeast (White, 2002).  The H2 region of Brf1 has also been 
shown to bind to TBP (Juo et al., 2003). Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.1.  Schematic linear illustration of the structure of mammalian Brf1. 
The regions of Brf1 are the Zn binding motif (ZR, residues 6-27), repeats 1 and 2 
(residues:  100-173;  193-266),  the  homology  regions:  H1  (residues:  291-308),  H2 
(residues: 423-504), H3 (residues: 520-546).  The arrows indicate the 13 possible 
CK2 targets within Brf1. 
The MAP kinase Erk can induce pol III transcription by binding and phosphorylating 
Brf1 (Felton-Edkins et al., 2003a).  This enhances the interaction of TFIIIB with both 
TFIIIC and pol III, resulting in an increase in pol III transcription (Felton-Edkins et al., 
2003a).  In mitosis, Brf1 is phosphorylated (Fairley et al., 2003) and unpublished data 
(J.Fairley  and  R.J.White)  suggest  that  Plk1  is  the  kinase  responsible.    Mitotic 
phosphorylation  of  Brf1  results  in  a  weakened  interaction  with  Bdp1,  which  can 
compromise  the  recruitment  of  pol  III  to  the  promoter  and  inhibit  class  III  gene 
expression (Fairley et al., 2003). 
To better understand the functional significance of the phosphorylation of Brf1 by CK2, 
it is important to identify the phosphorylation sites involved.  The aim of the work 
presented in this chapter was to identify the residue(s) phosphorylated by CK2 using 
several  approaches,  such  as  peptide  array,  glutathione-S-transferase  (GST)  fusion 
proteins, small synthetic Brf1 peptides, site directed mutagenesis and a phosphospecific 
antibody.  The data presented demonstrate that the Brf1 residue S450 found in the H2 
region of Brf1 is a target of phosphorylation by CK2. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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4.2 Results 
4.2.1  S450 is phosphorylated by CK2 in vitro 
In an attempt to map the phosphorylation sites of CK2 on Brf1, a rapid and general 
method was initially employed.  The Brf1 sequence from amino acids 1 to 677 was 
divided into 200 overlapping peptide fragments, each consisting of 15 amino acids with 
an offset of 2 amino acids.  The peptides were synthesised as an array of spots on a 
cellulose membrane, and remained covalently attached to the membrane via their C-
termini.  These membranes were then used in a kinase assay.  The entire set of peptides 
was incubated with radiolabelled [γ- 
32P] ATP and a kinase buffer, in the absence or 
presence of recombinant CK2.  After extensive washing, the membrane was dried and 
exposed to film.  The results shown in Figure 4.2 revealed that several peptides were 
phosphorylated.    However,  out  of  the  phosphorylated  peptides,  only  four  contained 
specific CK2 consensus sites.  The amino acids that were positively implicated were 
T245, S426, S450 and T520. 
This method was used to try and narrow down which particular residue(s) of Brf1 could 
be phosphorylated.  The method was not very specific, as many unspecific peptides 
were phosphorylated in vitro as shown in Figure 4.2.  However, it does not rule out the 
possibility that the residues T245, S426, S450 and T520 could be phosphorylated by 
CK2. 
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Figure 4.2.  Determination of phosphorylation sites for CK2 on Brf1 by peptide 
array. 
The  top  left  panel  shows  the  negative  control  Brf1  peptide  array  following 
incubation  with  radiolabelled  [γ- 
32P]  ATP  and  kinase  assay  buffers  minus 
recombinant  CK2.    The  top  right  panel  shows  the  peptide  array  following 
phosphorylation by recombinant CK2.  The boxed spots indicate peptides which 
have  been  phosphorylated  by  recombinant  CK2  and  bear  consensus  CK2 
sequences.  The linear schematic representation of Brf1 in the middle indicates the 
relative  positions  of  the  phosphorylated  sequences  on  Brf1.    The  table  at  the 
bottom represents the precise position of the phosphorylated residues and their 
relative domain position. 
In addition to the peptide arrays, an alternative method was also used to identify the 
Brf1  site(s)  of  CK2  phosphorylation.    Individual  Brf1  domains  were  isolated  from Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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bacteria as fusion proteins with GST (Figure 4.3) and subsequently subjected to in vitro 
kinase assays. 
 
 
Figure 4.3.  Schematic  illustration  of  the  GST  fusion  proteins  encompassing 
individual Brf1 domains. 
GST fusion proteins were generated from Brf1 represented at the top.  Individual 
fusion  proteins  were  made  incorporating  different  domains  of  Brf1.    The  Zn 
ribbon domain (GST-ZR), the H1 region (GST-H1) and the H2 region (GST-H2). 
As shown in Figure 4.3, only three fragment proteins of Brf1 that were successfully 
expressed:  The GST-fusion proteins incorporating the direct repeats and the H3 region 
could not be obtained in spite of several attempts at expression.  In the first instance, 
equal amounts of GST fusion proteins, as confirmed by Coomassie staining (Figure 4.4, 
bottom panel) were incubated with HeLa nuclear extracts which had been treated with 
chemical CK2 inhibitors including DMAT (Figure 4.3, top panel), quercetin (Figure 
4.4, second panel) and TBB (Figure 4.4, third panel) or with DMSO only (negative 
control).  Phosphorylation of the H1 and H2 fusion proteins appear to be reduced with 
the addition of CK2 inhibitors (lanes 6 and 8) compared to the control samples (lanes 7 
and 9).  In contrast, the GST-ZR fusion protein does not appear to be phosphorylated 
under these conditions (lanes 3 and 4), and the negative control GST protein alone was 
not phosphorylated, as expected.  These data show that phosphorylation in this system 
has specificity.  For both H1 and H2, the CK2 inhibitors block phosphorylation to a 
considerable  degree,  which  suggests  that  CK2  is  the  predominant  kinase  for  these 
domains under the conditions of this assay.  The inhibition of phosphorylation appeared 
to be greater for the H2 fusion protein. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.4.  The H1 and H2 regions of Brf1 are phosphorylated by CK2 in vitro. 
Equal amounts (bottom panel) of the fusion proteins of GST and individual Brf1 
domains were isolated from bacteria and subjected to in vitro kinase assay using 
HeLa extract in absence or presence of the CK2 inhibitors, DMAT (top panel), 
quercetin (second panel) and TBB (third panel). 
The GST fusion proteins were also incubated in the presence of recombinant CK2, 
kinase buffer and radiolabelled ATP (Figure 4.5).  The results demonstrate that the Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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GST-H2 fusion protein only is phosphorylated when low doses of recombinant CK2 are 
added.  In contrast, the GST-H1 fusion protein is not phosphorylated, which could be 
due to a requirement by CK2 for another protein to be present in cell lysates in order to 
enable phosphorylation of GST-H1.  Another possibility could be that GST-H1 could be 
phosphorylated by another kinase which can be inhibited by the chemical inhibitors 
used in Figure 4.4. 
. 
Figure 4.5  GST-H2 fusion proteins are phosphorylated by recombinant CK2 in 
vitro. 
The indicated fusion proteins of GST and individual Brf1 domains were isolated 
from  bacteria  and  subjected  to  an  in  vitro  kinase  assay  in  the  presence  of 
recombinant CK2 and radiolabelled ATP.  The samples were resolved by SDS-
PAGE  before  staining  with  Coomassie  brilliant  blue  (bottom  panel).  Gels  were 
dried and subjected to autoradiography (top panel). 
The combined data from the peptide array and the in vitro kinases assays point towards 
the H2 region of Brf1 as a potential target of phosphorylation by CK2.  The experiments 
described in the rest of this chapter focused on characterising phosphorylation targets 
within this region of Brf1. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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The H2 region of Brf1 contains three potential sites of phosphorylation by CK2: S410, 
S426 and S450.  Data from the peptide array suggested that the latter two residues could 
be targets of CK2 phosphorylation.  In order to explore this possibility further, site- 
directed mutagenesis of S410, S426 and S450 to non-phosphorylatable alanines was 
performed, and the mutants were expressed as GST fusion proteins.  The GST fusion 
proteins  bearing  the  mutations  were  then  used  in  an  in vitro  kinase  assay.    Equal 
amounts  of  the  GST  fusion  proteins  as  shown  in  Figure  4.6  (bottom  panel)  were 
incubated in the presence of CK2, kinase buffer and radiolabelled ATP.  The results 
showed  that  the  third  mutation,  S450A,  resulted  in  a  dramatic  decrease  in 
phosphorylation of the H2 region.  This indicates that Brf1 S450 is phosphorylated in 
vitro by recombinant CK2. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.6  S450 is phosphorylated in vitro. 
The indicated fusion proteins of GST and either wild-type H2 or mutated forms of 
H2: GST-H2 S410A, GST-H2 S426A, GST- H2 S450A, were subjected to an in 
vitro kinase assay in the presence of recombinant CK2, followed by Coomassie 
staining and autoradiography. 
Studies  using  small  synthetic  peptides  as  substrates  can  help  delineate  substrate 
specificity.  To further investigate whether the S450 residue is phosphorylated, a Brf1 
synthetic peptide bearing this residue (sequence: ELDLSGIDDL) was generated.  Small 
acidic peptides cannot bind to the cation-exchange P81 phosphocellulose paper as used 
previously  in  CK2  activity  assays.    To  circumvent  this,  multiple  lysine  or  arginine 
residues  can  be  added  to  the  peptide.    However,  this  could  have  effects  on  the 
conformation  and  specificity  of  the  peptide  substrate.    It  has  been  reported  that 
polyetheneimine  (PEI)-cellulose  thin  layer  chromatography  (TLC)  can  be  used  to Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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separate 
32P labelled acidic, neutral and basic substrate peptides.  Therefore, an in vitro 
kinase assay was therefore performed with no peptide control (lane 1), PKA peptide 
(lane 2), CK2 peptide (lane 3), Brf1 peptide bearing the S450 (lane 4) and Brf1 peptide 
consisting of residues 554 to 563 (lane 5) and were resolved using this TLC system.  
The results confirmed that S450 is phosphorylated in vitro by CK2. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.7.  S450 is phosphorylated by recombinant CK2. 
Autoradiogram of TLC separating the 
32P phosphopeptides from unincorporated 
[γ-
32P] ATP.  In vitro kinase assay using no peptide control (lane 1), PKA peptide 
(lane 2), CK2 peptide (lane 3), Brf1 peptide bearing the S450 (lane 4) and Brf1 
peptide consisting of residues 554 to 563 (lane 5). Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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4.2.2  Characterisation of the anti- phosphoS450Brf1 antibody 
To  determine  whether  S450  of  Brf1  is  phosphorylated  in  vivo,  an  antibody  was 
produced against a peptide from Brf1 [SHYD (p) SDGDKSD] phosphorylated at that 
residue (phosphoS450Brf1).  The antibody was affinity purified to reduce the possibility 
of the antibodies binding to epitopes not found in the original peptide.  Characterisation 
of the antibody was required to demonstrate its specificity to the phosphorylated residue 
S450. 
To  begin  with,  the  antibody  was  tested  to  determine  whether  it  recognised  a 
phosphorylated form of Brf1.  Pre-treatment of A31 cells and HeLa cells with alkaline 
phosphatase reduced the recognition of the endogenous Brf1 proteins by the antibody 
(compare lanes 1 and 2).  This experiment confirmed that the antibody recognises a 
phosphorylated form of Brf1. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.8   The  anti-phosphoS450Brf1  antibody  recognises  phosphorylated 
Brf1. 
Lysates from A31 and HeLa cells were pre-treated with alkaline phosphatase and 
subjected to Western blotting with anti- phosphoS450Brf1 (top panels), with anti- 
Brf1  antibody  (middle  panels)  and  with  anti-actin  antibody  (bottom  panels) 
respectively. 
It was also necessary to determine whether the antibody recognised specifically Brf1 
phosphorylated on S450.  The final bleed antibody (top panel) and the phospho-peptide 
affinity purified antibody (third panel) did not recognise bacterially expressed GST or 
the GST-H2 fusion protein (Figure 4.9, lanes 1-3).  In contrast, the antibody reacted 
strongly with the same GST-H2 fusion protein which had been phosphorylated in vitro 
by  recombinant  CK2  (Figure  4.9,  lane  4).    All  fusion  proteins  were  expressed  at 
equivalent levels as shown by the GST blot (bottom panel).  Moreover, the second panel 
shows that if the antibody was affinity purified against unphosphorylated peptide, there 
is no difference in immunoreactivity with GST-H2 or CK2 phosphorylated GST-H2 
(second panel, lanes 3 and 4).  These findings show that the anti-phosphoS450Brf1 
antibody is specific to the H2 region phosphorylated at S450.  
 
 
 Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.9.  The  anti-phosphoS450Brf1  antibody  is  specific  to  phosphorylated 
Brf1 H2. 
GST (lanes 1 and 2) and GST H2 (lanes 3 and 4) fusion protein were incubated in 
absence or presence of recombinant CK2 and subjected to an in vitro kinase assay.  
Proteins  were  resolved  by  SDS-PAGE  and  transferred  to  nitrocellulose  before 
being subjected to Western blotting with final bleed phospho-S450Brf1 antibody 
(top  panel),  non-phosphopeptide  specific  S450Brf1  antibody  (second  panel), 
affinity  purified  phosphoS450Brf1  antibody  (third  panel)  or  GST  antibody 
(bottom panel). 
It was then assessed whether the phosphospecific antibody would recognise the residue 
S450, the GST fusion proteins bearing mutations at S410, S426 and S450 were used in 
kinase assays, as previously, but in this instance resolved proteins were transferred to 
nitrocellulose and probed with the anti-phosphoS450Brf1 antibody.  This experiment Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
 
88 
revealed that the antibody did not recognise the GST fusion protein bearing the S450A 
mutation, indicating that it can specifically recognise this residue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10.  The anti-phosphoS450Brf1 antibody does not recognise the S450A 
mutant. 
Equal  amounts  of  GST  fusion  proteins  were  used  in  an  in  vitro  kinase  assay. 
Proteins  were  resolved  by  SDS-PAGE  and  Western  blotting  with  the  anti-
phosphoS450Brf1 antibody. 
Further confirmation that the antibody recognises phospho-S450 is provided in Figure 
4.11.    A  peptide  competition  assay  was  performed  using  one  Brf1  peptide 
phosphorylated at S450 and a second peptide which consists of the same sequence but 
not phosphorylated.  Excess amounts of the peptides were incubated individually with 
the antibody prior to use in the Western blot shown in Figure 4.11. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.11.   The  anti-phosphoS450Brf1  antibody  does  not  recognise  the  non-
phosho S450. 
Cell lysates from HeLa cells were subjected to Western blotting with either anti-
phosphoS450Brf1 or total Brf1 antibodies in the absence (lane 1) or presence of the 
indicated peptides (lanes 2 and 3 respectively). 
Band detection by the anti-phosphoS450Brf1 antibody was abolished in the presence of 
the phosphorylated peptide, but not its unphosphorylated equivalent.  This confirms that 
the antibody specifically recognises the phosphorylated version of Brf1 S450 from cells. 
4.2.3 S450 is phosphorylated by CK2 in vivo 
To determine whether CK2 is involved in the phosphorylation of S450 in vivo, A31 
cells were cultured in the presence or absence of DMAT.  As disruption of CK2 activity 
is lethal to both embryos and cultured cells (REF), the assays were performed under 
conditions of only partial CK2 inhibition to preserve cell viability.  Lysates from cells 
treated with either DMAT or DMSO alone were subjected to Western blot analysis with 
the anti-phosphoS450Brf1 antibody. 
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Figure 4.12  Effect of DMAT on S450 phosphorylation in vivo. 
A31 cells were treated with the indicated concentrations of CK2 inhibitor DMAT 
for 4 hours.  A. CK2 activity was measured in the cell extracts treated with DMSO 
or 5 µM, 10 µM, 25 µM and 50 µM DMAT respectively.  B. Whole cell lysates were 
subjected to Western blotting with either anti-phosphoS450Brf1 (top panel), anti-
total Brf1 (middle panel) or anti-actin (bottom panel). 
Exposure to DMAT resulted in a significant decrease in the phosphorylation of S450 
without  affecting  the  levels  of  Brf1.    The  combined  results  show  that  Brf1  is 
phosphorylated in vitro and in vivo by CK2 at S450. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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4.3   Discussion 
The  aim  of  this  chapter  was  to  investigate  which  residue(s)  of  Brf1  is  (are) 
phosphorylated by CK2 using several different approaches.  Initially, in vitro kinase 
assays using GST fusion proteins of various Brf1 fragments were performed.  These 
assays revealed that the H2 domain of Brf1 is a target of phosphorylation by CK2 
(Figure 4.2, Figure 4.4 and Figure 4.5).  However, data also indicated that possible CK2 
targets may also be found within the H1 region, since a decrease in phosphorylation was 
observed in the presence of selective CK2 inhibitors, as shown in Figure 4.4. 
Because the combined data from the peptide array and the kinase assays using the GST 
fusion  proteins  indicated  that  the  H2  region  was  a  strong  candidate  target  for 
phosphorylation by CK2, the second part of the chapter focused on this H2 region.  
Furthermore,  the  H2  region  of  Brf1  has  29%  sequence  identity  between  yeast  and 
humans and is a region where TBP can bind (Juo et al., 2003).  Mutagenesis studies of 
the H2 region revealed that out of the three potential CK2 phosphorylation sites only 
one of them (S450) appeared to be a target of phosphorylation by CK2.  The residue 
S450 was shown to be phosphorylated by CK2 in vitro, as shown in Figure 4.6 and 
Figure 4.7. 
Although the H2 region is conserved between yeast and mammals, sequence alignment 
of yeast Brf1 and human Brf1 revealed that human residue S450 is equivalent to residue 
E463 in S.cerevisiae as shown in Figure 4.13 below. 
 
Figure 4.13  Sequence alignment of residues in the H2 region of yBrf1 and hBrf1. 
Sequence shows part of the H2 of Brf1 in S. cerevisiae, and Homo sapiens.  The 
arrow indicates E463 in yeast and S450 in human. 
The  finding  that  S450  is  not  evolutionarily  conserved  is  very  interesting  since  this 
region is well conserved from yeast to humans.  The divergence between yeast and that 
of  higher  organisms  may  reflect  the  differences  in  the  regulation  of  transcription 
between lower and higher eukaryotes.  The residue has evolved from being an E in Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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lower eukaryotes to an S in higher eukaryotes.  The CK2-mediated phosphorylation of 
this region could be an important regulatory event in the functions of higher eukaryotic 
Brf1  proteins  and  could  highlight  the  fact  that  Brf1  might  require  to  be  negatively 
charged at this residue to be active.  As CK2 is ubiquitous and active, it remains to be 
determined  if  this  phosphorylation  is  a  constitutive  event  or  whether  it  can  vary 
depending on the physiological status of the cell and this will be considered in Chapter 
Six. 
Although it was clear that S450 is phosphorylated in vitro, it remained to be determined 
whether it was phosphorylated in vivo.  A phosphospecific antibody against that residue 
was  generated  and  characterised  (Figures  4.8  to  4.11).    Using  this  antibody,  it  was 
demonstrated  that  the  addition  of  DMAT  to  proliferating  fibroblasts  decreased 
phosphorylation of S450 in a dose-dependent manner (Figure 4.12).  This led to the 
conclusion that S450 is phosphorylated in vivo by CK2. 
A 2.95 Ǻ resolution crystal structure of the yeast Brf1-TBP-DNA ternary complex is 
available and shown in Figure 4.14 below.  This structure shows part of the H2 domain 
(residues  437-506)  (Juo  et  al.,  2003).    Figure  4.14  also  shows  where  the  E463 
(equivalent to human S450) lies within this complex.  In addition, the position of the 
residue equivalent to human S426, a site which was shown not to be phosphorylated by 
CK2 (Figure 4.6), is indicated.  As predicted from the crystal structure of yeast Brf1, the 
equivalent residue of S450 is solvent exposed and the side chain is readily available for 
modification.  This makes it an excellent site for CK2 phosphorylation, as opposed to 
the equivalent residue of S426, which is buried thus potentially explaining why it is not 
phosphorylated by CK2 in Figure 4.6. Serine 450 of Brf1 is Phosphorylated by CK2 in vitro and in vivo. 
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Figure 4.14.  Structural model of C terminal portion of yBrf1. 
Green represents TBP, dark blue represents Brf1, and pale blue represents DNA.  
The  red  residue  indicates  the  yeast  equivalent  of  human  S450  and  the  yellow 
residue indicates the yeast equivalent of human S426. 
Characterisation of mammalian TFIIIB indicated that types I and II promoters used 
different components of TFIIIB compared to the type III promoters (Schramm et al, 
2000).  Types I and II promoters were shown to require TBP and the homologue of 
yeast Brf1 known also as Brf1 (Lobo et al, 1992; White and Jackson, 1992).  However, 
type III promoters use a protein related to the N-terminal but not to the C-terminal 
region of Brf1, which is referred to as Brf2 (Schramm et al., 2000).  Hu et al (2004) 
showed that Brf2 does not appear to be a target of phosphorylation by CK2 in vitro.  It 
is noteworthy that Brf2 not contain the S450 residue and therefore does not contradict 
the data presented in this chapter. 
In summary, through in vitro kinase assays and the use of a phospho-specific antibody, 
this chapter has demonstrated for the first time that CK2 phosphorylates Brf1 at the 
S450 residue.  This modification is highly specific, since CK2 fails to phosphorylate 
other consensus phosphoacceptor sites within the same region of Brf1. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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5  Molecular  Mechanism  of  Activation  of  Pol  III 
Transcription by CK2. 
5.1   Introduction 
The data presented in Chapters Three and Four, demonstrate that pol III transcription is 
activated by CK2-mediated phosphorylation of the Brf1 residue S450.  The mechanisms 
responsible for this increase in pol III transcription are investigated in this chapter.  
In order for pol III to bind to the promoters of class III genes, it requires the productive 
assembly of a pre-initiation complex at the appropriate promoter [reviewed in (Schramm 
and Hernandez, 2002)].  For the majority of class III genes, recruitment of pol III to the 
promoter  requires  two  pol  III-specific,  basal  transcription  factors,  namely  TFIIIC  and 
TFIIIB (discussed in Chapter One).  Control of transcription initiation and pre-initiation 
complex assembly, is a major target for the regulation of class III gene expression.  In 
particular, regulation of TFIIIB activity is achieved through protein-protein interactions 
with various activators or repressors.  As discussed in Chapter One, Erk can induce pol III 
transcription by binding and phosphorylating the Brf1 subunit of TFIIIB (Felton-Edkins et 
al., 2003a).  This stimulates the interaction of TFIIIB with both TFIIIC and pol III, thereby 
increasing pol III output (Felton-Edkins et al., 2003a).  In addition, c-Myc can also target 
TFIIIB to regulate pol III transcription (Gomez-Roman et al., 2003).  c-Myc binds directly 
to  Brf1,  and  this  interaction  is  responsible  for  the  recruitment  of  c-Myc  to  pol  III 
promoters, rather than being recruited through DNA sequences, such as the E-box (Gomez-
Roman et al., 2003) and (Kenneth et al., 2007).  c-Myc is also able to recruit co-activator 
complexes such as the histone acetyltransferase (HAT) GCN5 and TRAPP to class III 
genes, which stimulate acetylation of histone H3 (Kenneth et al., 2007) and ultimately 
gives rise to an increase in pol III output. 
Repressors of pol III transcription such as RB and p53, also target TFIIIB directly when 
regulating  pol  III  transcription  (Crighton  et  al.,  2003;  Larminie  et  al.,  1997).    Both 
repressors bind TFIIIB and sequester the protein in an inactive complex when the cell is 
resting or under stress conditions (Crighton et al., 2003; Larminie et al., 1997; Sutcliffe et 
al., 2000).  Molecular Mechanism of Activation of Pol III Transcription by CK2 
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Changes in transcription factor expression may also contribute to the regulation of pol III 
output.    Alterations  in  transcription  factor  abundance  appear  to  be  an  important 
determinant of pol III transcription rates during mammalian cell differentiation (Alzuherri 
and White, 1998), viral infection (Felton-Edkins and White, 2002; Larminie et al., 1999; 
Wang et al., 1995) and tumourigenesis (Winter et al., 2000; Daly et al., 2005). 
Studies  from  Johnston  and  co-workers  showed  that  CK2  appears  to  regulate  pol  III 
transcription prior to initiation (Johnston et al., 2002).  The objectives of this chapter were 
to examine changes in pol III output and interactions between proteins associated with the 
pol III machinery, in response to phosphorylation of Brf1 at S450 by CK2.  These were 
performed in order to establish a mechanism for the regulation of pol III transcription 
during CK2 activation. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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5.2 Results 
5.2.1  Mutating the CK2 phosphoacceptor site in Brf1, decreases 
pol III transcription. 
The data presented in Chapter Four demonstrated that CK2 can phosphorylate Brf1 on 
residue S450 both in vitro and in vivo.  This section describes a series of experiments that 
were  performed  to  examine  the  effects  of  this  phosphorylation  event  on  pol  III 
transcription.  A Brf1 construct was generated by PCR-mediated site directed mutagenesis, 
in which S450 was mutated to alanine (A) (pBrf1-S450A).  Several techniques were used 
to  compare  pol  III  transcription  following  transient  transfection  of  the  wild  type  Brf1 
construct (pBrf1) or this mutant construct (pBrf1-S450A), in either HeLa or CCL39 cells. 
In  the  first  instance,  primer  extension  analysis  was  used  to  determine  pol  III  output 
following transfection of the constructs.  CCL39 fibroblast cells were transfected with 
equal amounts of control vector (referred to as empty vector) or vectors encoding either 
wild type or mutant Brf1.  In addition, vectors encoding the adenovirus VA1 RNA (as a 
pol  III  reporter)  and  green  fluorescent  protein  (GFP)  (to  normalise  for  transfection 
efficiency), were also transfected.  Western blotting (shown in Figure 5.1A) confirmed that 
the wild-type and mutant Brf1 constructs were expressed equally in the transfected cells 
and that mutation had not destabilised Brf1.  The primer extension analyses (shown in 
Figure 5.1B) revealed that transfecting CCL39 cells with wild-type Brf1 stimulated VA1 
transcription (upper panel, lane 2) in comparison to the control transfection (upper panel, 
lane 1).  However, mutation of S450 prevented this increase (upper panel, lane 3).  Primer 
extension of GFP RNA showed that transfection efficiency was similar in each case (lower 
panel).  Figure 5.1C shows a bar graph of the fold changes in pol III transcription after 
normalisation for GFP RNA levels.  The wild-type construct stimulated VA1 transcription 
by 1.8-fold, whereas the S450A mutation decreased VA1 transcription by 2-fold. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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Figure 5.1.  Mutating Brf1 S450 decreases pol III transcription. 
CCL39 cells were transiently transfected with empty vector, pBrf1 or pBrf1-S450A 
together with pVA1 and peGFP.  A. Cell extracts were resolved by SDS-PAGE and 
immunoblotted with an anti-HA antibody (top panel) to compare expression levels.  
Actin (bottom panel) was used as a loading control. B. Total RNA was extracted and 
VA1 and GFP RNA levels analysed by primer extension. C. VA1 and GFP RNA levels 
were  quantified  by  densitometry  and  VA1  expression  normalised  against  GFP 
expression (Normalisation of 3 independent experiments). 
Semi-quantitative RT-PCR analysis was also used to assess the effects of pBrf1-S450A on 
pol III transcription.  HeLa cells were transfected with equal amounts of the control and Molecular Mechanism of Activation of Pol III Transcription by CK2 
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Brf1  constructs  (Figure  5.2A).    Extracted  RNA  from  the  transfected  cells  was  then 
analysed by RT-PCR using primers specific for 5S rRNA, tRNA
Tyr and mRNA from the 
control pol II template, ARPP P0.  This RT-PCR analysis ( 
 
 
 
Figure 5.2B) revealed that there was an increase in the pol III transcripts 5S rRNA and 
tRNA
Tyr when wild-type Brf1 was transfected (upper panel, lane 2), in comparison to the 
control  vector  (lane  1).    However,  expression  of  the  S450A  mutant  reduced  pol  III 
transcription  (lane  3).    These  effects  are  specific,  as  the  level  of  ARPP  P0  mRNA  is 
unchanged. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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Figure 5.2.  S450A decreases pol III transcription in HeLa cells. 
HeLa cells were transiently transfected with empty vector, pBrf1 or pBrf1-S450A.  A. 
Cell  extracts  were  resolved  by  SDS-PAGE  and  immunoblotted  with  an  anti-HA 
antibody (top panel) to compare expression levels.  Actin levels were also measured to 
control  for  equal  protein  loading  (bottom  panel).  B.  Specific  primers  for  the 
transcripts indicated were used to PCR amplify cDNAs generated from total RNA of 
the transiently transfected HeLa cells. 
The effects of mutating the S450 to aspartate (S450D), which simulates phosphorylation, 
were also assessed.  CCL39 cells were transfected with equal amounts of control and Brf1 
constructs.    The  Western  blot  shown  in  Figure  5.3A  reveals  that  all  constructs  were 
expressed  equally.    RT-PCR  analysis  was  used  to  examine  the  effects  of  the  Brf1 
mutations on pol III transcription (Figure 5.3B).  The results reveal that, as with HeLa 
cells, there was an increase in 5S rRNA and tRNA
Tyr when the wild-type Brf1 construct 
was transfected (lane 2).  This increase was reduced when the pBrf1-S450A construct was 
transfected (lane 3).  In contrast, expression of the Brf1-S450D mutant (lane 4) activated 
tRNA expression even more than wild type Brf1 (lane 2).  These effects are specific, as the 
level of ARPP P0 mRNA was unchanged.  The changes in tRNA expression are more 
striking than the changes in 5S rRNA expression in both HeLa and CCL39 cells.  As Molecular Mechanism of Activation of Pol III Transcription by CK2 
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discussed in Chapter Three, the primers designed to assay the levels of tRNAs are intron-
specific  and  measure  rapidly  processed  precursors.    In  contrast,  the  5S  rRNA  primers 
measure steady-state levels.  These differences could explain the discrepancy between 5S 
rRNA and tRNA induction.  Molecular Mechanism of Activation of Pol III Transcription by CK2 
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Figure 5.3.  Phosphorylation of S450 increases pol III transcription in CCL39 cells. 
CCL39 cells were transiently transfected with empty vector, pBrf1, pBrf1-S450A or 
pBrf1-S450D. A. Cell extracts were resolved by SDS-PAGE and immunoblotted with 
an  anti-HA  antibody  (top  panel)  to  compare  expression  levels.  Actin  levels  were 
measured to control for equal protein loading (bottom panel). B. Specific primers for 
the transcripts indicated were used to PCR amplify cDNAs generated from total RNA 
of transiently transfected CCL39 cells.  
Primer  extension  and  RT-PCR  analyses  demonstrate  that  mutation  of  the  Brf1  CK2 
phosphoacceptor site S450 to A decreases pol III transcription in HeLa and CCL39 cells. 
Furthermore,  mimicking  phosphorylation  by  mutating  S450  to  D  can  increase  pol  III 
transcription more than wild-type Brf1.  Hence, it can be concluded that phosphorylation 
of Brf1 at S450 stimulates pol III transcription and that this is not cell type-specific. 
5.2.2 CK2 is found at type I and II promoters 
To test whether endogenous CK2 is present on pol III-transcribed genes in vivo, ChIP 
assays were performed.  Antibodies against CK2β, CK2 holoenzyme, c-Myc and TFIIA Molecular Mechanism of Activation of Pol III Transcription by CK2 
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were used to precipitate their respective proteins that had been cross-linked with chromatin 
in asynchronously growing HeLa cells. 
 
Figure 5.4.  CK2 associates with pol III templates in vivo. 
Chromatin  immunoprecipitation  of  HeLa  cells  were  performed  with  antibodies 
against  CK2β,  CK2  holoenzyme  and  c-Myc,  as  indicated.    As  negative  controls, 
TFIIA and beads only were used.  Association of each factor with 5S rRNA (top 
panel) and tRNA
Tyr (bottom panel) genes was quantified by PCR analysis using gene-
specific primers.  Input genomic DNA (10%, 2% and 0.4% of that used in the ChIPs) 
was analysed in the same PCR reactions. 
Endogenous  c-Myc  has  been  previously  detected  at  pol  III-transcribed  genes  (Gomez-
Roman et al., 2003) and the anti-c-Myc antibody was used as a positive control in ChIP 
assays (lane 8).  Figure 5.4 shows that in addition to c-Myc, CK2 is found at 5S rRNA 
(type I promoter, upper panel) and tRNA
Tyr (type II promoter, lower panel) genes.  The 
TFIIA  antibody  and  beads  were  used  as  negative  controls  and,  as  expected,  do  not 
precipitate the 5S rRNA and tRNA
Tyr genes.  The presence of the CK2β subunit (lane 4) at 
these promoters is more striking than the presence of the CK2 holoenzyme (lane 5).  This 
could reflect differences in the affinities of these antibodies.  Molecular Mechanism of Activation of Pol III Transcription by CK2 
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5.2.3 CK2 does not affect c-Myc binding to TFIIIB. 
c-Myc  has  been  shown  to  interact  with  Brf1.    Therefore,  the  next  experiment  was  to 
determine whether phosphorylation of Brf1 by CK2 could be a pre-requisite for c-Myc to 
bind Brf1.  HeLa cell extracts were pre-treated with the specific CK2 inhibitor DMAT, and 
the interaction between Brf1 and c-Myc was investigated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.   c-Myc binding to Brf1 is not affected by DMAT treatment 
HeLa extract was treated with either DMSO alone (lanes 1, 3 and 5) or with 10 µM 
DMAT  (lanes  2,  4  and  6).    The  extracts  were  then  immunoprecipitated  using 
antibodies against either c-Myc or cyclin D1. The precipitates were immunoblotted 
for Brf1 (using the 128-4 antibody). 
Co-immunoprecipitation experiments (shown in  
Figure 5.5) reveal that the association of endogenous c-Myc with Brf1 was not affected by 
the presence of the selective CK2 inhibitor and that Brf1 did not bind to the negative 
control  cyclin  D1.    The  data  suggest  that  the  binding  of  c-Myc  to  Brf1  and  the 
phosphorylation of Brf1 by CK2 are two events which can occur independently of each 
other. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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5.2.4  Phosphorylation  by  CK2  increases  pol  III  and  TFIIIB 
recruitment to type 1 and 2 promoters 
Enhanced promoter occupancy of polymerase at target genes often results in increased 
transcriptional output.  ChIP analyses were carried out to determine whether the binding of 
pol III and its transcription factors (TFIIIB and TFIIIC) to type I and II promoters was 
subject to regulation by CK2 phosphorylation.  Formaldehyde cross-linked chromatin was 
prepared from asynchronously growing A31/3T3 cells either treated with DMAT or with 
DMSO only for 4 hours.  Antibodies against a pol III subunit (RPC 155), TFIIIC subunit 
(TFIIIC110) and TFIIIB subunit (Brf1) were used to determine their occupancy.  TFIIA 
was used as a negative control, as it is not present on pol III- transcribed genes.  Molecular Mechanism of Activation of Pol III Transcription by CK2 
105 
 
Figure 5.6.  DMAT reduces TFIIIB and pol III, but not TFIIIC, binding to class III 
gene promoters in vivo. 
A31/3T3  fibroblast  cells  were  treated  with  either  50  µM  DMAT  or  DMSO  for  4 
hours.    ChIPs  were  performed  with  antibodies  against  Brf1,  TFIIIC110,  and  the 
largest pol III subunit (RPC155), as indicated.  As negative controls, ChIPs were 
carried out using a TFIIA antibody and beads alone. Association of each factor with 
5S rRNA, B2, tRNA
Leu and tRNA
Tyr promoters, in DMAT-treated and DMSO-treated 
cells, was quantified by PCR with gene-specific primers.  Input genomic DNA (10%, 
2% and 0.4% of that used in the ChIPs) was analysed in the same PCR reactions. 
PCR analysis showed that gene occupancy of pol III (Figure 5.6, lanes 7 & 8) and Brf1 
(Figure 5.6, lanes 9 & 10), on all promoter types, was diminished after the addition of 
DMAT.  In contrast, the levels of TFIIIC on each promoter type were similar in both 
DMAT-treated and DMSO – treated cells (Figure 5.6, lanes 11 & 12).  Molecular Mechanism of Activation of Pol III Transcription by CK2 
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The polymerase is recruited to class III genes by protein-protein interactions with TFIIIB. 
To examine whether TFIIIB recruitment is affected following phosphorylation of Brf1-
S450 by CK2, ChIP analyses were performed using HeLa cells which had been transfected 
with  either  the  pBrf1  or  the  pBrf1-S450A  expression  vectors.  TFIIIB  recruitment  was 
assessed using an antibody against HA.  As a negative control, an anti-TFIIA antibody was 
also used. 
 
Figure 5.7.  Mutation of S450A decreases association of TFIIIB with pol III genes in 
vivo. 
HeLa cells were transiently transfected with either pBrf1 (lanes 1, 3, 5, 7 and 9), or 
pBrf1S450A (lanes 2, 4, 6, 8 and 10).  ChIP assays were performed with antibodies 
against  HA  and  TFIIA  (negative  control),  as  indicated.  Association  of  HA-tagged 
Brf1 or Brf1-S450A with 5S rRNA and tRNA
Tyr promoters, in transfected cells, was 
quantified by PCR with gene-specific primers.  Input genomic DNA (10%, 5% and 
0.4% of that used in the ChIPs) was analysed in the same PCR reactions. 
Figure 5.7 reveals that the mutation of Brf1 residue S450 to A caused a marked decrease in 
TFIIIB binding to 5S rRNA and tRNA genes in vivo. 
The increased association of TFIIIB with promoters following phosphorylation by CK2 is 
likely to account for the enhancement of polymerase binding to type I and II promoters. 
This enrichment could explain the enhanced class III gene expression that occurs following 
Brf1 phosphorylation by CK2, as demonstrated in Chapter Three. 
The increase in TFIIIB occupancy at pol III templates in response to phosphorylation by 
CK2 might be a direct result of changes in abundance of TFIIIB.  Therefore, Western blot Molecular Mechanism of Activation of Pol III Transcription by CK2 
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analysis was performed using extracts treated with or without 50 µM DMAT to measure 
the levels of this transcription factor. 
 
Figure 5.8.  DMAT does not affect the levels of the TFIIIB subunits. 
HeLa extracts were treated with either DMSO alone or 50 µM DMAT and subjected 
to Western blotting with antibodies against Bdp1 (upper panel), Brf1 (second panel), 
TBP (third panel) and actin (bottom panel) as a loading control. 
No change in the abundance of TFIIIB subunits Brf1, Bdp1 or TBP was detected after the 
addition of DMAT, as shown in Figure 5.8 above. 
5.2.5  Phosphorylation of TFIIIB increases interaction with TFIIIC. 
The results so far demonstrate that the CK2-mediated phosphorylation of Brf1 at residue 
450 results in an enrichment of TFIIIB and pol III at class III genes (shown in Figure 5.6 
and Figure 5.7).  Furthermore, CK2 phosphorylation of TFIIIB did not appear to affect its 
stability (Figure 5.8).  Phosphorylation of transcription factors can modulate their activity 
by triggering conformational change and generating binding sites for interaction partners. 
The next series of experiments was performed to investigate the interactions of Brf1 with 
components of the pol III machinery.  In the first instance, a GST pull-down assay was 
performed using GST fusion proteins of the wild-type H2 region of Brf1 (GST-H2), and Molecular Mechanism of Activation of Pol III Transcription by CK2 
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the H2 region bearing a mutation at S450 (GST-H2S40A).  The binding of these fusion 
proteins to the TFIIIC subunit TFIIIC110 and the TFIIIB subunit TBP were then compared 
as shown in Figure 5.9 below. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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Figure 5.9.  S450A  specifically  reduces  TFIIIC  binding  but  not  TBP  binding  to 
Brf1. 
HeLa nuclear extracts were subjected to pull-down assays with the indicated fusion 
proteins or GST alone and tested for TFIIIC binding (top panel) and TBP binding 
(middle panel).  Proteins bound to the GST beads were resolved by SDS-PAGE and 
immunoblotted with the indicated antibodies. The bottom panel shows the relative 
amounts of recombinant fusion proteins used in each instance. 
The GST pull-down assay showed that the interaction of Brf1 and TFIIIC is compromised 
when S450 is mutated to A, suggesting that phosphorylation of this residue is important for 
the association of TFIIIC to Brf1.  In addition, the association of TBP and Brf1 does not 
seem to be affected by this mutation, indicating that the mutated protein is folded properly 
and is stable. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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As discussed in Chapter One, TFIIIB is brought to the promoter of class III genes by 
protein-protein interactions with TFIIIC.  Once TFIIIB is bound to the promoter, it recruits 
pol III and places it over the start site.  To investigate whether phosphorylation of Brf1 at 
S450 by CK2 could influence these interactions in vivo, co-immunoprecipitations were 
carried  out.  CCL39  cells  were  transfected  with  empty  vector,  pBrf1,  pBrf1-S450A  or 
pBrf1-S450D.  The cell lysates were then used in co-immunoprecipitation assays.  In the 
first  instance,  the  interactions  between  TFIIIC  and  wild-type  or  mutant  Brf1  were 
examined, as shown in Figure 5.10 below. Molecular Mechanism of Activation of Pol III Transcription by CK2 
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Figure 5.10.   S450A compromises binding of TFIIIB to endogenous TFIIIC. 
A.  Extracts from CCL39 cells transfected with empty vector, pBrf1, pBrf1-S450A 
and pBrf1-S450D, were subjected to Western blotting using an anti-HA antibody to 
verify  expression  levels  and  an  anti-actin  antibody  to  control  for  equal  protein 
loading.    B.  Subsequently  the  cell  lysates  were  immunoprecipitated  with  a  pre-
immune serum (lanes 5-8) and anti-TFIIIC antibody (subunit 110, lanes 1-4). The 
samples were resolved by SDS-PAGE and subjected to Western blotting using an 
antibody against the HA tag on the transfected wild-type Brf1 or mutant Brf1. 
The data reveal that when an anti-TFIIIC antibody was used to immunoprecipitate proteins 
from the transfected cells, only a small amount of TFIIIC was found to bind to Brf1-S450A 
(lane 3) in comparison to the wild-type Brf1 (lane 2).  However, the binding of Brf1-Molecular Mechanism of Activation of Pol III Transcription by CK2 
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S450D (lane 4) and TFIIIC was increased in comparison to wild-type Brf1 (lane 2).  No 
interaction was observed between Brf1 and TFIIIC, when the empty control vector was 
used, or when the negative pre-immune serum was used (lanes 5-8).  
Next,  the  interactions  between  pol  III  and  wild-type  or  mutant  Brf1  (S450A)  were 
investigated.  As before, CCL39 cells were transfected with empty vector, pBrf1 or pBrf1-
S450A and the cell lysates were used in co-immunoprecipitation assays. 
 
Figure 5.11.  Mutation of S450 to A does not compromise TFIIIB binding to pol III. 
Extracts  from  transfected  cells  were  immunoprecipitated  with  an  anti-pol  III 
antibody (lanes 4-6).  The samples were resolved by SDS-PAGE and subjected to 
Western blotting using an antibody against the HA tag on the transfected wild-type 
or mutant Brf1. 
The results indicate that binding of pol III to Brf1 is unaffected by the mutation of S450 to 
A. 
The combined data from the GST pull-down and co-immunoprecipitation assays suggest 
that  the  association  of  TFIIIC  and  TFIIIB  is  increased  specifically  when  CK2 
phosphorylates Brf1. Molecular Mechanism of Activation of Pol III Transcription by CK2 
113 
5.3  Discussion 
This chapter explores the influence of CK2 on molecular events involved in controlling 
transcription initiation complex assembly on class III genes with type I and II promoters, 
and provides an insight into how CK2 phosphorylation of Brf1 may be involved in the 
activation of pol III transcription.  Primer extension and RT-PCR assays revealed that 
mutation of the CK2 phosphoacceptor site found in the H2 region of Brf1 to A reduces pol 
III  output  in  human  and  rodent  cells.    Furthermore,  mutation  of  this  same  residue  to 
aspartate  activates  pol  III  transcription.    The  data  suggest  that  the  CK2-mediated 
phosphorylation of this Brf1 residue can contribute to the positive role of CK2 on pol III 
transcription.  This is consistent with the data presented in Chapter Three and previous 
studies which suggest that CK2 is a positive regulator of pol III transcription in yeast 
(Ghavidel and Schultz, 1997; Hockman and Schultz, 1996) and mammals (Johnston et al., 
2002; Hu et al., 2004). 
The role of CK2 as a regulator of pol III transcription is further supported by the detection 
of  endogenous  CK2  on  chromosomal  5S  rRNA  and  tRNA  genes  (Figure  5.4).    ChIP 
analyses by the Hernandez and Reinberg laboratories also found that CK2 can associate 
with promoter elements.  Specifically, Hu and co-workers demonstrated that CK2 binds to 
the U6 promoter (type III, pol III promoter) (Hu et al., 2004), and Lewis and co-workers 
have shown association of CK2 with the downstream promoter element (DPE) of a number 
of pol II-transcribed genes (Lewis et al, 2005).  Thus, association with regulatory promoter 
regions may be a common means through which CK2 can influence gene expression.  
c-Myc is known to regulate pol III transcription by binding to TFIIIB (Gomez-Roman et 
al., 2003).  In particular, Gomez-Roman and co-workers demonstrated that c-Myc binds to 
the Brf1 subunit of TFIIIB (Gomez-Roman et al., 2003).  In order to assess whether CK2 
phosphorylation of Brf1 could stimulate this binding, the effects of pre-incubating HeLa 
extracts with DMAT on c-Myc and Brf1 interactions were examined.   
Figure 5.5, shows that c-Myc binding to Brf1 is not affected by CK2 inhibition.  Consistent 
with this finding, unpublished data (N. Kenneth and R.J.White) identified the N-terminus 
of Brf1 as the site of c-Myc binding.  Since CK2 was found to phosphorylate the C-Molecular Mechanism of Activation of Pol III Transcription by CK2 
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terminal region of Brf1, this could explain why the interactions between c-Myc and Brf1 
were not affected by blocking CK2-mediated phosphorylation. 
Order-of-addition studies by Johnston and co-workers suggested that CK2 acts prior to 
transcription initiation (Johnston et al., 2002).  ChIP analyses were performed to establish 
whether CK2 could regulate pol III transcription during pre-initiation complex assembly. 
Addition of the CK2 inhibitor DMAT to fibroblast cells decreased TFIIIB and pol III 
recruitment, but not TFIIIC recruitment.  Therefore, the combined data suggest that CK2 
phosphorylation results in an increase in TFIIIB recruitment, which in turn is likely to 
account  for  increased  pol  III  binding  and  enhanced  pol  III  transcriptional  output  
Regulation of TFIIIB recruitment to class III genes is commonly used to control pol III 
transcription.    For  example,  reduction  in  TFIIIB  promoter  occupancy  has  also  been 
observed  when  cells  were  treated  with  Erk  inhibitors  (Felton-Edkins  et  al.,  2003a), 
following p53 induction (Crighton et al., 2003) and during mitosis (Fairley et al., 2003).  
The abundance of pol III transcription factors is elevated in a number of transformed cell 
types.  For example, TFIIIB has been shown to be elevated in fibroblasts transformed by 
SV40 (Fairley et al., 2003; Larminie et al., 1999) and Py (Felton-Edkins and White, 2002). 
However, the results in this chapter demonstrate that this does not occur following CK2 
activation, as inhibition of CK2 activity with DMAT does not change the levels of the 
individual TFIIIB subunits. 
Previous studies in S.cerevisiae have shown that the binding of Brf1 to TFIIIC represents 
the rate-limiting step in the assembly of the pol III pre-initiation complex (Moir et al, 
2004).  GST-pull down and co-immunoprecipitation assays revealed that S450A mutation 
compromises the binding of endogenous TFIIIC and Brf1 in vitro and in fibroblasts.  This 
effect is very selective, since the binding of pol III and TBP to Brf1 is not compromised 
when S450 is mutated to A.  The interactions between TFIIIC and Brf1 have been studied 
in  S.cerevisiae  and  it  has  been  shown  that  Brf1  can  interact  with  the  tetratricopeptide 
repeat (TPR)-containing TFIIIC subunit, TFC4 subunit. TPR motifs play a general role in 
protein-protein interactions and complex assembly (D'Andrea, 2003).  Mutations in the 
region  which  contains  the  TPR  motif  of  TFC4  can  result  in  the  activation  of  pol  III 
transcription in vitro and in vivo (Moir et al, 2002) and (Moir et al, 1997).  The mutations 
cause a conformational change in Tfc4 that can increase its affinity to Brf1, and hence the Molecular Mechanism of Activation of Pol III Transcription by CK2 
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recruitment of pol III (Moir et al, 1997).  In addition, a recent study by Liao and co-
workers has shown that the H region II of Brf1 is important for binding to TFC4 (Liao et 
al, 2006).  The region of TFC4 that contains the TPR motif is conserved in the human 
homologue  of  this  subunit  (TFIIIC102)  and  the  H2  region  of  Brf1  is  also  conserved 
through  evolution,  it  is  therefore  likely  that  the  interactions  between  TFIIIC  and  Brf1 
would be a target of regulation by CK2 in mammalian cells, consistent with the findings 
shown in this chapter. 
 
Figure 5.12.   Model of regulation of pol III transcription by CK2. 
Phosphorylation  of  Brf1  in  the  C-terminal  domain  can  result  in  an  increased 
association  with  DNA-bound  TFIIIC.    This  can  result  in  an  increase  in  pol  III 
recruitment to the promoters of class III genes and hence a rise in pol III output. 
The critical role that CK2 plays in general transcription has been recently emphasised by 
studies showing that this protein kinase is present on the promoters of pol I, II and III- 
transcribed genes (Panova et al, 2006; Lewis et al, 2005; Hu et al., 2004).  This study 
reinforces  the  concept  that  this  protein  kinase  is  an  important  regulator  of  nuclear 
transcriptional  machineries.    With  respect  to  pol  III  transcription,  the  experiments Molecular Mechanism of Activation of Pol III Transcription by CK2 
116 
described  in  this  chapter  suggest  that  CK2  is  recruited  to  pol  III  promoters  and 
phosphorylates the Brf1 residue S450.  Inhibition of CK2-mediated phosphorylation of 
Brf1 leads to a decrease in TFIIIB occupancy to class III genes, leading to a reduction in 
pol III transcription. 
The data in this chapter support the role of CK2 as an activator of pol III transcription. 
However,  studies  from  Hu  and  co-workers  have  also  suggested  that  CK2  can 
phosphorylate  the  Bdp1  subunit  of  TFIIIB  and  contribute  to  the  repression  of  pol  III 
transcription  during  mitosis  (Hu  et  al.,  2004).    The  next  chapter  will  examine  the 
phosphorylation status of Brf1 during virus-induced cell transformation and mitosis.  
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6  The regulation of Brf1 by phosphorylation 
6.1 Introduction 
Chapters Three, Four and Five have demonstrated that CK2 can phosphorylate the Brf1 
residue S450, and that this phosphorylation event can activate pol III transcription.  The 
objectives of this chapter were to investigate whether phosphorylation of Brf1 S450 can 
change during processes in which fluctuations in pol III activity have been observed, for 
example during virus induced-transformation and mitosis.  
6.1.1  
6.1.2 Regulation of pol III transcription in response to viruses of 
the Polyomaviridae family. 
Viruses  can  induce  cellular  transformation  and  represent  an  important  risk-factor  for 
cancer development in humans.  About 15% of human cancers are thought to arise from 
viral  infection  (Rosenthal,  2001).    Two  classes  of  viruses  can  give  rise  to  tumour 
formation,  the  DNA  tumour  viruses  and  RNA  tumour  viruses.    RNA  tumour  viruses 
consist  of  the  Retroviridae  family,  and  DNA  tumour  viruses  consist  of  six  different 
families  namely  Adenoviridae,  Hepadnaviridae,  Herpesviridae,  Polyomaviridae, 
Papillomaviridae and Poxviridae [reviewed in (Knipe D.M., 2007)]. 
The Polyomaviridae family can cause cellular transformation by integrating their DNA 
into the host genome, and allow a high level of expression of viral oncogenic proteins 
(White, 2004a).  Py (Stewart et al., 1958) and SV40 (Sweet and Hilleman, 1960) were the 
first polyomaviruses to be discovered and are the two best studied.  Py is able to induce a 
variety of different tumours when inoculated into newborn mice (Stewart et al., 1958), and 
several groups have reported that SV40 can cause tumours in rodents as well as induce 
transformation of primary cultures of human cells (Eddy et al., 1961; Eddy et al., 1962; 
Shein and Enders, 1962; Rabson and Kirschstein, 1962; Rabson et al., 1962).  The Regulation of Brf1 by Phosphorylation 
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Py and SV40 are very closely related in genome structure and DNA sequence, but differ 
slightly with respect to the oncoproteins they encode (White, 2004a).  Both viruses encode 
a multifunctional nuclear phosphoprotein termed large T antigen that is directly involved in 
the  initiation  of  viral  DNA  replication  (DeLucia  et  al.,  1983;  Jones  and  Tjian,  1984).  
Furthermore, large T antigen has been shown to be sufficient to transform a variety of 
primary rodent cells (Bikel et al., 1987; Zhu et al., 1992).  The transforming properties of 
large T antigen rely on its ability to bind and perturb the tumour suppressor proteins p53 
(Lane  and  Crawford,  1979)  and  RB  (DeCaprio  et  al.,  1988).    This  results  in  aberrant 
stimulation of the cell cycle and is the driving force for oncogenic transformation.  In 
addition, both viruses encode a low molecular weight protein termed small t antigen that 
contains sequence in common with the amino terminus of large T antigen and its own 
unique  C-terminal  sequence.    Unlike  SV40,  Py  encodes  a  distinct  third  early  protein, 
termed middle T antigen (Ito, 1979).  Middle T antigen also shares the N-terminus of large 
T antigen and small t antigen (Schaffhausen et al, 1982).  Middle T antigen is an integral 
membrane  protein  primarily  associated  with  the  plasma  membrane  (Ito,  1979; 
Schaffhausen et al, 1982).  
Both SV40 and Py can elevate pol III transcription (Camacho et al., 1990; Carey et al., 
1986; Scott et al., 1983).  In fact, studies with SV40-transformed murine fibroblasts were 
the first to suggest that pol III transcription changes in response to cell transformation 
(Carey et al., 1986; Scott et al., 1983).  Comparison of different SV40-transformed cell 
lines indicates that rates of pol III transcription are higher in those that most efficiently 
induce tumours, compared to the less tumourigenic cell lines (Camacho et al., 1990; Scott 
et al., 1983).  In addition, experiments using temperature sensitive mutants of the SV40 
oncoprotein large T antigen (Yang et al., 2001), and expression vectors carrying single 
viral oncogenes (Loeken et al., 1988; Damania et al., 1998) have demonstrated that pol III 
transcription is increased following transformation. 
To increase pol III output, these two viruses employ several distinct mechanisms which 
involve the basal transcription factors TFIIIB and TFIIIC.  Indeed, one of the mechanisms 
by which the Polyomaviridae viruses have been shown to increase pol III transcription is 
by promoting the release of TFIIIB from repression by RB (Felton-Edkins and White, 
2002; Larminie et al., 1999), due to the ability of large T antigen to bind and neutralise RB 
(DeCaprio  et  al.,  1988).    As  a  consequence,  the  proportion  of  endogenous  TFIIIB The Regulation of Brf1 by Phosphorylation 
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associated with RB is substantially diminished in SV40-and Py-transformed cells (Felton-
Edkins and White, 2002; Larminie et al., 1999)  
Cells transformed by these viruses overexpress the Bdp1 subunit of TFIIIB at both the 
protein and mRNA levels (Felton-Edkins and White, 2002).  Despite the overexpression of 
Bdp1, the abundance of the other TFIIIB components is unperturbed following SV40 and 
Py  transformation.    In  contrast,  all  five  subunits  of  TFIIIC  are  elevated  in  fibroblasts 
transformed by Py and SV40 (Larminie et al., 1999;  Felton-Edkins and White, 2002).  
Increased levels of these subunits contribute to the enhancement of pol III transcription. 
Both viruses employ the same mechanisms to activate pol III transcription.  Py, however, 
differs from SV40 in encoding a highly oncogenic middle T antigen.  Middle T antigen 
localises outside the nucleus, activates several signal transduction pathways and can serve 
as a potent activator of a pol III reporter in transfected cells (Felton-Edkins and White, 
2002).  
Data  presented  in  this  chapter  will  reveal  whether  the  phosphorylation  of  Brf1  S450 
changes when mouse fibroblasts have been transformed by either SV40 or Py. 
6.1.3 Mitotic regulation of pol III transcription. 
Nuclear gene expression is repressed when cells enter mitosis (Prescott and Bender, 1962).  
Mitotic repression of transcription can occur via several mechanisms.  At the onset of 
mitosis,  chromosome  condensation  occurs.    This  process  could,  in  principle,  limit  the 
accessibility of the DNA template to the transcriptional machinery and result in repression 
of pol III transcription (Johnson and Holland, 1965).  In addition, reversible inhibitory 
phosphorylation of the polymerase and/or the basal transcription factors could result in 
their displacement from the mitotic chromosomes, and thus also account for the repression 
of pol III transcription (Martinez-Balbas et al., 1995; Hershkovitz and Riggs, 1995; Segil et 
al., 1996) 
Mitotic repression of pol III transcription has been studied in both Xenopus egg and HeLa 
extracts  [reviewed  in  (Gottesfeld  and  Forbes,  1997)].    Hartl  and  colleagues  (1993) 
established that mitotic repression of transcription could be reproduced in vitro by the The Regulation of Brf1 by Phosphorylation 
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addition of purified cyclin B to Xenopus egg extracts (Hartl et al., 1993).  The activity of 
pol III observed in extracts obtained during interphase was dramatically decreased when 
extracts  were  converted  to  mitosis  in  this  way  (Hartl  et  al.,  1993).    The  authors  also 
demonstrated that the repression did not require normal chromatin condensation (Hartl et 
al., 1993), but instead revealed that phosphorylation of a component of the transcription 
machinery by a protein kinase, either cdc2 kinase and/or a kinase activated by it, caused 
the mitotic repression of pol III transcription (Hartl et al., 1993).  In addition, Gottesfeld 
and co-workers showed that repression of Xenopus pol III transcription by cdc2 could be 
reversed by addition of highly purified TFIIIB, whereas TFIIIC had no effect, and revealed 
that Xenopus egg mitotic extract showed a greatly diminished TFIIIB activity (Gottesfeld 
et al., 1994).  The authors concluded that TFIIIB appeared to be the target for inhibitory 
phosphosphorylation during mitosis in Xenopus (Gottesfeld et al., 1994).   
Xenopus  eggs  only  undergo  S  and  M  phases,  whereas  somatic  cells  undergo  a  more 
complex  cell  cycle  that  involves  sequential  passage  through  G1,  S,  G2  and  M  phases.  
White  and  colleagues  (1995)  used  HeLa  cells  that  were  synchronised  at  mitosis  to 
investigate the molecular basis of transcriptional repression in a human system.  Their 
findings  demonstrate  that  mitotic  HeLa  cells  repress  pol  III  transcription  in  a  similar 
manner to Xenopus oocytes and found that transcriptional activity could be restored in the 
mitotic cells with the addition of TFIIIB derived from interphase cells (White et al., 1995).  
This suggests that TFIIIB is targeted for mitotic phosphorylation in human cells.  
In both the frog and human systems, TBP becomes hyperphosphorylated during mitosis.  
However, mitotic repression of transcription appeared to be due to a specific loss of TAF 
activity, since expression could not be restored by the addition of recombinant TBP to 
mitotic extracts (White et al., 1995; Gottesfeld et al., 1994).  In contrast, affinity-purified 
TFIIIB  TAFs  reversed  repression  efficiently  and  could  restore  transcription  in  mitotic 
extracts (White et al., 1995; Gottesfeld et al., 1994).  Using Xenopus eggs, it was shown 
that the mitotic kinase cdc2/cyclin B phosphorylates a 92kDa TAF (possibly the Xenopus 
homologue of Brf1) (Gottesfeld et al., 1994).  Fairley and co-workers found that Brf1 is 
hyperphosphorylated when HeLa cells are arrested in metaphase (Fairley et al., 2003).  
However, the authors found that this repression was caused by a kinase other than cdc2-
cyclin B in humans.   The Regulation of Brf1 by Phosphorylation 
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Plk1is a protein kinase that is active at late G2 and during M phases of the cell cycle, and 
has several roles in mitosis.  Unpublished data (J. Fairley and R.J.White) show that Plk1 
can inhibit the expression of pol III-transcribed genes during mitosis and that Plk1 can bind 
and phosphorylate Brf1.  Hyperphosphorylation of Brf1 by a mitotic kinase such as Plk1 
can weaken the interaction between Brf1 and Bdp1, resulting in the release of Bdp1 from 
types  I  and  II  promoters  (Fairley  et  al.,  2003).    The  productive  assembly  of  the  pre-
initiation complex is prevented, and pol III transcription is repressed during mitosis.  
Hu and colleagues found that Bdp1 is also hyperphosphorylated during mitosis (Hu et al., 
2004).  In addition, they confirmed that Bdp1 is released from promoters, preventing the 
productive recruitment of pol III (Hu et al., 2004).  The authors suggested that CK2 is the 
kinase involved in phosphorylating Bdp1 during mitosis.  
Upon exit from mitosis, the hyperphosphorylation of TFIIIB is reversed rapidly.  Despite 
this, TFIIIB activity remains low in early G1 and then increases only gradually as cells 
move through G1 into S phase.  Maximal expression is reached during S and G2 phases 
(White et al., 1995).  In G1, pol III transcriptional activity is mainly regulated by RB. 
Figure 6.1, below, illustrates the regulation of TFIIIB throughout the cell cycle. 
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Figure 6.1  Schematic model of the cell cycle regulation of TFIIIB in mammalian 
cells. 
During G0 and early G1, underphosphorylated RB binds and represses TFIIIB, but 
this interaction decreases as cells approach S phase, since cyclin D and E-dependent 
kinases phosphorylate RB and prevent its binding to TFIIIB.  CK2 phosphorylates 
TFIIIB during interphase and activates pol III transcription.  During mitosis, TFIIIB 
is hyperphosphorylated by several kinases including Plk1 and CK2.  This results in 
the repression of pol III transcription.  
TFIIIB is an important target for the regulation of pol III transcription during both mitosis 
and interphase of actively proliferating HeLa cells.  This chapter investigates whether the 
phosphorylation  of  Brf1  S450  could  contribute  to  the  decrease  in  pol  III  transcription 
during mitosis. The Regulation of Brf1 by Phosphorylation 
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6.2 Results 
6.2.1 Phosphorylation of Brf1 in transformed cells 
Previous studies have shown that DNA tumour viruses employ several mechanisms to 
increase  pol  III  transcription  (as  described  in  Section  6.1  above).    The  next  set  of 
experiments was performed to determine whether the phosphorylation of S450 varies in 
cells transformed by SV40 or Py, compared to untransformed control cells.  
Cell extracts were obtained from cells transformed by SV40 (SV3T3Cl38) and from the 
parental Balb/c 3T3 A31 cells.  The cell lysates were resolved by SDS-PAGE and were 
subjected to Western blotting with anti-phosphoS450Brf1, anti-total Brf1 and anti-actin 
antibodies (Figure 6.2A).  The extracts were also subjected to a CK2 kinase activity assay 
(Figure 6.2B). 
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Figure 6.2.  The Brf1 residue S450 is phosphorylated following transformation by 
SV40. 
A.  Cell lysates (50µg) from Balb/c 3T3 A31 (lane 1) or SV3T3Cl38 cells (lane 2), were 
resolved  by  SDS-PAGE  and  subjected  to  immunoblotting  with  antibodies  against 
phosphoS450Brf1 (upper panel), total Brf1 (middle panel) and actin (bottom panel).  
B.  CK2 activity assay of extracts from Balb/c 3T3 A31 and SV3T3 Cl38 cells.  The 
activity of the parental control cell extracts was normalised to 1, and the activity of 
the transformed cell extracts is represented as a fold change of the control (the error 
bars indicate the standard deviation from the mean, where n=3). 
The results demonstrate that there is an increase in phosphorylation of Brf1 S450 following 
SV40 infection.  This coincides with elevated CK2 activity in the SV3T3Cl38 cell extracts. The Regulation of Brf1 by Phosphorylation 
125 
In addition, the phosphorylation of the Brf1 S450 was also examined in cells transformed 
by Py (Py3T3).  Extracts derived from the murine cell line Py 3T3 and the parental A31 
cells (an immortalised Balb/c 3T3 line) were resolved by SDS-PAGE and subjected to 
Western  blot  analysis  with  antibodies  against  phosphoS450Brf1,  total  Brf1  and  actin 
(shown in  
Figure 6.3, below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3  Brf1 S450 is phosphorylated following transformation by Py. 
Cell lysates (50µg) from Balb/c 3T3 (lane 1) and Py3T3 (lane 2) cells were resolved by 
SDS-PAGE  and  subjected  to  immunoblotting  with  anti-phosphoS450Brf1  (upper 
panel), anti-total Brf1 (middle panel) and anti-actin (lower panel) antibodies. 
The results indicate that, as with SV40 transformed cell extracts, there is an increase in 
phosphorylation of Brf1 S450 in the Py-transformed cell extracts compared to the parental 
Balb/c 3T3 A31 cell extracts.  
In conclusion, the combined data from Figure 6.2 and 6.3, indicate that there is an increase 
in phosphorylation of Brf1 S450 following transformation of A31 cells by SV40 and Py. The Regulation of Brf1 by Phosphorylation 
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6.2.2 Phosphorylation of S450 in mitosis 
Pol III transcription is repressed and Brf1 is hyperphosphorylated during mitosis (Fairley et 
al., 2003).  To determine whether the phosphorylation of Brf1 S450 is changed during 
mitosis, cell lysates from cells that had been arrested in either S or M phase were analysed 
by Western blotting with anti-phosphoS450Brf1 antibody, anti-total Brf1 and anti-actin 
antibodies (Figure 6.4A).  In addition, the activity of CK2 in these two phases was also 
assessed by a CK2 activity assay (Figure 6.4B). The Regulation of Brf1 by Phosphorylation 
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Figure 6.4  Phosphorylation of Brf1 S450 does not change during mitosis. 
A.  Cell lysates (50 µg) from HeLa cells arrested in S phase (lane 1) or arrested in M 
phase (lane 2), were resolved by SDS-PAGE and subjected to immunoblotting with 
antibodies  against  phosphoS450Brf1  (upper  panel),  total  Brf1  (middle  panel)  and 
actin (bottom panel).  B.  The activity of the S phase extracts was normalised to 1 and 
the activity of the mitotic extracts is shown as a fold difference of the S phase extracts 
(the error bars indicate the standard deviation from the mean, n=3). 
Figure 6.4A reveals that the phosphorylation of Brf1 S450 remains the same in S and M 
phases.  In addition, no change in the activity of CK2 was observed (Figure6.4B).  The Regulation of Brf1 by Phosphorylation 
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The repression of pol III transcription is caused by inhibitory phosphorylation of TFIIIB 
during mitosis.  Fairley and co-workers (2003) found that Brf1 is phosphorylated during 
mitosis,  resulting  in  the  weakening  of  the  interactions  between  Brf1  and  Bdp1.  
Unpublished data by Fairley and co-workers suggest that Plk1 can phosphorylate Brf1 on 
T270  during  mitosis.    Co-immunoprecipitation  analysis  was  performed  to  determine 
whether mutating T270 to non-phosphorylatable alanine (T270A) or to the phosphorylation 
mimic aspartate (T270D) would affect binding of TFIIIB to TFIIIC or pol III.  The Regulation of Brf1 by Phosphorylation 
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Figure 6.5  Mutation of T270 to aspartate decreases interactions between Brf1 and 
pol III. 
Extracts from HeLa cells transfected with empty vector, pBrf1, pBrf1-T270A and 
pBrf1-T270D  were  subjected  to  immunoprecipitation  using  anti-HA,  anti-TFIIIC, 
anti-pol III or anti-TAFI48 (negative control) antibodies.  The samples were resolved 
by SDS-PAGE and subjected to Western blotting using anti-HA antibody. 
The co-immunoprecipitation analysis revealed that binding of Brf1 to TFIIIC is not greatly 
affected by mutation of T270 to either A or D (Figure 6.5).  However, the binding of Brf1 
to pol III does appear to decrease when T270 is mutated to D, but increased slightly when 
the residue is mutated to A. The Regulation of Brf1 by Phosphorylation 
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Discussion 
Several DNA tumour viruses have been shown to induce expression of pol III products 
including adenovirus, hepatitis B virus, SV40, Py and human papilloma virus (Camacho et 
al., 1990; Carey et al., 1986; Felton-Edkins and White, 2002; Larminie et al., 1999a; Scott 
et al., 1983).  This up-regulation of pol III transcription in transformed cell lines occurs 
mainly through mechanisms which target TFIIIB.  This chapter focused on elucidating the 
effects  that  members  of  the  Polyomaviridae  family,  SV40  and  Py,  have  on  the 
phosphorylation of Brf1 S450.  Figures 6.2 and 6.3 reveal that the phosphorylation of Brf1 
S450  increases  following  transformation  by  both  SV40  and  Py.    As  demonstrated  in 
Chapter Five, the phosphorylation of Brf1 at this residue can increase pol III output.  The 
increase in phosphorylation of Brf1 S450 could contribute to the ability of DNA tumour 
viruses to enhance pol III transcription, which is consistent with previous studies that have 
shown that these viruses can elevate the expression of pol III transcripts by several shared 
mechanisms  (Felton-Edkins  and  White,  2002;  Larminie  et  al.,  1999).    Figure  6.2 
demonstrates that there is an increase in CK2 activity following transformation by SV40.  
CK2 has been shown to phosphorylate and regulate large T antigen (Grasser et al., 1988).   
Indeed, phosphorylation of the large T antigen by CK2 has been shown to increase its 
nuclear import (Grasser et al., 1988).  The increase of large T antigen in the nucleus could 
promote the release of more TFIIIB from RB repression and activate pol III transcription.  
The onset of mitosis is accompanied by an increase in the level of protein phosphorylation.  
Indeed, Fairley and co-workers (2003) reported that Brf1 is hyperphosphorylated during 
mitosis.  Figure 6.4 examined whether phosphorylation of Brf1 S450 changes throughout 
the cell cycle.  The data reveal that S450 phosphorylation does not vary between mitotic or 
interphase cells.  In addition, CK2 activity remained unchanged when cells are in mitosis.  
This is consistent with findings from Bosc and co-workers who examined the expression of 
CK2α, CK2α’ and CK2β, as well as CK2 activity, in cells during different phases of the 
cell cycle and found no major fluctuations in the expression and activity of CK2 (Bosc et 
al., 1999). 
Mitosis is associated with a decrease in transcription, and TFIIIB was found to be the 
target  of  inhibitory  phosphorylation.    Brf1  residue  T270  was  found  to  be  specifically 
phosphorylated  during  mitosis  and  mutation  of  T270  to  aspartic  acid  resulted  in  the The Regulation of Brf1 by Phosphorylation 
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repression of pol III transcription (J.Fairley and R.J.White, unpublished data).  The data 
suggest that T270 is a mitotic site of phosphorylation by Plk1 and contributes to the mitotic 
repression of pol III transcription.  Fairley and co-workers showed that upon mitotic Brf1 
hyperphosphorylation, the interactions between Bdp1 and Brf1-TBP are affected, resulting 
in the release of Bdp1 from the promoter (Fairley et al., 2003).  The resulting Brf1-TBP 
complex is not sufficient to recruit pol III to the promoters.  Indeed, ChIP assays revealed a 
reduction of polymerase at the promoters of pol III-transcribed genes, but found no change 
in the occupancy of TFIIIC and Brf1 (Fairley et al., 2003). Figure 6.5 examined whether 
mutation of T270 to A or to aspartic acid would affect the interactions of Brf1 with pol III 
and TFIIIC.  The data reveal that Brf1 binding to pol III was disrupted when this T residue 
was  mutated  to  aspartic  acid,  which  is  consistent  with  an  inhibitory  role  for  the 
phosphorylation  of  the  residue.    In  contrast,  the  Brf1  interactions  with  TFIIIC  were 
unaffected when the residue was mutated to either A or aspartic acid.  These results are 
consistent with the model of mitotic pol III transcriptional repression suggested by Fairley 
and colleagues (Fairley et al., 2003) 
Transcription in mitotic extracts was restored by cellular overexpression of not only Brf1 
but also Bdp1 (Fairley et al., 2003).  Indeed, Hu and colleagues (2004) showed that Bdp1 
is  also  hyperphosphorylated  during  mitosis.    The  authors  suggested  that  CK2 
phosphorylation of Bdp1 is directly responsible for the mitotic transcription shut-down.  It 
is uncertain how CK2, which is constitutively active and is a positive regulator of pol III 
transcription during interphase, can induce Bdp1 phosphorylation specifically at mitosis 
giving rise to a repression of pol III transcription (Hu et al., 2004).  CK2 has been shown to 
specifically  phosphorylate  DNA  topoisomerase  IIα  during  mitosis,  Escargueil  and 
colleagues  (2007)  found  that  phosphorylation  of  this  protein  is  suppressed  during 
interphase  due  to  competing  dephosphorylation  by  protein  phosphatase  2A.    Protein 
phosphatase 2A is excluded from the nucleus during early mitosis which then allows CK2 
to phosphorylate topoisomerase IIα (Escargueil et al, 2007) Therefore; it is possible that a 
similar mechanism could regulate the phosphorylation of Bdp1 whereby an inhibitory site 
of  phosphorylation  found  on  Bdp1  could  be  unavailable  for  phosphorylation  by  CK2 
during interphase.  Despite no change in CK2 activity, Bdp1 could be phosphorylated 
specifically during M phase due to the exit of protein phosphatase 2A from the nucleus. 
This mechanism could contribute to the mitotic repression of pol III transcription.  The Regulation of Brf1 by Phosphorylation 
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Reversible phosphorylation is a prevalent mechanism by which the activity of eukaryotic 
transcription factors is regulated rapidly.  Indeed, this chapter has shown that the multisite 
phosphorylation of TFIIIB is an important regulatory step used to control pol III output in 
response to changes in cellular environment.  
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7  Final Discussion 
7.1 Activation of pol I and III transcription by CK2. 
Pol I and pol III are together responsible for generating the four rRNAs (28S, 18S, 5.8S 
and 5S), which are required in equimolar amounts for ribosome assembly.  Therefore, 
synthesis of rRNA by these two polymerases is often regulated co-ordinately.  Indeed, 
CK2 has been found to stimulate transcription by pols I and III in both mammals and yeast 
(Ghavidel and Schultz, 1997; Ghavidel and Schultz, 2001; Hu et al., 2003; Johnston et al., 
2002; Lin et al., 2006; Panova et al, 2006).  Consistent with these findings, Chapter Three, 
demonstrated by several techniques, such as in vitro transcription assays, Northern blotting 
and RT-PCR (shown in Figures 3.1 to 3.5), that CK2 increases pol III transcription in vitro 
and in vivo.  Pol III output is significantly reduced upon inhibition of endogenous CK2 
with  specific  chemical  inhibitors  such  as  TBB  and  DMAT,  in  comparison  to  vehicle 
treated cells or cell extracts.  To confirm that the effects of these inhibitors on pol III 
activity were mediated by the blockage of CK2, rather than of other kinases, an alternative 
method of decreasing endogenous CK2 activity, such as RNA interference (RNAi) could 
have been used.  RNAi against CK2, is a non-pharmacological and selective method of 
decreasing CK2 catalytic activity, and has been successfully carried out in other areas of 
CK2 research.  For example, Di Maira (2005) and colleagues were studying the effects of 
CK2 phosphorylation on Akt/PKB, they were able to reduce the level of expression and 
activity of the CK2 catalytic subunit by about 60%, using this approach.  In addition to the 
assays measuring pol III output following CK2 inhibition, ChIP assays show that CK2 is 
associated with class III genes with types I and II promoters (Figure 5.4) and type III 
promoters (Hu et al, 2004).  Collectively, these data support the role of CK2 as a regulator 
of pol III transcription. 
7.2 Brf1 S450 as a target for CK2 phosphorylation 
The transcription of a class III gene is dependent on pol III recruitment to the appropriate 
promoter.    For  the  majority  of  genes  transcribed  by  pol  III,  this  is  determined  by  the 
transcription  factors  TFIIIC  and  TFIIIB,  which  bind  specific  promoter  sequences  and 
directly recruit the polymerase, respectively [reviewed (Schramm and Hernandez, 2002)].  Final Discussion 
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Transcription factors are frequently targeted by numerous control strategies according to 
changes in the cellular environment.  In particular, TFIIIB, has been well documented as a 
key regulator of pol III transcription in eukaryotic cells (summarised in Figure 7.1 below) 
(Felton-Edkins et al., 2003a; Crighton et al., 2003; Johnston et al., 2002; Gomez-Roman et 
al., 2003; Larminie et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1  TFIIIB is highly regulated by several activators and repressors. 
The growth repressors RB and p53 can repress TFIIIB by direct interactions.  Their 
function can be blocked by several viral proteins including large T antigen from SV40 
and Py, the adenovirus E1A, the HPV E6 and E7 and the cellular oncoprotein Hdm2. 
The mitotic kinase Plk1 can also repress pol III transcription by phosphorylating 
TFIIIB directly.  In contrast, a variety of oncoproteins have been shown to stimulate 
TFIIIB directly, including Erk, c-Myc and CK2.  Figure was adapted from (White, 
2004c). 
Chapters Three and Four confirmed that the Brf1 subunit of TFIIIB is a substrate for 
phosphorylation by the protein kinase CK2 (Figures 3.6, 4.4 to 4.7 and 4.12), in agreement 
with previous observations (Johnston et al., 2002).  Furthermore, the present study has 
advanced the current knowledge by showing that the Brf1 residue S450 is a major target 
for phosphorylation by CK2.  Analysis of available structural data for a portion of the C-
terminal  domain  of  Brf1  (Figure  4.14),  S450  is  exposed  and  readily  available  for 
phosphorylation,  thus  further  strengthening  the  conclusion  that  this  residue  is  indeed 
phosphorylated by CK2. Final Discussion 
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S450 of human Brf1 is equivalent to the residue E463 in yeast.  Both of these residues lie 
within the H2 region of Brf1, which is well conserved from yeast to humans (Larminie, 
1998).  Despite the divergence between yeast E463 and human S450, both phospho-S and 
E are acidic.  This indicates that Brf1 function may require acidity at this particular region 
but  may  also  reflect  a  difference  in  the  regulation  of  transcription  between  lower  and 
higher eukaryotes. 
The remainder of this thesis focused on the H2 region of Brf1, and particularly on the 
phosphorylation of residue S450.  However, Figures 4.4 and 4.5 indicate that the H2 region 
could also be a target for phosphorylation by CK2.  To further examine potential sites 
within Brf1, several attempts were made to express the H3 region and core domain of Brf1 
as GST fusion proteins.  However, these attempts were unsuccessful and, therefore, these 
regions were not tested in the phosphorylation assays.  Thus, the possibility that other Brf1 
residues in addition to S450 are targets of CK2 phosphorylation cannot be ruled out and 
should be examined further. 
The preferred method for identifying phosphorylation sites would have been through the 
use of mass spectrometry.  Indeed, several months of this project were dedicated to trying 
to  locate  the  phosphorylation  sites  within  Brf1  by  matrix-assisted  laser 
desorption/ionisation (MALDI) mass spectrometry.  However, the results obtained were 
inconclusive  due  to  several  experimental  issues,  including  problems  during 
phosphopeptide  enrichment  of  the  sample  by  high  performance  liquid  chromatography 
(HPLC), low counts of 
32P incorporation in Brf1, as well as technical problems such as 
mass spectrometry instrument failure.  Due to time constraints, the remainder of the project 
was focused on characterising the S450 site which was identified using in vitro kinase 
assays and confirmed in vivo with a phosphospecific antibody.  Future studies using an 
improved protocol and better mass spectrometry facility would be of great interest and 
should be pursued. Final Discussion 
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7.3 CK2 and regulation of pol III transcription during cell 
transformation. 
A wide variety of transformed cell lines and tumours have abnormally high levels of pol III 
(Carey et al., 1986; Daly et al., 2005; Scott et al., 1983; Winter et al., 2000) and CK2 
activity (Ahmed et al., 2000; Dessauge et al., 2005; Tawfic et al., 2001).  These include 
cell  lines  transformed  by  DNA  tumour  viruses  of  the  Polyomaviridae  family  (Felton-
Edkins  and  White,  2002;  Larminie  et  al.,  1999b;  Scott  et  al.,  1983).    The  levels  of 
phosphorylation of Brf1 S450 were higher in the SV40- and Py- transformed fibroblasts 
compared to the untransformed parental control cells (Figure 6.2 and  
Figure  6.3).    This  increase  in  phosphorylation  could  contribute  to  the  mechanisms 
employed by these viruses to achieve the high pol III output, as previously observed in 
these cell lines (summarised in Figure 7.2, below). 
Virus-induced transformation in cell culture has played a major role in elucidating the 
molecular  mechanisms  of  oncogenesis.  This  thesis  has  only  investigated  the 
phosphorylation of Brf1 S450 following transformation by Py and SV40.  Other types of 
DNA and RNA tumour viruses can induce pol III transcription and it would be interesting 
to assess whether they share similar deregulatory mechanisms. Final Discussion 
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Figure 7.2  Regulation  of  pol  III  transcription  during  cell  transformation  by 
Polyomaviridae viruses. 
CK2 phosphorylates the large T antigen and enhances its nuclear import (1 & 2). 
Following transformation, the cells overexpress Bdp1, resulting in an increase in the 
number of TFIIIB complexes (3 & 4).  The large T antigen can bind and neutralise 
RB, releasing TFIIIB from RB inhibition (5 & 6).  The free TFIIIB complexes are 
available for phosphorylation by CK2 and to recruit pol III to the promoters of class 
III genes(7) and. transcription of class III genes is enhanced (8) (Felton-Edkins and 
White, 2002; Larminie et al., 1999; Scott et al., 1983). 
Neoplastic change is also associated with changes in the intracellular localisation of CK2, 
so that a higher nuclear localisation is observed in tumour cells compared to normal cells 
(Tawfic et al., 2001).  Pol III products are overexpressed in tumour samples (Daly et al., 
2005; Winter et al., 2000).  Therefore, it would be interesting to investigate whether the Final Discussion 
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nuclear shuttling of CK2 during neoplastic changes contributes to an increase in S450 
phosphorylation, and thus pol III output. 
7.4 Regulation of Brf1 during mitosis 
The  entry  into  mitosis  is  accompanied  by  an  increase  in  the  level  of  protein 
phosphorylation and a decrease in nuclear gene transcription (Prescott and Bender, 1962).  
Several  studies  have  described  the  direct  involvement  of  inhibitory  phosphorylation  of 
TFIIIB  to  be  one  of  the  likely  mechanisms  which  organisms  use  to  repress  pol  III 
transcription during M phase (White et al, 1995).  Fairley and colleagues (2003) found that 
cdc2 is unlikely to account for the mitosis-specific phosphorylation of Brf1 in mammalian 
cells.    Instead,  Hu  and  colleagues  (2004)  suggested  that  CK2  is  responsible  for 
phosphorylating Bdp1 and leading to a decrease in pol III output during mitosis.  Figure 
6.4 investigated whether the phosphorylation of Brf1 S450 varies when cell lysates from M 
phase  were  compared  to  cell  lysates  in  S  phase,  and  revealed  no  change  in  the 
phosphorylation status of that residue.  Plk1 is activated during mitosis and unpublished 
data  (J.Fairley  and  R.J.White)  show  that  this  mitotic  kinase  phosphorylates  the  Brf1 
residue T270.   
Figure  6.5  showed  when  Brf1  T270  was  mutated  to  aspartate  (which  mimics 
phosphorylation)  interactions  of  Brf1  with  pol  III  were  diminished,  whereas  the 
interactions  between  Brf1  and  TFIIIC  interactions  were  not  greatly  affected.    These 
findings support the role of T270 as an inhibitory mitotic phosphorylation site.  When 
S450 is phosphorylated it activates pol III transcription (Figures 5.1 to 5.3); despite this, it 
remained phosphorylated during mitosis (Figure 6.4A).  The increase of level and activity 
of Plk1 can shift the balance towards inhibitory phosphorylation, allowing transcription to 
be repressed. 
Hu  and  colleagues  proposed  that  CK2  phosphorylation  of  pol  III  itself  is  required  for 
activating for pol III transcription at a type III promoter (Hu et al., 2003).  Further work 
from this group suggested that CK2 is directed to phosphorylate different targets within the 
basal pol III transcription machinery at different times during the cell cycle, with opposite 
transcriptional effects (Hu et al., 2004).  They reported that CK2 treatment of pol III is 
required for transcription, whereas treatment of Brf2-TFIIIB is inhibitory (Hu et al., 2003, Final Discussion 
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2004) and occurs through the phosphorylation of Bdp1 during mitosis (Hu et al., 2004). 
However, inhibition of CK2 in S phase extracts debilitates transcription (Hu et al., 2004).  
A minimal system consisting of recombinant and purified factors was used by Hu and 
colleagues and their findings remain to be shown in vivo.  It remains unclear how CK2 
which is constitutively active throughout the cell cycle (Figure 6.4B; Bosc et al, 1999), 
could have opposite effects on pol III transcription depending on phase.  Another way to 
induce  mitotic  phosphorylation  is  by  reduction  in  the  level  or  activity  of  the  protein 
phosphatase  during  mitosis.    Escargueil  and  Larsen  (2007)  provide  evidence  of  an 
alternative  mechanism  to  attain  specific  phosphorylation  by  CK2  during  mitosis.    The 
authors  found  that  topoisomerase  II  is  co-localised  with  both  CK2  and  PP2A  during 
interphase and argue that PP2A is able to dephosphorylate the CK2 site during interphase. 
During early mitosis, PP2A is translocated from the nucleus to the cytoplasm, giving CK2 
the possibility to phosphorylate the phosphoacceptor site.  This model could be a possible 
explanation for the observations made by Hu and co-workers (2004) who found that Bdp1 
can be phosphorylated by CK2 specifically during mitosis. 
7.5 Mechanism  of  regulation  of  pol  III  transcription  by 
CK2 
ChIP assays were used to monitor pre-initiation complex assembly on class III genes in 
response to CK2 phosphorylation.  This revealed a specific increase in TFIIIB promoter 
occupancy on tRNA and 5S rRNA genes, while the association of TFIIIC was essentially 
unaffected (as shown in Figures 5.6 and 5.8).  Therefore, it was concluded that polymerase 
binding, and hence transcription initiation, are regulated at the level of TFIIIB recruitment.  
Phosphorylation  can  modulate  the  activity  of  transcription  factors  at  various  levels  of 
regulation, such as facilitating protein-protein interactions (reviewed in Holmberg et al, 
2002).  Indeed, through the use of phospho-mimicking/ablation mutants of Brf1 S450, it 
was established that the phosphorylation of Brf1 S450 by CK2 can enhance interactions 
with TFIIIC, and thereby stimulate pre-initiation complex assembly.  This results in an 
increase in class III gene expression. 
The regulation of TFIIIB by phosphorylation is an important regulatory step used in many 
instances in which the growth potential of a cell has to be altered.  Experiments from Final Discussion 
140 
Michael  Schultz’s  laboratory  have  shown  that  CK2  normally  associates  through  its  β 
subunit  with  the  TBP  subunit  of  TFIIIB,  phosphorylates  TBP  and  activates  pol  III 
transcription (Ghavidel et al., 1999; Ghavidel and Schultz, 1997; Hockman and Schultz, 
1996b).  Indeed, blockage of CK2 causes the synthesis of tRNA and 5S rRNA to decrease 
by 80-90%.   They also found that transcriptional repression induced by DNA damage is 
achieved by the down regulation of TBP-associated CK2, which occurs through the release 
of the catalytic subunits from the complex (Ghavidel et al, 2001).  A role for CK2 in 
mediating pol III transcription repression following DNA damage signals remains to be 
investigated in mammalian cells. 
7.6 Conclusions 
Transcription is essential to every living organism and it impinges upon all biological 
processes,  such  as  growth,  development  and  the  ability  to  respond  to  environmental 
circumstances.  Defects in transcription are known to characterise the majority of diseases.  
This  thesis  has  provided  evidence  in  support  of  the  direct  role  of  CK2  in  pol  III 
transcription.    Induction  of  Brf1  was  found  to  increase  cell  proliferation  and  cause 
oncogenic  transformation. (Marshall  et  al,  2008) and phosphorylation  of  Brf1  by CK2 
could be significant during cell transformation.  The work presented contributes to the 
current  understanding  of  the  mechanisms  underlying  CK2  phosphorylation  of  Brf1.  
Appreciating the molecular basis of CK2 activation of pol III transcription could have 
important implications for the design of treatments aimed at the prevention of cancer. 
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